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Abstract 
The type of cancer pain management used may have an effect on the quality of life 
(QOL) of cancer patients. Researchers have determined that cancer patients are 
inadequately treated for pain and pain management is an essential determinant of patient 
survivability and QOL. Numerous clinical studies have been accomplished concerning 
opioid administration and noncancer and cancer pain management exist. Previous studies 
have examined the relationship between cannabinoid products, noncancer pain, cancer 
pain, and related QOL for patients but have not focused on the QOL of cancer patients 
while also moderating for gender. These relationships were investigated using the health 
belief model. The cancer pain management treatments (opioids and/or marijuana 
[cannabis]) and QOL, measured with World Health Organization Quality of Life Survey 
(WHOQOL-BREF), of 236 cancer patients were analyzed using analysis of variance 
(ANOVA), planned contrasts, post hoc tests, and moderated ANOVA (PROCESS tool) in 
the causal–comparative research. Research findings indicated significant benefit in cancer 
patient physical and psychological QOL in participants using marijuana when compared 
to participants using opioids and physical QOL for participants using marijuana over 
participants using both opioids and marijuana combined. Enhanced pain management 
options for cancer patients in order to reduce opioid side effects, increase pain treatment 
effectiveness, and improve patient QOL could yield positive social change. Growing 
rates of opiate addiction, abuse, and mortality are public health concerns and cannabis 
may be an effective pain treatment to reduce these social costs. This research may be of 
use to legislators considering rescheduling marijuana to less than Schedule I. 
  
 
Pain Management, Gender, and Quality of Life in Cancer Patients 
by 
John R. Buhmeyer 
 
MA, University of Montana, 1996 
BS, University of South Florida, 1987 
 
 
Dissertation Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Doctor of Philosophy 
Health Services 
 
 
Walden University 
August 2017 
  
Dedication 
To Melissa, who was the inspiration of this dissertation and my PhD journey. She 
was a daughter, sister, Marine, mom, and wife, who never stopped living and fighting. As 
a warrior and mentor, she was a positive influence to many people around the globe who 
were and are battling cancer. She is still spirit breathin’. I also dedicate this 
accomplishment to Valerie, who inspires and helps me to be a better person everyday. 
  
Acknowledgments 
I want to thank Dr. Robert Hoye, who has been my faculty mentor since my first 
day at Walden University and is my dissertation committee chair. Dr. Hoye has been a 
rock of support throughout my PhD journey including personal issues that shook my 
world. To my committee member, Dr. Jim Goes, thank you for all your time and effort to 
equip me with recipes for success in dissertation and scholarly research. Thank you to Dr. 
LaToya Johnson for all your inputs and help throughout the review process.  
Completion of the PhD journey would not have been possible without the 
encouragement and support of my parents and family. I am also thankful to many 
colleagues and staff members of the Walden community. A special acknowledgement to 
Dr. Mariana Daniela Torchia, aka Hermione, who I met at the first residency and was a 
friend and supporter during the many ups and downs of our PhD journeys. 
 
 i 
Table of Contents 
List of Tables ...................................................................................................................... v	
List of Figures ................................................................................................................... vii	
Chapter 1: Introduction to the Study ................................................................................... 1	
Introduction ................................................................................................................... 1	
Background ................................................................................................................... 2	
Problem Statement ........................................................................................................ 4	
Purpose of the Study ..................................................................................................... 6	
Research Questions and Hypotheses ............................................................................ 7	
Theoretical Framework ................................................................................................. 8	
Nature of the Study ..................................................................................................... 11	
Definitions ................................................................................................................... 12	
Assumptions ................................................................................................................ 13	
Scope and Delimitations ............................................................................................. 14	
Limitations .................................................................................................................. 15	
Significance ................................................................................................................. 16	
Summary ..................................................................................................................... 19	
Chapter 2: Literature Review ............................................................................................ 21	
Introduction ................................................................................................................. 21	
Literature Search Strategy ........................................................................................... 22	
Employment of Health Belief Model .......................................................................... 22	
HBM and Quality of Life ...................................................................................... 25	
 ii 
Operationalizing the Framework .......................................................................... 26	
Employing the WHOQOL-BREF ......................................................................... 28	
Limitations ............................................................................................................ 29	
Traditional Pain Management and QOL ..................................................................... 31	
Cancer Patient ....................................................................................................... 31	
Opioids .................................................................................................................. 33	
Nontraditional Pain Management and QOL ............................................................... 38	
Complementary and Alternative Medicines ......................................................... 38	
Cannabis ................................................................................................................ 39	
Opioid and Cannabis Use on QOL ............................................................................. 47	
Patient Perspective Concerning Dosing ...................................................................... 52	
Gender and Pain Treatment ........................................................................................ 54	
Summary and Conclusions ......................................................................................... 56	
Chapter 3: Research Method ............................................................................................. 60	
Introduction ................................................................................................................. 60	
Research Design and Rationale .................................................................................. 61	
Methodology ............................................................................................................... 63	
Population ............................................................................................................. 63	
Sampling and Sampling Procedures ..................................................................... 64	
Procedures for Data Collection, Recruitment, and Participation .......................... 69	
Instrumentation and Operationalization of Constructs ......................................... 73	
Threats to Validity ...................................................................................................... 86	
 iii 
Ethical Procedures ...................................................................................................... 87	
Summary ..................................................................................................................... 88	
Chapter 4: Results ............................................................................................................. 91	
Introduction ................................................................................................................. 91	
First Research Question and Hypotheses .............................................................. 92	
Second Research Question and Hypotheses ......................................................... 92	
Data Collection ........................................................................................................... 93	
Data Analysis Procedure ....................................................................................... 95	
Demographics ....................................................................................................... 96	
Overall Quality of Life ........................................................................................ 100	
Analyses of Research Questions 1 and 2 .................................................................. 101	
Assumptions, Data Cleaning, and Conversion ................................................... 103	
Normal Populations ............................................................................................ 105	
Homoscedasticity ................................................................................................ 107	
Results of Hypothesis 1 ...................................................................................... 112	
Results of Hypothesis 2 ...................................................................................... 125	
Summary ................................................................................................................... 127	
Chapter 5: Discussion, Conclusions, and Recommendations ......................................... 132	
Introduction ............................................................................................................... 132	
Interpretation of Findings ......................................................................................... 133	
Limitations of the Study ............................................................................................ 137	
Recommendations ..................................................................................................... 143	
 iv 
For Medical Practitioners .................................................................................... 143	
For Researchers ................................................................................................... 145	
For Health Policy-makers ................................................................................... 146	
Implications for Social Change ................................................................................. 148	
Conclusion ................................................................................................................ 153	
References ....................................................................................................................... 156	
Appendix A: WHOQOL-BREF ...................................................................................... 188	
Appendix B: WHOQOL-BREF Permission ................................................................... 192	
Appendix C: SurveyMonkey Permission ........................................................................ 193	
Appendix D: Frequency Counts of Participants’ Cancer Types ..................................... 194	
Appendix E: WHOQOL-BREF 26-Question SPSS Coding and Question Numbers ..... 196	
Appendix F: WHOQOL-BREF Domains, Questions, Scaling, and Scoring .................. 197	
Appendix G: Research Questions (#2 – #38) in SurveyMonkey Format ....................... 199	
Appendix H: Analysis of Participants’ Cancer Stage by Pain Management 
Therapy ..................................................................................................... 207	
 
 
 v 
List of Tables 
Table 1. Power Analysis Estimated Parameters and Results ............................................ 68 
 
Table 2. Variables and Statistical Tests Used to Evaluate Research Questions 1 and 2 .. 95 
 
Table 3. Frequency and Percent Statistics of Participants’ Gender and Age Groups ....... 96 
 
Table 4. Frequency and Percent Statistics of Participants’ Highest Level of Education and 
Marital Status ..................................................................................................... 97 
 
Table 5. Frequency and Percent Statistics of Participants’ Level of Chronic Pain, Cancer 
Stage, and Type of Pain Management Therapy ................................................. 98 
 
Table 6. Frequency and Percent Statistics of Participants’ Highest Reported Cancer Types
 ............................................................................................................................ 99 
 
Table 7. Frequency and Percent Statistics of Participants’ Overall Quality of Life ....... 101 
 
Table 8. Descriptive Statistics and S-W Scores of Participants’ Overall Composite QOL 
Scores and by Pain Management Therapy Type and Gender .......................... 105 
 
Table 9. Standardized Skewness and Kurtosis Statistics of Participants’ Overall 
Composite QOL Scores by Pain Management Therapy Types and Gender .... 107 
 
Table 10. Summary of Levene’s Tests for Research Questions 1 and 2 (Composite QOL)
 ........................................................................................................................ 108 
 
Table 11. Descriptive Statistics of Participants’ Overall Transformed Domain Scores and 
by Pain Management Therapy Type and Gender ........................................... 110 
 
Table 12. Summary of Levene’s Tests for Research Questions 1 and 2 (Transformed 
Domain) .......................................................................................................... 111 
 
Table 13. Summary of Cronbach’s α for Domain-related Questions ............................. 112 
 
Table 14. Model Summary of the ANOVA Analysis for Hypothesis 1 ......................... 116 
 
Table 15. Model Summary of Planned Contrasts and Post Hoc Test Analysis for 
Hypothesis 1 ................................................................................................... 117 
 
 
 
 
 vi 
List of Tables (Cont.) 
Table 16. Model Summary of the ANOVA Analysis for General QOL and Health 
Questions ........................................................................................................ 123 
 
Table 17. Model Summary of Post Hoc Test Analysis for General QOL and Health 
Questions ........................................................................................................ 124 
 
Table 18. Model Summary of the PROCESS Tool Analysis for Hypothesis 2 .............. 127 
 
Table 19. Summary of Results for Research Questions 1 and 2 ..................................... 130 
 
 
 
 
 vii 
List of Figures 
Figure 1. Power Plot Graph .............................................................................................. 68 
Figure 2. WHOQOL-BREF Domain Factors and Items ................................................... 74 
Figure 3. Transformation of Scale Scores ......................................................................... 80 
Figure 4. Planned Contrasts for Variance ......................................................................... 83 
Figure 5. Gender as Categorical Moderator ...................................................................... 84 
Figure 6. Moderation Statistical Model ............................................................................ 85 
Figure 7. Transformed Physical QOL Across Pain Management Therapy .................... 119 
Figure 8. Transformed Psychological QOL Across Pain Management Therapy ........... 120 
 
 
 
 
1 
 
Chapter 1: Introduction to the Study 
Introduction 
 According to the Centers for Disease Control and Prevention ([CDC]; 2016), 
deaths related to prescription opioids have reached epidemic levels over the last decade 
as 78 people die from overdose every day. Medical marijuana use, as a substitute for or 
complement to opiates, has shown similar or greater chronic pain relief while reducing 
opiate-related side effects (Lucas, 2012). States allowing medical marijuana use indicated 
a mean reduction in opioid-related deaths by 24.8% (Hayes & Brown, 2014). Therefore, 
use of medical marijuana for the treatment of chronic pain could provide social benefits 
by reducing mortality rates. 
Cancer patients commonly use opioids to relieve mild to severe pain (World 
Health Organization [WHO], 1996). Haroutounian et al. (2016) studied medicinal 
cannabis use for chronic pain and showed reduced opioid use (i.e., a significant 
percentage of participants quit using opioids) while improving pain and functional 
outcomes over a 6-month study. Marijuana use has also been associated with 
improvements of pain, cognitive, and quality of life (QOL) factors in chronic pain suffers 
(Ware, Wang, Shapiro, Collet, & COMPASS Study Team, 2015). Current researchers 
have not measured cancer patients’ pain and functional outcomes as related to QOL and 
opioid and/or medical marijuana pain management treatment choice. In this chapter I 
examine how the growing problems of opioid use and abuse are affecting society, 
background concerning opioid and medical marijuana use for pain, the purpose of this 
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study, the theoretical framework used, assumptions, scope, limitations, and significance 
of the study. 
Background 
The most effective pain management strategies often incorporate multiple 
mechanisms of action or methods (Rowe & Caprio, 2013). According to Pelayo-Alvarez, 
Perez-Hoyos, and Agra-Varela (2013), advanced cancer patients often rely on a strategy 
that focuses on symptom management and QOL maintenance; however, no current 
standard exists to measure the QOL of patients. Although QOL is related to the intensity 
of pain encountered, patients worldwide are experiencing inadequate and unacceptable 
levels of pain management therapies (Baek et al., 2013; Kwon et al., 2013; Wengström et 
al., 2014).   
These inadequate pain management therapies could be the result of medical 
providers’ concern for opioid abuse. These providers must balance efficacy and safety 
concerns when prescribing opioids because it has an association with abuse, overdose, 
and death (Rowe & Caprio, 2013). Zoëga, Fridriksdottir, Sigurdardottir, and 
Gunnarsdottir (2013) found 15% of their participants received adequate pain relief from 
stable doses of opioids, however, 53% had partial pain relief, and 19% experienced 
inadequate pain relief. Consequently, there is a gap in understanding pain management 
strategies because many complementary and alternative medicines are often not 
considered or available as viable options to traditional opioid treatments.  
The use and effect of marijuana on men and women needs further research. 
Researchers reported medical marijuana was used by men and women almost equally 
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(i.e., 6% versus 5%) and most commonly for chronic pain, arthritis, migraine, and cancer 
(i.e., 31%, 11%, 8%, and 7%, respectively; Ryan-Ibarra, Induni, & Ewing, 2015). Despite 
apparent equal use, men and women do not respond equally to marijuana and research 
concerning these differences is lacking (Craft, Marusich, & Wiley, 2013).  
Carter, Javaher, Nguyen, Garret, and Carlini (2015) presented evidence that 
marijuana could be a safer substitute or complementary treatment to address the growing 
medical concern over the opioid epidemic. Marijuana’s research potential and medical 
acceptance have been prevented by several barriers: (a) political hesitancy and 
nonacceptance, (b) practitioner educational and training deficiencies, (c) patient-
practitioner communication breakdown, and (d) practitioner concern over opioid abuse 
and hesitancy to advocate marijuana (Carter et al., 2015). Johnson, Lossignol, Burnell-
Nugent, and Fallon (2013) indicated a reduction in pain levels in many advanced cancer 
patients over the long-term with level doses of a cannabis oromucosal spray (i.e., 50% 
tetrahydrocannabinol [THC] / 50% cannabidiol [CBD] mixture known as nabiximols or 
Sativex®). Other researchers indicated that cannabis use was associated with pain level, 
QOL, and cognitive function improvements over a 1-year study (Ware et al., 2015). 
Further, Kral et al. (2015) indicated that cannabis use was associated with reduced pain 
levels and nonmedical use of opioids in participants. Cannabis reset opiate analgesia and 
eliminated chronic users need to increase opiate dosage to reduce pain (Lucas, 2012).  
Chronic pain elicits many burdens on society, and the cost of lost productivity and 
medical treatments attributable to chronic pain were estimated at $635 billion each year 
in the United States alone (Institute of Medicine, 2011). Researchers indicated chronic 
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pain patients being treated for opioids encountered more problems than those treated with 
medical marijuana (Feingold, Goor-Aryeh, Bril, Delayahu, & Lev-Ran, 2016). Although 
nontraditional pain management treatments exist (i.e., cannabis), for many chronic pain 
sufferers (e.g., cancer patients) this option is not always viable because medical use of 
cannabis is not legal in all states, countries, territories, or areas of the world (Rowe & 
Caprio, 2013). 
Problem Statement 
According to the WHO (1997b), the QOL of individuals incorporate life 
perceptions in the context of cultural and value systems as related to expectations, 
concerns, standards, and goals. The QOL of patients is often correlated to pain endured 
and the corresponding pain management mechanism(s) of action; in general, patients 
around the globe have not received sufficient pain therapies thus QOL is affected (Baek 
et al., 2013; Kwon et al., 2013; Wengström et al., 2014). Opioids are the most commonly 
used substance to ease cancer patients’ mild to severe pain (WHO, 1996).   
Concerning cancer outpatient pain management care, opioids are the traditional 
and gold standard treatment (Baek et al., 2013; Whistler, 2012), and researchers have 
completed many studies using opioid administration as the primary pain management 
methodology concerning patient QOL (Baek et al., 2013; Gaertner & Schiessl, 2013; 
Kwon et al., 2013; Lee et al., 2014). Both sales and deaths related to opioids have 
quadrupled over the last 15 years (CDC, 2016). Further, chronic pain suffers (e.g., cancer 
patients) often face dependence and side effect escalation issues due to opioid-related 
tolerance increases (Whistler, 2012). Opioid use, especially chronic use, can cause many 
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side effects including respiratory depression (Baldini, Von Korff, & Lin, 2012; Perlman 
et al., 2013; Whistler, 2012), constipation (i.e., 40-95% occurrence rate; Kumar, Barker, 
& Emmanuel, 2014; Perlman et al., 2013), cardiovascular effects, central nervous system 
effects (Cobaugh et al., 2014; Baldini et al., 2012), musculoskeletal system effects, 
endocrine system effects, and immune system effects (Baldini et al., 2012). Opioids also 
increased hyperalgesia, stress, and depression (Berland & Rodgers, 2012; Cobaugh et al., 
2014; Hayes & Brown, 2014), led to abuse, even for nonmedical users (Hayes & Brown, 
2014), increased the need for health care, and lowered QOL (Berland & Rodgers, 2012; 
Cobaugh et al., 2014). 
The use, abuse, morbidity, and related mortality of opioids have reached epidemic 
levels in society (CDC, 2012, 2016; Garcia, 2013; Rowe & Caprio, 2013). In the United 
States, 78 people die from opioid overdose every day and 60% of all drug overdose 
deaths involve opioids (CDC, 2016; Rudd, Aleshire, Zibbell, & Gladden, 2016). Because 
new cancer pain pharmacological developments in research and development are 
exclusively opioid related (Caraceni et al., 2012), the focus of research on opioids has led 
to opportunities to study other pain management treatments. Therefore, understanding 
traditional opioid treatments and nontraditional, nonopioid alternatives on cancer 
patients’ QOL is worthy of further research (Rowe & Caprio, 2013). Research concerning 
the efficacy of many nontraditional pain management treatments in relationship to cancer 
patient QOL and gender has not been conducted to date. 
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Purpose of the Study 
The purpose of the nonexperimental research was to determine the effects 
different types of cancer pain management treatments may have on cancer patients’ QOL. 
The study involved elements of the health belief model (HBM; Hochbaum, Rosenstock, 
& Kegels, 1952) including benefits, barriers, cues to action, and self-efficacy concepts 
(Abraham & Sheeran, 2005; Broussard & Weber-Breaux, 1994; Rosenstock, Strecher, & 
Becker, 1988; Wallace, 2002). Pain management therapies for cancer patients (i.e., 
defined by traditional [i.e., opioids], nontraditional [i.e., marijuana, also known as 
cannabis], and combined nontraditional and traditional) are often related to these HBM 
concepts and QOL is affected. Pain management is an essential determinant of patient 
outcomes because unrelieved pain significantly comprised patient QOL and effective 
pain management was associated with patient survival (Perlman et al., 2013).  
Gender (i.e., male and female) was also examined to determine if it affects the 
difference in cancer patient pain management and QOL. Researchers have indicated 
mixed results concerning use and abuse of both opioids and marijuana when gender is 
considered (Greenfield, Back, Lawson, & Brady, 2010). Relationships concerning 
gender, pain sensitivity, and pain management treatments warrant further investigation 
(Cooper & Haney, 2016; Lenz et al., 2011). Gender provided a research opportunity 
because effects of opioid and marijuana on cancer patient QOL have not been evaluated 
under these conditions. 
Pain is a secondary health problem that many cancer patients suffer which may 
relate to their QOL (Shneerson, Taskila, Gale, Greenfield, & Chen, 2013). Cancer 
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patients often use (i.e., 40% in North America, Australia, and Europe) complementary 
and alternative medicine (CAM) options to reduce the side effects of treatment and 
improve QOL, but many of these CAM options require further study in order to 
determine their efficacy (Horneber et al., 2011; Shneerson et al., 2013). Ben-Arye et al. 
(2014) explored CAM in cancer care and determined relationships with expected QOL 
improvement, pain reduction, and herbal medicine use; however, cannabis use was not 
part of the research parameters. Zaller, Topletz, Frater, Yates, and Lally (2015) studied 
200 medial cannabis users and found chronic pain management, improved pain relief, and 
opioid alternative as the predominant reasons for cannabis use. My research focused on 
nontraditional (i.e., cannabis) and/or traditional pain management (i.e., opioids) 
treatments and their relationship to cancer patients’ QOL. 
Research Questions and Hypotheses 
Two quantitative research questions (RQs) and corresponding null and alternative 
hypotheses were derived from theory and provided the focus for this study. 
Research Question 1: To what extent, if any, is there a difference between cancer 
patient’s quality of life (QOL) and types of cancer pain management therapy (i.e., 
traditional prescription based therapy [i.e., opioids], nontraditional based therapy [i.e., 
cannabis], and combined traditional and nontraditional therapy)? 
Independent variable: Cancer pain management, described as:  
• Traditional prescription based therapy (opioids) 
• Nontraditional based therapy (cannabis) 
• Traditional and nontraditional therapy 
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Dependent variable: Quality of life 
Ho1: Quality of life will not differ between cancer pain management types. 
Ha1: Quality of life will differ between cancer pain management types. 
Research Question 2: To what extent, if any, does gender affect the relationship 
between cancer patient’s quality of life and types of cancer pain management therapy 
(i.e., traditional prescription based therapy [i.e., opioids], nontraditional based therapy 
[i.e., cannabis] and combined traditional and nontraditional therapy? 
Independent variable: Cancer pain management, described as:  
• Traditional prescription based therapy (opioids) 
• Nontraditional based therapy (cannabis) 
• Traditional and nontraditional therapy 
Dependent variable: Quality of life 
Moderator: Gender (female or male) 
Ho2:  The impact of cancer pain management type on quality of life is not 
moderated by gender. 
Ha2:  The impact of cancer pain management type on quality of life is moderated 
by gender. 
Theoretical Framework 
In the early 1950s, social scientists developed the HBM in order to close gaps in 
psychological models when trying to enhance health education programs, assist 
preventative health behavior services, and explain how individuals fail to adopt disease 
prevention strategies (Abraham & Sheeran, 2005). There are six latent constructs used to 
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describe the HBM: perceived susceptibility, perceived severity, perceived benefits, 
perceived barriers, cues to action, and self-efficacy (Jensen, Nielson, & Kerns, 2003). 
The first four constructs were developed to describe the original HBM while self-efficacy 
(Rosenstock et al., 1988) and cues to action were added to the HBM construct as research 
progressed (Abraham & Sheeran, 2005). The HBM is descriptive in nature rather than 
causal (Abraham & Sheeran, 2005). HBM is based upon Lewin’s (1951) idea of valence 
and the expectancy-value model where the perceiver’s beliefs, either positive or negative, 
determines what an individual will and will not do (Lewin as cited in Abraham & 
Sheeran, 2005). 
The original HBM focused on the preventative behavioral perspective but later 
was expanded to other health related activities (Abraham & Sheeran, 2005; Beehler, 
Rodrigues, Kay, Kiviniemi, & Steinbrenner, 2014). Individuals choose various courses of 
actions depending on their perceptions of potential benefits and costs related to the health 
behavior (Abraham & Sheeran, 2005; Rosenstock, 1974). HBM does not suggest 
strategies to change or predict health behavior but only describes tenants that could 
influence the health related action and/or behaviors (Abraham & Sheeran, 2005; Davey, 
2011). Other limitations concerning HBM exist. 
Limitations of the HBM include its explanatory focus and exclusion of 
environmental factors. HBM does not account for personality traits and habitual schemas 
(e.g., extraversion, agreeableness, neuroticism, openness, or conscientiousness; Abraham 
& Sheeran, 2005; Davey, 2011). Abraham and Sheeran (2005) cited that HBM fails to 
account for many environmental factors during personal decision-making. Other 
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researchers consider environmental factors while examining the barriers construct (Tuzcu 
& Bahar, 2015) or consider using them during future HBM-based framework studies 
(Coursaris et al., 2015).  
The strongest predictors of individuals’ health beliefs were perceived barriers and 
benefits as indicated by various scaled assessment measures (Jones, Smith, & Llewellyn, 
2014). Jones et al. (2015) found barriers to be the most powerful indicator. My research 
focused on the various HBM concepts related to the pain management and QOL of 
cancer patient participants, and these concepts were expanded in Chapter 2. Measuring 
QOL reliably can be a challenge because no universal instrument exists (Pelayo-Alvarez 
et al., 2013).  
Skevington, Lotfy, and O'Connell (2004) validated a QOL instrument and found it 
to be a reliable assessment tool for patients. The QOL instrument is based on a 5-point 
standard intensity scale broken down into four domains (i.e., physical health, 
psychological, social relations, and environment; Skevington et al., 2004). I used this 
instrument during my dissertation research. Because cancer patients suffer multiple 
physical and psychological symptoms that relate to QOL, researchers can use descriptive 
statistics on quantitative data derived from QOL instruments (Barre, Padmaja, Saxena, & 
Rana, 2015). Josyula and Lyle (2013) used the HBM construct and converted survey data 
into continuous variables and multiple methods including analysis of variance (ANOVA) 
in their evaluation. 
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Nature of the Study 
The quantitative, nonexperimental research design included causal-comparative 
design, descriptive statistics, and cross-sectional survey data. Causal–comparative 
research does not seek cause and effect relationships because the data are collected 
through environmental course and not experimental design (Field, 2013). This approach 
provided the method to assess the difference between participant dependent variable (i.e., 
QOL) and pain management choice and gender. The research variables, as related to the 
specific participants, were analyzed using ANOVA and inferential statistics (Creswell, 
2009). Data were gathered at a specific time rather than over multiple time periods to 
reduce the effects that time might have on QOL (Creswell, 2009; Field, 2013).   
The design was essentially correlational because an experimental design was not 
used. According to Ravid (2011), correlational designs measure the relationship between 
variables; however, a correlational design does not support causal direction in variable 
relationships and many variables are often not controlled (Field, 2013). Further, survey 
data in social science research frequently uses cross-sectional design (Creswell, 2009; 
Frankfort-Nachmias & Nachmias, 2015). Therefore, instead of focusing on cause and 
effect, the study used descriptive, co-occurring proximal measurements to reveal the 
categorized outcomes of participants (Field, 2013).  
Concerning measurement of the dependent variable, QOL, an existing validated 
and reliable instrument (i.e. WHOQOL–BREF) was used. The WHOQOL-BREF survey 
(See Appendix A) is a shortened version (i.e., 26-questions) of the original WHOQOL-
100 (i.e., 100-questions) survey and was used in accordance with WHOQOL Group 
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standard procedures (Bonomi, Patrick, Bushnell, & Martin, 2000; Skevington et al., 
2004; WHOQOL Group, 1996). Because web-based collection was preferred, the paper 
version of the WHOQOL-BREF was converted to an Internet version to facilitate 
administration, data collection, and analysis. The WHO approved use of the WHOQOL-
BREF for my dissertation research (See Appendix B). Data collection was accomplished 
with this valid, reliable, and usable instrument (Skevington et al., 2004). The information 
gathered was treated as sensitive, and appropriate data security procedures were followed 
(e.g., data files were password protected; research computers were password protected 
and in secured locations; and SurveyMonkey used secure data protection technology; 
SurveyMonkey, 2016a).  
Definitions 
For purposes of this study, the following terms were defined: 
Quality of Life: Given the perception of culture, values, goals, expectations, 
standards, and concerns, a broad concept incorporating individuals’ “physical health, 
psychological state, level of independence, social relationships, personal beliefs and their 
relationship to salient features of their environment” (WHO, 1997b, p. 1). 
Cancer pain management therapy: Treatments to relieve pain in cancer patients 
that may be caused by the cancer itself, cancer related issues (e.g., constipation, muscle 
spasm, bedsores), or concurrent processes (e.g., osteoarthritis; WHO, 1996).  
Traditional prescription based therapy [e.g., pharmaceuticals]: Various opioid 
treatments; three-step analgesic protocol incorporates opioids for mild to moderate (i.e., 
Step 2) and moderate to severe (i.e., Step 3) cancer pain management (WHO, 1996). 
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Non-traditional based therapy [i.e., cannabis]: Medical marijuana or cannabis; 
outside of standard medical approaches through acceptance of alternative medical 
treatments (e.g., many U.S. states have accepted marijuana as a nontraditional medical 
treatment for pain; Witte, 2013). 
Combined traditional and non-traditional therapy: Use of both types of 
treatments for cancer pain management. 
Gender: Either male or female from the participant’s perspective (Kuper, 
Nussbaum, & Mustanski, 2012). 
Assumptions 
The positivist perspective was taken over the antipositivist perspective. The 
relationship between pain management and QOL was assumed to be objective and 
externally observable vice subjective (Jean-Lee, 1992). Researchers using a positivistic 
approach attempt to study parts of the whole situation by uncovering causal relationships 
to understand the world (Jean-Lee, 1992). The researcher using the antipositivist 
perspective examines the complexity of social reality by “being involved in these 
realities” (Doğan, 2013, p. 248). Positivist researchers provide unbiased reports of 
empirical findings and descriptions of the observed reality (Wicks & Freeman, 1998). My 
research took the positivist perspective through survey methodology, data collection, and 
analysis to reveal the relationships between relevant variables. 
Because pain is one of the biggest indicators of cancer patient QOL, it is assumed 
the WHOQOL-BREF survey captures relevant HBM constructs relative to pain 
management choice. Pain management is an essential determinant of patient QOL 
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(Perlman et al., 2013). Thus, the four domains (i.e., physical health, psychological, social 
relations, and environment) captured in the WHOQOL-BREF represented the HBM 
constructs examined (Skevington et al., 2004).  
An anonymous and voluntary participation protocol was used via a computer-
administered survey tool (i.e., via SurveyMonkey), which increased the probability of 
collecting honest responses (Lucas, Gratch, King, & Morency, 2014). The assumption of 
honesty in participant responses should reveal an objective reality. Also, the purposive 
sampling methodology was assumed to produce a relative representative sample. 
Although convenience sampling has limitations, it provided an opportunity to collect vital 
information from population participants that may replicate the whole research 
population. 
Scope and Delimitations 
The scope of the study was limited to cancer patients meeting specific inclusion 
criteria (i.e., diagnosed with cancer, at least 18 years of age, experienced chronic pain, 
and may or may not be undergoing treatment), which reduced the effect of confounding 
variables. Patient QOL is often correlated to pain endured, which corresponds to the pain 
management therapy used (Baek et al., 2013; Kwon et al., 2013; Wengström et al., 2014). 
The choice of cancer patient pain management therapies (i.e., opioids and cannabis) and 
QOL variables are related and may determine patient outcome and survival (Perlman et 
al., 2013; Shneerson et al., 2013). Further, a quantitative approach using a validated, 
reliable, and usable instrument helped reduce the effect of researcher bias. This 
15 
 
instrument ensured the effect being measured, QOL, was accurately reflected 
(Skevington et al., 2004). 
Every survey method has advantages and disadvantages, and online surveys are 
not excluded. Online surveys have a limited sampling frame (i.e., only 75% of the 
population has computer access) and racial disparity via this access exists (Rudestam & 
Newton, 2015). Although the personal interview method has high response rates (i.e., 
unless potential participants are unwilling), the cost of personal interviews due to the 
geographic separation of the target population and the personal nature of some survey 
questions (i.e., asked in an open, nonprivate setting) are both prohibitive factors 
(Rudestam & Newton, 2015). Both active and passive recruitment strategies were used in 
targeted areas to address the potential cost and response problems (Fleming et al., 2015). 
Specifically, distribution of recruitment flyers in participating organizations in 
combination with the purposive sampling technique helped obtain a sample that 
represents the specified cancer patient population.  
Limitations 
Potential weaknesses of the study include sampling technique, inferential 
statistics, and type of statistical analysis used. Because a purposive sampling 
methodology was used, generalization to the greater population may be limited 
(Frankfort-Nachmias & Nachmias, 2015). However, it is assumed that the targeted 
sample will be a representative sample of the population under study. Additionally, 
because inferential statistics was used to draw conclusions, the possibility of committing 
a Type I error exists; that is, where a true null hypothesis is incorrectly rejected 
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(Frankfort-Nachmias & Nachmias, 2015). However, to mitigate this concern, the 
confidence level to determine acceptance of the null hypothesis was set at .05. This 
means that the probability of error will be less than 5%.  
Comparative designs naturally limit generalizability given the nature of the 
variables (Tabachnick & Fidell, 2014). The dependent and independent variables were 
assigned by environmental relationship not experimentation. The large population base 
limited use of a true experimental methodology using random assignment.  
Significance 
Determining relationships between pain management methods and cancer 
patients’ QOL may help to enhance lives and contribute to positive social change. The 
number of annual cancer cases worldwide will reach over 20 million in the next 15 years, 
and pain management and QOL for cancer patients are primary concerns to health 
providers and affected patients (Kwon et al., 2013; Pelayo-Alvarez et al., 2013; WHO, 
2015). New medical therapies hold the potential to create positive social change if they 
are found to provide significant benefit over current therapies (Benton, González-Jurado, 
Beneit-Montesinos, & Fernández, 2013). Pain management alternatives with less side 
effects, morbidity, or related mortality that provide patients equal or greater QOL could 
provide positive social value. 
Overall, opioid related abuse, morbidity, and mortality have reached epidemic 
proportions in society (CDC, 2012, 2016; Garcia, 2013; Rowe & Caprio, 2013). Political 
obstacles and corporate influences (e.g., pharmaceutical industry) have created barriers 
for researchers studying cannabis (Bostwick, 2012; Cohen, 2009a, 2009b, 2010). These 
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researchers have been excluded from participating in established drug testing protocols 
and processes (Bostwick, 2012; Cohen, 2009a, 2009b, 2010). As researchers examine 
evidence concerning pain management options, benefits, barriers, cues to action, and self-
efficacy could be affected. The potential effects of medical interventions on 
psychological factors, such as QOL, have been inadequately studied, and assessment of 
cancer patients’ QOL is a neglected research area (Barre et al., 2015). 
Findings from my study could provide medical practitioners greater 
understanding concerning how pain management preference affects cancer patients’ QOL 
and contribute to positive social change. Effective pain management is an essential 
determinant of patient QOL, outcome, and survival (Perlman et al., 2013). Many cancer 
patients suffer pain related symptoms and problems and these health related factors may 
correspond to their QOL (Shneerson et al., 2013). Cancer patients experienced 
significantly lower QOL with higher levels of pain; despite use of strong opioids, many 
cancer patients regularly encountered severe pain (Zoëga et al., 2013). 
Because over 80% of cancer patients require opioids for pain management and 
patients are often undertreated for pain (Nersesyan & Slavin, 2007; Tanco, Bruera, & 
Bruera, 2014), individual choice of opioid use needs to be more personalized (Tanco et 
al., 2014). Enhancement of available pain management mechanisms of action that reduce 
opioid side effects and may improve patient QOL could provide significant benefit to 
society. Exploration into the under treatment of cancer pain is a necessity because 
improving cancer patient QOL is an important goal of health care (Zoëga et al., 2013).  
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The long-term effects of opioid use are mostly negative because only the minority 
of patients experience benefits (Becker, Fiellin, Black, & Kostovich, 2016). The negative 
consequences of long-term opioid use include safety issues (e.g., mild to severe 
toxicities), overdose, and death (Becker et al., 2016). The adverse effects of opioid use 
make it a poor long-term option (Hayes & Brown, 2014). In the majority of cases 
concerning opioid treatments, patients are either being undertreated and experience 
constant pain or over treated and experience various levels of harmful toxicity. 
Determining acceptable treatment alternatives to help balance these extreme situations 
could lead to policy changes and treatment options that could contribute to positive social 
change.  
Despite yielding benefits to patient QOL, very few nontraditional or traditional 
pain treatments are without complications and side effects. Cannabis use for chronic pain 
has shown increased risk of nonserious adverse events (e.g., most common were nausea, 
dizziness, drowsiness, headache, and nasopharyngitis) but no difference in risk of serious 
adverse events in a 1-year control group study were indicated (Ware et al., 2015). 
Further, long-term side effects of cannabis medical use have yet to be fully studied 
(Haroutounian et al., 2016; Ware, et al., 2015). Although opioids have many adverse side 
effects and addictive potential, researchers recommend continued opioid therapy for 
chronic cancer pain in order to provide pain relief for patients (Nersesyan & Slavin, 
2007) and find high dose opioids safe and effective for terminal cancer patients (Baek et 
al., 2013). Because complementary and alternative treatments for opioid pain 
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management treatments exist and cannabis seems to have less long-term side effects, 
further research is warranted. 
Research into substituting cannabis for or adjutant with opioids in pain-related 
cases is justified for public health reasons due to cannabis being a potentially safer 
mechanism of action (Lucas et al., 2015). The United States is a prime area of concern 
because its population typically consumes 80% of the world’s opioid supply while having 
less than 5% of the global population (Manchikanti, Fellows, & Ailinani, 2010). Between 
1999 and 2010, U.S. states with medical marijuana legislation had nearly a 25% lower 
mean annual rate of opioid overdose and mortality than states without such laws 
(Bachhuber, Saloner, Cunningham, & Barry, 2014). Potentially reducing the toxic effect 
of opioids on cancer patients should be a treatment consideration. A single focused 
strategy to decrease cancer patient pain without consideration of these toxic and 
potentially deadly side effects seems counterintuitive to overall patient QOL. Further, my 
findings may help advance the in-depth understanding about how gender affects the 
relationship between pain management preference and QOL.  
Summary 
Pain management for cancer patients is inadequate and additional research and 
treatments are needed to improve patient QOL (Zoëga et al., 2013). In many U.S. states 
and areas of the world, opioids are the primary, legal pharmacological option for 
relieving cancer pain. Opioids are the primary pain management therapy for cancer 
patients (Nersesyan & Slavin, 2007; WHO, 1996). Even with strong doses of opioids, 
many cancer patients are still undertreated and encounter severe pain, which impacts their 
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QOL (Nerseyan & Slavin, 2007; Tanco et al., 2014; Zoëga et al., 2013). According to 
Nersesyan and Slavin (2007), more than 50% of cancer patients are insufficiently treated 
for and about 25% die in pain. Long-term opioid use is also associated with many 
negative side effects, which can decrease patient QOL (Berland & Rodgers, 2012; Hayes 
& Brown, 2014).  
Opportunity exists to enhance pain management options for cancer patients in 
order to reduce opioid side effects, increase pain treatment effectiveness, and improve 
patient QOL. Haroutounian et al. (2016) suggested that cannabis therapy for patients 
suffering chronic pain resulted in decreased opioid use while improving patient pain and 
QOL measures over the long-term. Understanding the relationship between cannabis 
and/or opioid use for cancer patient pain management and their QOL outcome could help 
further the existing body of knowledge. 
I introduced the problem and study in Chapter 1 and provided background, 
purpose, theoretical base, terms, assumptions, limitations, and significance to support the 
project. Chapter 2 will include a review of current literature and studies related to 
cannabis, opioids, pain management, and QOL. 
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Chapter 2: Literature Review 
Introduction 
The QOL of patients and their pain management treatment are often correlated, 
and patients worldwide are being treated for pain ineffectively (Baek et al., 2013; Kwon 
et al., 2013; Wengström et al., 2014). Opioids are the most commonly used substance to 
ease cancer patients’ mild to severe pain (WHO, 1996). The majority (i.e., 70-80%) of 
cancer patients with advanced disease suffer moderate to severe pain but many do not 
receive appropriate pain relief (Caraceni et al., 2012). For outpatient cancer related pain 
management, opioids are the primary and gold standard treatment (Baek et al., 2013; 
Whistler, 2012). Chronic opioid users face dependence and many associated side effects 
(Whistler, 2012), including lower patient QOL (Berland & Rodgers, 2012; Cobaugh et 
al., 2014). Over the last 15 years, opioid related sales and deaths have quadrupled (CDC, 
2016).  
Patient outcomes rely on pain management treatments because unrelieved pain 
significantly comprised QOL and affected cancer patient survival (Kahan, 2014; Perlman 
et al., 2013; Shneerson et al., 2013). The purpose of the causal comparative research was 
to determine the effects different types of cancer pain management treatments may have 
on the QOL of cancer patients. Pain management therapies defined by traditional (i.e., 
opioids), nontraditional (i.e., marijuana), and combined nontraditional and traditional 
were examined. Although 28 states, the District of Columbia, Puerto Rico, and Guam 
have medical marijuana programs (National Conference of State Legislators, 2016), 
many cancer patients do not have legal access to these treatment options (Rowe & 
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Caprio, 2013). Understanding the relationship between marijuana and opioid use for 
cancer patients and their related QOL provides opportunity to reduce side effects, 
increase pain treatment effectiveness, and improve patient QOL.  
In this chapter, I review current research and literature related to pain, cancer, 
opioids, marijuana, gender, and QOL. Key areas include the literature search strategy, 
theoretical foundation review, and review of key variables and concepts. 
Literature Search Strategy 
Research articles were found through Walden University databases including 
EBSCOhost, ProQuest, MEDLINE, PubMed, CINAHL Plus, ScienceDirect, and Sage; 
Google Scholar, American Medical Directors Association, and Research Gate were also 
used. I included peer-reviewed literature since 2010 and prior seminal literature identified 
by using keywords pain, pain management, cancer, opioid, cannabis, marijuana, gender, 
quality of life, health belief model, and theoretical framework. 
Employment of Health Belief Model 
Although the HBM was originally constructed to analyze preventative health 
behaviors, it has been used for other health related contexts (Abraham & Sheeran, 2005; 
Beehler et al., 2014). Badr et al. (2013) examined childhood cancer survivors and 
associated lifestyle behaviors and intervention preferences with specific QOL 
determinants. Lim, Gonzalez, Wang-Letzkus, and Ashing-Giw (2009) studied the 
relationship between health behaviors and QOL determinants from the perspective of 
various social and cultural factors using HBM. Park, Clement, Hooyman, Cavalie, and 
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Ouslander (2015) used the HBM construct as a foundation to evaluate various 
nonpharmacological pain management treatment options for chronic pain suffers. 
Expanding upon these previous QOL and pain management related studies, my 
research used HBM to explore whether there was a relationship between pain 
management treatment therapy and personal perceptions of QOL. HBM helps explain the 
relationship between an individual’s beliefs, including perceived benefits, perceived 
barriers, perceived severity, perceived susceptibility, self-efficacy, and cues to action, and 
their influence on healthcare related behaviors (Rosenstock, 1974; Rosenstock et al., 
1988). The developers of HBM primarily focused on the present beliefs of the perceiver 
and the perceiver’s physical environment only to the extent of how it affected these 
beliefs and impending behavior (Rosenstock, 1974). Although HBM has been used in 
many health behavior related studies, the specific strength of relationships, influence, and 
interaction between all six constructs is not known (Jones et al., 2015).  
Previous studies have discovered various strengths, limitations, and interactions 
for the constructs that inspire use of HBM. The perceived benefits criteria are often 
subjective and not always based upon objective facts (Coursaris et al., 2015). While 
perceived benefit outcomes included increased self-confidence, social support, and 
mental focus, perceived barriers that hindered success included lack of internal 
motivation, external social support, and options and time (Das & Evans, 2014). Park et al. 
(2015) determined that the strongest predictor of nonpharmacological pain treatment was 
perceived severity while perceived barriers was the weakest. Janz and Becker (1984) and 
Jones et al. (2015) found perceived barriers to be the most powerful overall indicator.  
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The perceived constructs have many influences. Self-efficacy criteria are not 
always negative because it also represents positive factors that help an individual obtain 
the desired health goal or outcome (Coursaris et al., 2015). The perceived barriers and 
self-efficacy criteria often relate to physical and psychological factors creating avoidance 
mechanisms to obtain the health related behavior (Rosenstock et al., 1988). HBM’s self-
efficacy and cues to action components open up behavioral components of individuals to 
be analyzed in depth (Skinner, Tiro, & Champion, 2015).  
Cues to action for a patient can be either internally (e.g., mental or physical state 
of being) or externally (e.g., reminder trigger or message) driven (Coursaris et al., 2015). 
These cues can provide the impetus to act when the other factors were insufficient to tip 
the balance (Rosenstock, 1974). Positive factors of confidence, support, and knowledge 
can counter negative feelings of depression, low self-esteem, and distress to help patients 
adapt to their changing circumstances and environment (Coursaris et al., 2015). 
Measuring the effects of cues to trigger action can be difficult (Rosenstock, 1974). 
Another complex construct in the HBM is self-efficacy. 
Self-efficacy toward an outcome accomplishment often varies on perceptions and 
expectations of effort required (Broussard & Weber-Breaux, 1994). Positive or negative 
self-efficacy often determines how well an individual is able to handle both expected and 
unexpected events and circumstances (Broussard & Weber-Breaux, 1994). Internal and 
external lived, learned, and persuasive forces influence both the level and direction of 
self-efficacy (Broussard & Weber-Breaux, 1994). While self-efficacy is included as a 
separate element in HBM, it can influence the other constructs and the overall perception 
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and action taken (Rosenstock et al., 1988). Despite the advantages of incorporating self-
efficacy and cues to action constructs into a research construct, most research focuses on 
one or more of the four other criteria (Jones et al., 2015). 
HBM and Quality of Life 
Researchers found that QOL consideration of individuals encompassed both 
mental and social health-related issues (Das & Evans, 2014). Scales measuring perceived 
barriers, perceived benefits, and self-efficacy were found to be both valid and reliable 
when assessing cancer screening health beliefs for women (Anagnostopoulos, 
Dimitrakaki, Niakas, & Tountas, 2013). Badr et al. (2013) examined the association 
between childhood cancer survivors’ diet and exercise behaviors and their QOL. Badr et 
al. (2013) concluded that barriers to reducing risk, increasing healthy lifestyles, and 
improving cancer patient QOL need further research.  
The overall premise of HBM rests upon individuals taking health-related actions 
in order to avoid negative health conditions (Ghaffari, Tavassoli, Esmaillzadeh, & 
Hassanzadeh, 2012). Individuals take and avoid actions and activities based upon a 
balance between perceived positive and negative forces impacting their life space 
(Rosenstock, 1974). Beehler et al. (2014) discovered six factors related to positive or 
negative influences toward achievement of a health change behavior in cancer patients 
(i.e., environmental, health service delivery, health-related, attitude, self-efficacy, and 
motivation). Finding one appropriate measurement to collect and evaluate all of these 
health change factors remains a challenge (Beehler et al., 2014). These previous factors 
relate closely to those measured by the WHOQOL-BREF survey.  
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This survey is broad and complex capturing elements of physical, psychological, 
independence, social relationships, personal beliefs, and environment related to the health 
of an individual (WHO, 1997b). The influence of one factor (e.g., social support) to 
different constructs of the HBM (e.g., perceived benefits and barriers) seems to indicate 
the possible use of an overall assessment of a factor (e.g., QOL measure based upon 
multiple influences or domains) to represent a construct of the various HBM components. 
The WHOQOL-BREF captures the positive and negative aspects of a participant’s life 
and is one of the leading generalized QOL instruments (Skevington et al., 2004). 
Operationalizing the Framework 
The theoretical components of HBM are based upon psychological and behavioral 
factors influencing individuals’ pursuit of a health outcome and estimate of actions to 
achieve the goal (Janz & Becker, 1984). HBM helps researchers analyze behavioral 
change as the balance between perceived incentives, threats, benefits, costs, and 
competency of taking action to change (Rosenstock et al., 1988). Conceptualization of 
HBM incorporates behavior to achieve the health-related end state and perception of the 
effectiveness of these actions or inaction (Janz & Becker, 1984). Most researchers using 
the HBM construct have developed new ways to operationalize their specific variables 
(Janz & Becker, 1984).  
Self-evaluation surveys, including life satisfaction criteria, are considered valid 
instruments to evaluate health status and have shown to have better predictive properties 
than many objective measures (Idler & Benyamini, 1997). Aggarwal et al. (2013) used 
QOL surveys to evaluate the effectiveness of medical marijuana treatments. Park et al. 
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(2015) used a modified HBM structure to determine the influence of individual health 
beliefs on pain management choice. Self-evaluative HBM structured surveys have been 
used to help capture the complexities concerning patient QOL and pain management 
decisions. 
Social and environmental factors of HBM often play an important part in 
decision-making and QOL for individuals. The beliefs of individuals, influenced by 
social and environmental pressures, concerning the “availability and effectiveness of 
various courses of action, and not the objective facts about the effectiveness of action” 
determine the specific course taken (Rosenstock, 1974, p. 331). Lim et al. (2009) 
examined the relationship of cultural health beliefs on health behaviors in order to affect 
participant QOL. Patient QOL is multifaceted. 
According to Baek et al. (2013), “one of the purposes of pain control for cancer 
patients is to improve QOL” and QOL should be used in the assessment of pain control 
(p. 1870). The HBM construct helped operationalize scaled values representing chronic 
pain with associated nonpharmacological pain therapies (Park et al., 2015). Bauml et al. 
(2015) found that the attitudes and beliefs of cancer patients were the most important 
factor regarding the use of CAM and integrative treatments. HBM has been used to 
evaluate various pain management treatments.  
Researchers synthesized studies and determined that the majority (i.e., 50%–91%) 
of cancer patients adhered to prescribed opioid medication recommendations but others 
(i.e., 22%–27%) used opioids as needed (Butow & Sharpe, 2013). Although 
nonadherence to prescribed pain treatments is common, self-managed adherence typically 
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is positively associated with perceived benefits (Butow & Sharpe, 2013). Carter et al. 
(2015) identified various barriers related to medical practitioners including political, 
educational, training, and communication factors affecting prescribed pain management 
treatments. There are concerns with the current pain management approach (e.g., patient 
perception of intervention and patient-medical provider communication problems; Butow 
& Sharpe, 2013). Pain endured and corresponding pain management treatments are often 
correlated to the QOL of patients (Baek et al., 2013; Kwon et al., 2013; Wengström et al., 
2014). 
Employing the WHOQOL-BREF 
The WHO defines and measures health from the perspective of QOL, which 
includes physical, mental, social, and disease perspectives (WHO, 1997b). These QOL 
assessments and measures include self-perceptions of life circumstances including 
culture, social relationships, beliefs, values, independence, expectations, goals, standards, 
and concerns (WHO, 1997b). The WHOQOL-BREF focuses and derives values 
representative of individuals’ perception of well-being, general health belief, and QOL 
(WHO, 1997b). The WHOQOL-BREF has been tested for validity and reliability across 
different populations and countries, has been used in health research, and can help to 
evaluate various treatments (WHO, 1997b). The WHOQOL-BREF assesses four 
domains: physical, psychological, social relationships, and environment. 
The pain cancer patients experience is based on many different domains (i.e., 
physical, psychological, social, cultural, self-perception [e.g., senses, cognition, and 
behavior]; Dalal, Tanco, & Bruera, 2013). Based upon all of these factors, cancer patients 
29 
 
choose the most appropriate pain management therapy (Dalal et al., 2013). The QOL of 
patients can be assessed and measured through self-perceptions of life circumstances 
including physical, psychological, social relationships, and environment (WHO, 1997b). 
A valid, reliable, and precise health-related QOL measures the effects of emotional, 
physical, social, and lifestyle issues and can evaluate whether treatments lead to a life 
worth living (Bowling, 2014). These factors create a link and opportunity to assess the 
relationship between the QOL of patients and their respective pain management therapy. 
Limitations 
There are several limitations to this framework. Although researchers have 
consistently used the flexibility of the HBM, this practice has led to a lack of 
standardization in interpreting results (Janz & Becker, 1984). Badr et al. (2013) did not 
assess treatment or cancer type into their QOL study, which may limit the impact of 
various cancer types and treatment options causing a differential in participant QOL. This 
study used a comprehensive, summary measure for HBM and did not evaluate the 
specific type or methodology of cannabis or opioid used in pain management.  
Opioid and cannabis use for pain management offers a complex array of choices. 
There are multiple clinical guidelines concerning the use of opioids for pain relief 
(Caraceni et al., 2012). There are hundreds of different cannabis strains and many 
different methods of consumption or use (e.g., smoking, vaporizing, oil, edible, and 
topical; Kral et al., 2015). Given all of these possible variations, the assumptions were 
opioid and cannabis users had experimented with many of the possible types, strains, and 
methods available and had determined the options that best met their situation. The 
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personal preferences of cancer patients should be a vital factor in their own pain 
management therapies (van den Beuken-van Everdingen et al., 2016). 
Cost and legality was also not factored into the analysis. Two barriers to cannabis 
use include affordability and fear because prescription medications are typically 
subsidized in most medical insurance programs and cannabis is not widely accepted 
legally at various governmental levels (Lucas et al., 2015). Without federally approved 
synthetic cannabis medications for pain, U.S. patients must self-fund cannabis-related 
products through legal state controlled dispensaries or illegally through other suppliers 
(Boehnke, Litinas, & Clauw, 2016). 
The current Schedule I status of cannabis has limited past and limits future 
research (Savage et al., 2016). Concerning cannabis, scientific evidence and political 
ideology often collide when efficacy, safety, individual choice, and public health are 
debated (Savage et al., 2016). Researchers have been affected by strict government 
control limiting funding, restricting cannabis supplies and types, and risks of criminal 
prosecution (Aggarwal, 2013; Savage et al., 2016). Although some medical associations 
and groups (e.g., Institute of Medicine [IOM], American Medical Association [AMA], 
and American College of Physicians [ACP]) have supported reclassification to enhance 
future studies, the Schedule I status remains (Aggarwal, 2013; Cohen 2009a, 2009b, 
2010; DEA Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 2016). 
Specific dosing and recommendations concerning cannabis treatments are challenging 
because scientific studies concerning product variability, method of administration, 
effects, and side effects are lacking (Savage et al., 2016). 
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Traditional Pain Management and QOL  
Cancer Patient 
There is a relationship between pain management treatments of cancer patients 
and their perceptions and experiences on many different levels (i.e., physical, 
psychological, social, and cultural; Dalal et al., 2013). Chronic pain is often associated 
with physical, psychological, and social symptoms and maladies (Park et al., 2015). After 
a systematic review of 52 articles, researchers determined that many cancer patients 
commonly experience pain (i.e., cured patients [33%], in treatment [59%], and advanced-
stage [64%]; van den Beuken-van Everdingen et al., 2016). Management of these chronic 
pain related problems are often treated pharmacologically (Park et al., 2015). According 
to Baek et al. (2013), for terminal cancer patients, high doses of opioids for palliative care 
were found to be both safe and efficient. Dalal et al. (2013) posit that cancer patients are 
inadequately treated for pain and more than 70% of advanced cancer patients suffer 
significant pain.  
Cancer pain management is complex and subjective because treatments are most 
effective when individual perceptions and circumstances are involved in the process 
(Dalal et al., 2013). Chronic cancer pain can lead to functional, emotional, social, and 
spiritual problems for patients (van den Beuken-van Everdingen et al., 2016). Chronic 
pain can significantly affect cancer patient QOL for years even after treatments stop 
(Paice et al., 2016). Some cancer patients suffer rapid onset of intense pain lasting short 
durations (i.e., breakthrough cancer pain [BTCP]; Wengström et al., 2014). Uncontrolled 
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cancer pain can include neuropathic pain and BTCP and each patient manages these 
symptoms differently (Dalal et al., 2013).  
Breakthrough cancer pain (BTCP) sufferers typically have a poorer medical 
outcome and lower satisfaction with opioid treatments (Fortner, Okon, & Portenoy, 
2002). There is no standard-of-care treatment for BTCP, and patients experiencing BTCP 
suffer pain-related medical costs 5 times greater per year (i.e., $12,000 vice $2,400 for 
additional hospital, emergency department, and physician office costs) over non-BTCP 
suffers (Fortner et al. 2002; Haugen, Hjermstad, Hagen, Caraceni, Kaasa, & European 
Palliative Care Research Collaborative, 2010). Further, research is needed to evaluate 
patient QOL improvements with more effective analgesic treatments given the 
implications of BTCP on cancer patients (Fortner et al. 2002). 
The majority (i.e., 70-80%) of cancer patients with advanced disease suffer 
moderate to severe pain (Caraceni et al., 2012). For outpatient cancer related pain 
management, opioids are the primary and gold standard treatment (Baek et al., 2013; 
Whistler, 2012). Morphine has been the first choice for treating moderate to severe 
cancer pain for over two decades due to “familiarity, availability, and cost rather than 
proven superiority” (Caraceni et al., 2012, p. e59). Various oral opioids (i.e., morphine, 
oxycodone, and hydromorphone) provide similar weak results as the first choice for 
moderate to severe cancer pain (Caraceni et al., 2012). Although various traditional pain 
management treatments exist, many cancer patients do not get appropriate pain relief 
(Caraceni et al., 2012).  
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Opioids 
Opioids are the most abused drug for chronic pain management situations 
(Manchikanti et al., 2010). Opioid use over short- and long-terms has produced 
contradictory results. Over an 8-week study, opioid use reduced patient pain intensity 
significantly and improved QOL significantly (e.g., activity and sleeping; Baek et al., 
2013). Although 318 participants completed this 8-week study, 168 participants dropped 
out due to advanced disease progression or decreased QOL due to pain (Baek et al., 
2013). During other studies, opioid use increased hyperalgesia, stress, and depression 
(Berland & Rodgers, 2012; Cobaugh et al., 2014; Hayes & Brown, 2014), led to abuse, 
even for nonmedical users (Hayes & Brown, 2014), increased the need for health care, 
and lowered QOL (i.e., per a 10-year study; Berland & Rodgers, 2012; Jensen, Thomsen, 
& Højsted, 2006). 
Helping patients self-evaluate pain intensity and opioid side effects in order to 
reduce opioid harms is a good initiative (Becker et al., 2016). Chronic pain in cancer 
patients affects many QOL dimensions (e.g., physical, psychological, social, and cultural; 
Dalal et al., 2013). While the adverse effects of opioids (e.g., negative gastrointestinal, 
neurological, cognitive, and hyperalgesia) affect cancer patient QOL, individualized, 
carefully monitored, multidimensional, and rotational opioid treatment plans could 
increase patient analgesia (Dalal et al., 2013). Pain management plans without 
complementary or alternatives to opioids may not solve the need of increasing patient 
QOL while decreasing the consequences of opioid side effects.  
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Side effects. Various types of strong opioids (i.e., oxycodone, morphine, and 
hydromorphone) have indicated similar analgesia and side effects when used for cancer-
related pain (Baek et al., 2013). According to Dalal et al. (2013), opioids are a standard 
pain management treatment for cancer patients suffering moderate to severe pain because 
opioids do not have a pharmacology ceiling effect or direct physiological effect on the 
kidneys, liver, and coagulation. On the other hand, common opioid side effects include 
nausea, sedation, dizziness, euphoria, dysphoria, constipation, itching, pruritus, 
respiratory depression, sexual dysfunction, muscle rigidity, myoclonus, sleep disturbance, 
pyrexia, diminished psychomotor performance, and cognitive impairment (Manchikanti 
et al., 2010). Chronic use of opioids can cause hormonal effects, immune effects, abuse, 
addiction, hyperalgesia, increased medical costs, and decreased QOL (Manchikanti et al., 
2010). Opioid suppression of the immune system may also increase tumor progression 
(Paice et al., 2016). 
Despite billions of dollars spent and decades of research developing new opioid 
types, opioids still cause many side effects, tolerance, and dependence issues for society 
(Whistler, 2012). Opioid use, especially chronic use, can cause many side effects 
including respiratory depression (Aronoff, 2016; Baldini, et al., 2012; Perlman et al., 
2013; Whistler, 2012), constipation (i.e., 40-95% occurrence rate; Kumar et al., 2014; 
Perlman et al., 2013), bowel obstruction, nausea, vomiting, abdominal cramping, bloating 
(Baldini et al., 2012), cardiovascular effects, central nervous system effects (Cobaugh et 
al. 2014; Baldini et al., 2012), risk of addiction, edema, pruritus, urinary retention, 
hyperhidrosis (Aronoff, 2016), musculoskeletal system effects, endocrine system effects, 
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immune system effects, sleep disorder, dizziness, increased risk of falls and fractures, 
depression, and impaired QOL (Baldini et al., 2012). Further, chronic pain suffers (e.g., 
cancer patients) often face dependence and side effect escalation issues due to opioid-
related tolerance increases (Whistler, 2012).  
Epidemic. Since 2000 in the United States, drug overdose death rate doubled and 
opioid related overdose death rate tripled when compared to 2014 (Rudd et al., 2016). In 
2014, the United States had 78 people die from opioid overdose every day and 61% of all 
drug overdose deaths involved opioids (CDC, 2016; Rudd et al., 2016). Natural and 
semisynthetic opioids (e.g., opioid pain relievers, hydrocodone, and oxycodone) are 
related to more overdose deaths when compared to any other type of opioid (Rudd et al., 
2016). Since 1999 in the United States, opioid pain reliever prescriptions and deaths 
related to opioid prescriptions (e.g., hydrocodone, oxycodone, and methadone) have 
quadrupled (CDC, 2016).  
Opioid use, abuse, morbidity, and related mortality are at epidemic levels (CDC, 
2012, 2016; Garcia, 2013; Rowe & Caprio, 2013). The long-term effect of opioid use is 
mostly negative because only the minority of patients experience benefits (Becker et al., 
2016). Gastrointestinal related issues are the most frequently occurring opioid side effect 
(Aronoff, 2016). Other negative consequences of long-term opioid use include safety 
issues (e.g., mild to severe toxicities), overdose, and death (Becker et al., 2016). 
According to Hayes and Brown  (2014), the adverse effects of opioid use make it a poor 
long-term option. Before prescribing opioids for pain, medical professionals should 
balance its effectiveness versus side effects to the QOL of patients (Baldini et al., 2012).  
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In the United States, the overuse and abuse of opioids are multifaceted. Fischer, 
Keates, Bühringer, Reimer, and Rehm  (2014) identified the following factors: (a) 
extensive advertising promoting prescription medication use; (b) alternative and 
complementary medicines are given a minor role; (c) organization and delivery of 
medical care (i.e., time limitations, patient loads, and profit motives) incentivize 
prescription based interventions; and (d) patients are satisfied with prescription based 
medical care. Hursh, Galuska, Winger, and Woods (2005) analyzed several factors that 
may affect behavioral economic decisions in drug abuse situations including availability 
and cost of substitutes, governmental policy, and legal implications. Prescription opioid 
misuse was associated with increased adverse health consequences and behaviors 
(McCabe, West, & Boyd, 2013). Patients may continue opioids because their medical 
provider continues writing prescriptions not because the treatment is the most effective 
alternative (Becker et al., 2016). 
Developments. New cancer pain pharmacological developments are being 
researched and developed which are opioid related (Caraceni et al., 2012). Frequent 
switches between various opioids (i.e., morphine, hydromorphone, or fentanyl) to 
methadone to affect dose titration and lower side effects achieved some success (Caraceni 
et al., 2012). Alternative opioid administration methods (e.g., transdermal, subcutaneous, 
epidural, intravenous, intranasal, and rectal) are also being studied to control advanced 
cancer pain but no standards exist (Caraceni et al., 2012). There is low quality evidence 
concerning effective adjuvant pain treatments for cancer patients (van den Beuken-van 
Everdingen et al., 2016). The traditional opioid research and methodology focus has led 
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to opportunities to study other pain management treatments. Research into substituting 
cannabis for or adjutant with opioids in pain-related cases is justified for public health 
reasons due to cannabis being a potentially safer mechanism of action (Lucas et al., 
2015). 
Conflicting evidence exists concerning the effectiveness and safety of opioids. 
According to Manchikanti et al. (2010), opioids seem to be ineffective for long-term 
noncancer pain, but they conclude that opioids are safe and effective to treat cancer pain. 
According to Sullivan and Howe (2013), long-term opioid use causes more demonstrated 
harms to patients (i.e., clinically, socially, and culturally) then benefits. Zoëga et al. 
(2013) identified cancer patient pain as one of top (i.e., 90%) symptoms affecting QOL. 
 Opioids are also unreliable in predicting the response, tolerance, or superiority 
for each type on every patient (Prommer & Ficek, 2012). Due to insufficient evidence, 
cancer patients should help tailor their pain treatments with personal preferences (van den 
Beuken-van Everdingen et al., 2016). Even though many cancer patients used strong 
doses of opioids, the common occurrence of severe pain and decreased QOL indicated 
under treatment and presented an opportunity for future research (Zoëga et al., 2013). 
More pain management options and enhanced communication could provide 
solutions for cancer patients. The most effective cancer pain management decision-
making included collaboration between the medical providers and patients (Dalal et al., 
2013; Paice et al., 2016). Each cancer survivor has unique needs because no two cancers 
are the same and patients have different capabilities and experiences (Paice et al., 2016). 
Cancer patients need long-term pain management options that are individualized and 
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positively affect their QOL (Taverner, 2015). Opioids are a poor long-term option due to 
their adverse effects (Hayes & Brown, 2014). Due to the many problems, side effects, 
and complications associated with pharmacological treatments that decreased patient 
QOL, complementary and alternative treatments for pain management are needed (Park 
et al., 2015). 
Nontraditional Pain Management and QOL 
Complementary and Alternative Medicines 
The National Center for Complementary and Integrative Health (NCCIH; 2016a) 
defines nonmainstream practices as complementary when used together with 
conventional medicine and as alternative when used in place of conventional medicine. 
Integrative medicine is defined by incorporation of complementary practices into 
mainstream practices (NCCIH, 2016a). Health care providers often focus on quantity vice 
QOL for cancer patients and often CAM treatments are not adequately considered (Singh 
& Chaturvedi, 2015). The NCCIH (2016b) includes herbs as complementary treatments 
but they do not recognize cannabis as an herb.  
Complementary and alternative medicines (CAM) provide a challenge to 
practitioners providing conventional cancer treatment (Bar-Sela, Danos, Visel, Mashiach, 
& Mitnik, 2015). Worldwide, CAM is used by 30-40% of cancer patients yet many of 
these therapies do not have evidence-based assessments of interactions with conventional 
treatments (Bar-Sela et al., 2015). A majority of cancer patients (i.e., 83%) would 
incorporate CAM into cancer treatments to supplement care (e.g., help improve QOL and 
reduce pain) if they were part of normal protocols (Ben-Arye et al., 2014). Shneerson et 
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al. (2013), Bao et al. (2014), Ben-Arye et al. (2014), and Bar-Sela et al. (2015) explored 
CAM in cancer care and determined a relationship with expected and significant QOL 
improvement. Although all these researchers considered herbs in their studies, only Bao 
et al. (2014) included cannabis and found evidence of potential benefit for cancer pain. 
Further research concerning the efficacy and safety of CAM treatments are needed so 
medical providers can counsel patients appropriately concerning integrative cancer care 
options (Bauml et al., 2015). 
Cannabis 
Cannabis is an herb that is primarily combusted but it can be consumed in other 
ways (e.g., eating or drinking; Schauer, King, Bunnell, Promoff, & McAfee, 2016). 
Cannabis prescriptions remain relatively low because information on potential side 
effects and effects, insurance coverage, cost, and medical provider advocacy are lacking 
(Savage et al., 2016). Cannabis was used primarily for pain, sleep, and anxiety problems 
although further research and familiarity was needed to connect therapeutic use with risk 
and benefit perceptions of participants (Walsh et al., 2013). In a small, convenience, 
qualitative study, Peters (2013) found some participants used cannabis as an alternative 
or reduction agent for traditional opiate medicines. Although most participants viewed 
cannabis as a less effective analgesic than strong opioids, many preferred cannabis over 
opiates due to reduced adverse side effects and increased QOL (Peters, 2013).  
In other studies, cannabis has shown significant analgesic results, but the diversity 
in plant strain types and concentrations and lack of FDA guidance make specific efficacy 
and side effect predictions difficult (Savage et al., 2016). According to Hazekamp, Ware, 
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Muller-Vahl, Abrams, and Grotenhermen (2013), although participants scored herbal 
nonpharmaceutical cannabis more satisfactorily than pharmaceutical cannabis products, 
patients are different and must find the right dose and application method for their 
situations. Further, there is a need to compare cannabis with the traditional 
pharmaceutical treatments (Walsh et al., 2013). 
For chronic pain participants, medical cannabis use significantly decreased opioid 
use (i.e., by 64%), decreased side effects, and improved QOL (i.e., by 45%; Boehnke et 
al., 2016). Boehnke et al. (2016) opine the benefits of marijuana use may represent the 
synergistic effects between cannabis and opioids or the greater potential marijuana may 
hold over other classes of medications to reduce chronic pain. Degenhardt et al. (2015) 
found cannabis use in chronic noncancer pain patients reported greater pain relief with 
adjuvant opioid use vice opioids used without cannabis. Hoggart et al., (2015) found the 
benefits of using an adjutant THC/CBD spray for neuropathic pain seemed to outweigh 
the risks for many patients. Morley, Cao, and Shum (2016) consider cannabis use during 
palliative and end-of-life care to decrease pain and enhance QOL of patients. These 
identified relationships need further research (Boehnke et al., 2016; Haroutounian et al., 
2016). 
Side effects. Many studies have been conducted concerning the effects of 
marijuana and the results are mixed. Some studies indicated that marijuana might pose 
risks of addiction, adolescent brain development, mental illness, anxiety, life performance 
deficiencies, increased motor vehicle accidents, respiratory symptoms, and cancer (Hill, 
2015; Volkow, Baler, Compton, & Weiss, 2014). In a long-term neuropathic pain study 
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with a THC/CDB spray, 59% of participants experienced at least one mild or moderate 
adverse event (e.g., dizziness [19%] and nausea, dry mouth, taste issue, fatigue, and 
intoxication [all <10%] that was treatment related; Hoggart et al., 2015). Due to political 
and legal limitations set by Schedule I drug status, many marijuana researchers have been 
hampered or excluded from participating in established drug testing protocols and 
processes (Bostwick, 2012; Cohen, 2009a, 2009b, 2010). Given these negative finding, 
some researchers have discovered conflicting evidence and potential positive aspects of 
marijuana use. 
Cannabis use for chronic pain has shown increased risk of nonserious adverse 
events (e.g., nausea, dizziness, drowsiness, headache, and nasopharyngitis) but no 
difference in risk of serious adverse events were indicated (Ware et al., 2015). Although 
cannabis has been associated with various negative side effects (e.g., nausea, dizziness, 
headache, heart rate, auditory, verbal, visual, and memory), its use in chronic pain 
situations to potentially increase patient QOL while decreasing opioid use needs further 
study (Haroutounian et al., 2016). Further, long-term side effects of cannabis medical use 
have yet to be fully studied (Haroutounian et al., 2016; Ware et al., 2015).   
In 71% of 38 published randomized controlled studies, cannabinoid use was 
associated with nonserious side effects, good tolerance, and statistically significant pain 
relief (Aggarwal, 2013). Tripp et al. (2014) reported exploratory evidence that the 
majority of their chronic pelvic pain syndrome participants used cannabis and had 
improved pain, mood, muscle spasms, and sleep with no increase in side effects. Zaller et 
al. (2015) studied 200 medial cannabis users and found chronic pain management, 
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improved pain relief, and opioid alternative as the predominant reasons for cannabis use. 
In a short-term study, Ware et al. (2010) found herbal cannabis reduced the intensity of 
pain and improved sleep without significant side effects. In a 1-year study, Ware et al. 
(2015), found cannabis improved pain, function, and QOL of participants while an 
increased risk of mild to moderate nonserious adverse events was noted. 
Cannabis treatments have both health risks and benefits (Hill, 2015). Two-dozen 
high-quality studies indicated positive results in treating neuropathic pain, chronic pain, 
and spasticity due to multiple sclerosis using medical marijuana (Hill, 2015). In 38 
randomized controlled trials published between 1978 and 2010 that evaluated the pain-
relieving properties of cannabis, 27 (71%) concluded pain-relieving effects and 11 (29%) 
did not (Aggarwal, 2013). Nineteen cannabis treatment studies for chronic pain, between 
1975 and 2008, were examined and evidence of efficacy was determined (Martín-
Sánchez Furukawa, Taylor, & Martin, 2009). During the course of cannabis treatment for 
chronic pain, several significant side effects resulted (e.g., euphoria, blurred vision, 
confusion, speech disorder, muscle twitching, impaired memory, and numbness) which 
may offset the potential benefits of using cannabis (Martín-Sánchez et al., 2009). In a 
long-term study using a THC/CBD spray for cancer-related pain, the primary side effects 
included dry mouth, dizziness, nausea, vomiting, sleepiness, and confusion (Johnson et 
al., 2013). 
In 31 research studies (i.e., 23 randomized controlled trials and 8 observational 
studies) on cannabis-related medications, there was no evidence of a higher rate of 
serious side effects for participants when compared to control groups (Aggarwal, 2013). 
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The majority (i.e., 96.6%) of adverse side effects related to the cannabis-related 
medications were nonserious (Aggarwal, 2013). These nonserious side effects included 
dizziness (15.5%), drowsiness (8.2%), muscle spasm (6.3%), gastrointestinal problem 
(6.2%), pain (6.0%), dry mouth (5.2%), and bladder disorder (4.8%; Aggarwal, 2013). 
Although there was an increase in the risk of nonserious side effects in the cannabis-
related groups, these effects were modest and tolerated (Aggarwal, 2013). Wilsey et al. 
(2013) found psychoactive effects of vaporized cannabis treatments (i.e., low and 
medium strength THC) were minimal, reversible, and well tolerated. Other researchers 
suggested that marijuana use might result in alleviation of some clinical symptoms for 
bipolar patients without additional cognitive impairment (Sagar et al., 2016). Cohen, 
Heinz, Ilgen, and Bonn-Miller (2016) suggested that future pain management studies 
should compare the efficacy and side effects of cannabis to opioids. 
According to the IOM, negative effects of cannabis, except those associated with 
smoking, are within a normal range tolerated for similar medications (Joy, Watson, & 
Benson, 1999). Pletcher et al. (2012) found occasional use of smoked cannabis was not 
associated with adverse pulmonary function. Use of marijuana (i.e., up to 20 years for 
participants aged 18 to 38) was associated with periodontal disease but was not 
associated with lung, systemic inflammation, and metabolic health problems (Meier et 
al., 2016). Tobacco use within the same participant pool (i.e., 1,037 total participants 
from New Zealand South Island) was associated with worse lung, systemic inflammation, 
and metabolic health problems (Meier et al., 2016). The IOM recommended further 
research using cannabis and developing other safe and reliable delivery mechanisms 
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although for certain patients, such as terminally ill, the long-term risks of smoking were 
not a great concern (Joy et al., 1999). 
Barriers. According to Penington (2015), patients should be able to use cannabis 
to seek relief given proper medical recommendation and following state laws. Several 
barriers have prevented research and medical acceptance of marijuana. These barriers 
include the following: (a) political hesitancy and nonacceptance, (b) practitioner 
educational and training deficiencies, (c) patient-practitioner communication breakdown, 
and (d) practitioner concern over opioid abuse and hesitancy to advocate marijuana 
(Carter et al., 2015).  
There are only a few approved cannabinoid-related prescription medications on 
the market (i.e., dronabinol [Marinol®; synthetic THC], nabilone [Cesamet®; synthetic 
molecule similar to THC], and nabiximols [Sativex®; THC and CBD extract]; Savage et 
al., 2016). The small number of cannabis treatment options available are most likely due 
to the lack of clinical research, cost issues, inconsistent insurance coverage, little to no 
standardization or guidance in use, and medical professional reluctance to support 
(Savage et al., 2016). Medical professionals who have patients using cannabis for pain or 
other symptoms should educate themselves on existing cannabis research and monitor the 
side effects, symptoms, and impending effects on the QOL of their patients (Savage et al., 
2016).  
The controversy concerning cannabis use for chronic and cancer pain is 
multifaceted. In Canada, despite being a legal option, marijuana was often not prescribed 
for chronic noncancer pain due to the uncomfortableness of medical providers in using 
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cannabis as a pain management option (i.e., only 23% prescribed; St-Amant, Ware, 
Julien, & Lacasse, 2015). Opioids are one of the most commonly used medications for 
palliative pain but may be inappropriate for chronic noncancer pain because short-term 
vice long-term effectiveness and efficacy have been indicated (Manchikanti et al., 2010). 
Although concrete evidence concerning opioid safety and effectiveness in the treatment 
of chronic pain is inconclusive, opioids remain a reasonable and primary treatment option 
(Manchikanti et al., 2010). Ineffective long-term efficacy of opioids would seem to open 
up opportunities to find solutions for the long-term pain management care and QOL 
enhancement for both noncancer and cancer patients. 
Some medical professionals have prescribed cannabis for pain and other 
symptoms. Aggarwal et al. (2013) conducted research and determined that medical 
marijuana was prescribed for intractable pain for 25% of their participants while over 
25% of the participants listed reduction of five different types of pain (i.e., 
musculoskeletal [51.4%]; neurological [45.7%]; head, ears, eyes, nose, and throat 
[37.1%]; dermatological [31.4%]; and abdominal [25.7%]). Other symptoms found to be 
reduced or improved through use of medical marijuana which all improved QOL 
included the following: Reduced anxiety (71.4%), improved mood (68.6%), reduced 
nausea (65.7%), stimulated appetite (54.3%), reduced respiratory pain (20.0%), reduced 
genitourinary pain (17.1%), reduced chest pain (8.6%), and reduced breast pain (5.7%; 
Aggarwal et al., 2013). Researchers continue to examine the evidence concerning 
cannabis, opioids, and patient QOL. 
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Carter et al. (2015) presented evidence that marijuana could be a safer substitute 
or complementary treatment to address the growing medical concern over the opioid 
epidemic. Due to the mechanism of action of cannabis, it has no known lethal dose 
(Savage et al., 2016). Use of cannabis-based medicines to substitute or complement 
opiate-based medicines for pain could possibly save thousands of lives (Carter et al., 
2015). Cannabis could be used to reduce patient pain while reducing use of opioids (Kral 
et al., 2015). Concerning neuropathic pain, Collen (2012) opines cannabis should often be 
considered the first choice treatment option over opioids as an effective harm reduction 
strategy. The lethality problem of opioids combined with political and societal ideology 
against cannabis often trumps emerging scientific evidence and affects cannabis-based 
medicines from being prescribed for pain (Carter et al., 2015). Some researchers have 
indicated medical marijuana legal states have improved associations related to opioid 
mortality statistics.  
Legislation. States with medical marijuana laws have shown decreases in some 
opioid related mortality statistics. Researchers analyzed Fatality Analysis Reporting 
System (FARS) data (i.e., 1999–2013) from 18 states and found a significant association 
between U.S. states with marijuana laws and reductions in opioid related fatal driving 
incidents for 21-40 year-olds who died within 1 hour (Kim et al., 2016). Between 1999 
and 2010, U.S. states with medical marijuana laws had a 25% lower mean annual rate of 
opioid overdose and mortality than states without such laws (Bachhuber et al., 2014; 
Hayes & Brown, 2014). Researchers have speculated a general relationship between 
medical marijuana laws and opioid analgesic related overdose deaths that strengthened 
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over time: Through year 6 after law implementation, mortality rates decreased 
(Bachhuber et al., 2014). Finney, Humphreys, and Harries (2015) opine that general 
state-level data need refinement with individual level analysis concerning patients’ pain 
treatment of choice (e.g., marijuana, opioid) and other detailed information. Powell, 
Pacula, and Jacobson (2015) found consistent evidence that states with medical marijuana 
laws and provided sales through dispensaries had lower pain medicine addiction 
admissions and opioid overdose deaths. 
Concerning integrative cancer care options, increased research into the efficacy 
and safety of CAM treatments is needed (Bauml et al., 2015). Cannabis has shown 
significant analgesic results, but substance variations and lack of standardizations make 
efficacy and safety predictions difficult (Savage et al., 2016). During a 1-year study, 
Ware et al. (2015) found cannabis improved pain, function, and QOL of participants 
while an increased risk of mild to moderate nonserious adverse events was noted. There 
is a need to compare cannabis with the traditional pharmaceutical treatments (Walsh et 
al., 2013). Other researchers suggest future pain management studies should compare the 
efficacy and side effects of cannabis to opioids (Cohen et al., 2016). 
Opioid and Cannabis Use on QOL 
Researchers indicated chronic pain patients being treated for opioids encountered 
more use problems than those treated with medical marijuana (Feingold et al., 2016). 
Symptoms of high levels of pain may suggest the greater problematic use of opioids over 
cannabis, and opioid induced hyperalgesia may contribute to increased levels of 
perceived pain (Feingold et al., 2016). Between 2010 and 2013, Bradford and Bradford 
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(2016) found the use of prescription drugs for pain declined significantly (i.e., 1,826 daily 
doses per physician per year) for Medicare Part D enrollees in states where medical 
marijuana was a clinical alternative. Temple (2016) cited similarities between 
cannabinoid and opioid receptors in the nervous system that may explain preclinical data 
concerning the synergistic effect between the two substances.  
Currently, few studies have examined the efficacy of cannabis as an adjunct 
therapy in order to reduce opioid treatments (Meng et al., 2016). Zaller et al. (2015) 
found that 55.5% of their 200 participants indicated substituting cannabis for prescription 
medications, 85% of chronic pain suffers reported improved pain profile, and 91.5% 
reported fewer unwanted side effects with cannabis use over prescriptions. Meng et al. 
(2016) found adjunct cannabis treatment helped wean a patient with a 4-year, 
multifaceted chronic pain problem and recent postoperative pain from high opioid 
consumption and dependence. As a result, total opioid consumption was reduced from 30 
mg to 6 mg a day and opioid side effect reduction enabled the patient to resume work 
(Meng et al., 2016). More studies concerning opioids, cannabis, and the adjunct role of 
cannabis and opioids concerning noncancer pain are needed (Degenhardt et al., 2015; 
Meng et al., 2016). 
Narang et al. (2008) conducted phase 1 and 2 trials that compared chronic 
noncancer pain treatments (i.e., exclusive opioid therapy to opioid therapy with synthetic 
THC [i.e., dronabinol aka Marinol ®] added). The dronabinol/opiate therapy significantly 
increased QOL and decreased pain intensity compared to the opiate therapy without 
dronabinol (Narang et al., 2008). The dronabinol/opiate therapy produced mild to 
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moderate negative (e.g., dry mouth and drowsiness) and positive (e.g., sleep quality) side 
effects while participants were overall satisfied with the treatment (Narang et al., 2008). 
Dronabinol may be a useful adjuvant treatment with opioids for chronic pain patients 
(Narang et al., 2008). 
In a 5-week study, 263 advanced cancer participants, with previous poor opioid 
analgesic response, experienced significant decrease in average pain criteria with 
adjuvant use of low and medium doses of a THC/CDB oromucosal spray (i.e., Sativex®; 
(Portenoy et al., 2012). Johnson et al. (2013) indicated a reduction in pain levels in a 
small sample of advanced cancer patients over the long-term using level doses of a 
THC/CBD oromucosal spray. Pain of the terminal participant base (i.e., 43 in total) had 
not been fully relieved by use of strong opioids alone (Johnson et al., 2013). Participants 
also had improvements of sleep outcomes throughout the THC/CBD complementary 
treatment period without increases in safety concerns (Johnson et al., 2013). Paice et al. 
(2016) do not recommend cannabis as a first-line pain treatment for cancer survivors, but 
they suggest evidence warrants consideration of cannabis as an adjuvant treatment in 
accordance with state laws. 
There is evidence of successful adjuvant use of cannabis for pain in some 
research. Haroutounian et al. (2016) suggested that adjuvant cannabis therapy for 206 
participants suffering chronic pain (i.e., 93% noncancer related) resulted in significant 
decreased opioid use (i.e., 73 opioid using participants reduced by 44%) and improved 
patient pain, functional outcome, and QOL measures with low incidence of adverse 
effects over the long-term. Ware et al. (2010) reported cannabis improved participant 
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mood, pain, and sleep outcomes without significant side effects. The overall well being of 
patients was improved with cannabis when previous conventional pain management 
therapies had failed (Ware et al., 2010). 
Several studies have been conducted concerning advanced cancer pain, opioids, 
and adjuvant use of various cannabinoid oromucosal formulations (Johnson et al., 2013; 
Portenoy et al., 2012). A THC/CBD oromucosal spray (i.e., Sativex®) was investigated 
in both short- and long-term studies for both noncancer and cancer pain (Hoggart et al., 
2015; Johnson et al., 2013; Portenoy et al., 2012; Serpell et al., 2014). In a 15-week 
study, 173 treatment-resistant, randomized participants suffering peripheral neuropathic 
pain indicated improvements in pain and had significant improvements in sleep and QOL 
with adjunct use of the THC/CBD spray (Serpell et al., 2014). In a 38-week study, 
Hoggart et al. (2015) indicated a significant improvement in peripheral neuropathic pain 
for 234 participants using an adjunct THC/CBD spray while continuing traditional pain 
therapy. Researchers observed the neuropathic pain improvements throughout the 38-
week study period without tolerance issues while the majority of adverse events were 
mild or moderate (Hoggart et al., 2015). 
The substitution of cannabis for prescription drugs occurred in 80.3% of 
participants and the highest rated reason for conversion was pain-related conditions 
(Lucas et al., 2015). Cannabis has indicated lower dependence risk, fewer side effects, 
and no fatal dose possibility when compared with opioid medications (Lucas, 2012). For 
chronic pain participants, cannabis reset opiate analgesia, decreased opiate dosage, and 
reduced pain levels experienced (Lucas, 2012). Abrams, Couey, Shade, Kelly, and 
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Benowitz (2011) found pain treatments of cannabis used in conjunction with opioids 
significantly decreased pain without reducing plasma opioid levels. Wilsey et al. (2013) 
found vaporized cannabis (i.e., low and medium dose THC) may be an effective 
treatment for neuropathic pain disorders. In the first 3 months of a longitudinal, pilot 
study, Gruber et al. (2016) indicated no cognitive executive functioning deficits, some 
improved cognitive function, positive changes in QOL, and 42% decrease in opiate use 
among 24 regular, recreational marijuana users. Because evidence suggests cannabis 
could be a safer alternative to or complement with opioids, further research is warranted 
(Lucas, 2012; Lucas et al., 2015). 
There is an ethical mandate to relieve cancer patient pain (Sullivan & Howe, 
2013). Management of pain and improving cancer patient QOL is a main goal of cancer 
care (Zoëga et al., 2013). Adjuvant treatments to complement or replace opioid 
treatments to control pain and improve QOL during end of life care are a primary concern 
(Prommer & Ficek, 2012). According to Caraceni et al. (2012), over 70% of cancer 
patients with advanced disease suffer moderate to severe pain and many do not receive 
appropriate pain relief. Opioids are the traditional and gold standard treatment for cancer 
pain management (Baek et al., 2013; Whistler, 2012). Prommer and Fick (2012) included 
cannabis to the list of available adjuvant analgesics to complement opioids for end of life 
care. According to Abrams (2016), some terminal cancer patients have added cannabis to 
reduce high opioid-based therapies and increase communication with loved ones. If long-
term opioid treatments fail to improve patient pain, function, and QOL, then other 
methods must be pursued (Sullivan & Howe, 2013). 
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Patient Perspective Concerning Dosing 
Cannabis dosing mechanisms and strain types are two variables that need further 
research. There is a lack of data concerning various cannabis use mechanisms (e.g., 
smoked, ingested, vaporized; Bowles, O’Bryant, Camidge, & Jimeno, 2012; Schauer et 
al., 2016) and conventional versus unconventional pain medications concerning cancer-
related non-neuropathic or neuropathic pain (Bowles et al., 2012). Cannabis strains differ 
in potency of THC and CBD levels, so fine-tuning the right treatment for specific 
situations can be very individualized (Savage et al., 2016). High-THC cannabis strains 
were associated with physical and mental side effects while high-CBD strains had less 
mental side effects while associated with various types of pain relief (Savage et al., 
2016). Research concerning the amounts of THC and/or CBD to use for pain treatments 
is also needed. 
Johnson et al. (2013) indicated in a small sample that a cannabis extract of 1:1 
THC and CDB was more effective than an extract of THC alone in relieving long-term 
cancer patient pain. High CDB derivatives are often more effective than THC derivatives 
concerning analgesia (Abrams, 2016). Meng et al. (2016) found a medical cannabis user 
was able to adjust the strains used (i.e., various THC and CBD concentrations) for 
different purposes (e.g., nausea or analgesia). As clinical studies are conducted, the body 
of knowledge concerning various cannabis-related strains and products should become 
more refined and effective (Savage et al., 2016). 
Birdsall, Birdsall, and Tims (2016) cite the need for better quality control, 
efficacy testing, and regulation of cannabis because over 75% of states have laws 
53 
 
allowing full (i.e., THC and CBD) or partial (i.e., CBD only) medical use. There are 
many cannabis strains that are grown without regulatory compliance, and each strain may 
contain various potencies of cannabinoids (e.g., THC and CDB; Thomas & Pollard, 
2016). All the various cannabis strains fall into three different categories (i.e., sativa, 
indica, and hybrids; Cohen et al., 2016). Cohen et al. (2016) found chronic pain patients 
typically use indica strains over sativa and had less cannabis use problems than 
nonchronic pain users. Pearce, Mitsouras, and Irizarry (2014) observed a similar 
significant preference for indica strains among chronic pain sufferers. Chronic pain is a 
qualifying medical condition to use cannabis in medically legal states and patients seem 
likely to use most effective cannabis strain for their pain (Cohen et al., 2016). 
Although medical use of marijuana in low doses does not seem to cause harm, 
heavy use, especially when combined with tobacco, has indicated the potential for 
respiratory harm (Joshi, Joshi, & Bartter, 2014). Because cannabinoid receptors are not 
on the brain stem, cannabis side effects do not include respiratory depression leading to 
death, which is a classic and common side effect of opioid overdose (Lucas, 2012). 
Researchers determined no causal association between long-term marijuana use and 
development of head and neck cancer (de Carvalho et al., 2015). Other evidence suggests 
that marijuana may have efficacy in the treatment of other cancer side effects (e.g., 
nausea and appetite stimulation; Abrams, 2016) and cancer itself (Abrams, 2016; Joshi et 
al., 2014). Therefore, noncombustible forms of marijuana could be a perceived and 
potential societal benefit for cancer patients (Abrams, 2016; Joshi et al., 2014). 
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Sufficient evidence exists concerning the effectiveness of cannabis for pain to 
warrant further research of plant variety and administration choice on acute and chronic 
conditions (Zaller et al., 2015). Besides recent Sativex® studies, research using 
noncombustible forms of marijuana have been limited to some small-scaled studies. 
Martellucci et al. (2015) collected efficacy data on 18 cancer patients in Italy and found 
infusions of cannabis seemed to help control emesis and improve QOL but seemed 
insufficient at reducing pain.  
Similar to opiate use strategies for pain management, cannabis use offers many 
possibilities. Given medical provider guidance, the personal preferences of cancer 
patients should be a vital factor in determining the right pain management plan (van den 
Beuken-van Everdingen et al., 2016). There are many cannabis varieties and ways to 
intake the substance, so patients must find the right dose for their condition and 
circumstances (Hazekamp et al., 2013). According to Paice et al. (2016), each cancer 
survivor has unique needs because no two cancers are the same and patients have 
different capabilities and experiences. Even the gender of a patient may affect this 
individualized pain management plan. 
Gender and Pain Treatment 
The most commonly used illicit drug is marijuana (Manchikanti et al., 2010). 
Women seem to be using marijuana at an increasing rate and seem to indicate more 
addictive tendencies than men (e.g., higher abuse, dependence, relapse, and severe 
withdrawal symptoms; Craft et al., 2013). Evidence indicates that ovarian hormones alter 
the effects of cannabinoid sensitivity between post-adolescent gender participants (Craft 
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et al., 2013). Women were also found to use additional drugs to enhance the effect of 
opioids but less than 3% of participants stated use of marijuana (Back et al., 2009). Other 
studies indicate mixed results concerning use and abuse of both opioids and marijuana 
when gender is considered (Greenfield et al., 2010).  
Individuals often view the same barrier or benefit in different ways. Das and 
Evans (2014) discovered that gender consideration when examining the components of 
HBM could give researchers new intervention alternatives. Gender perspective 
identification and interpretation often provide an additional dimension to consider in 
some studies (Das & Evans, 2014). Pearce et al. (2014) expressed a need for researchers 
to compare the efficacy of various cannabis types by gender. 
Differences in gender provided a research opportunity because rates and effects of 
marijuana use have produced conflicting evidence for researchers. When gender and drug 
use were compared, males dominate illicit drug (i.e., 9.9% vs. 6.3%) and marijuana (i.e., 
7.9% vs. 4.4%) categories, while both genders had similar rates of psychotherapeutic 
drug (i.e., 2.6% vs. 2.4%) and pain reliever (i.e., 2.0% vs. 1.8%) use (Manchikanti et al., 
2010). Ryan-Ibarra et al. (2015) determined that men and woman in California used 
medical marijuana at a similar rate (i.e., 6% vs. 5%).  
Despite an apparent equal use of medical marijuana, research indicated that men 
and women do not respond equally to its effects (Craft et al., 2013). According to Cooper 
and Haney (2016), male cannabis smokers exhibited greater analgesia when compared to 
women cannabis smokers. Lenz et al. (2011) noted a hyperalgesia in similar testing 
methodology (i.e., cold-pressor test) using opioid medications although all participants 
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were male. These identified relationships concerning gender, pain sensitivity, and pain 
management treatments warrant further investigation (Cooper & Haney, 2016; Lenz et 
al., 2011). Although illicit and legal marijuana use may be an influencer affecting usage, 
for my study, gender was included as a modulating factor. 
Summary and Conclusions 
Both opioid and cannabis prescription and/or use for pain should focus on side 
effects, physical function, symptom management, possible addiction, and QOL of 
patients (Savage et al., 2016). Cannabis treatments have been modestly effective and safe 
treatments in chronic pain patients, but most studies have focused on noncancer pain vice 
cancer-related pain (Aggarwal, 2013). More high quality, large sample size, long-term 
exposure, and analgesic comparative assessments concerning pain relief and physical 
functioning are needed (Aggarwal, 2013; Degenhardt et al., 2015; Kahan, 2014).  
Cannabis may be an effective pain treatment to reduce opioid abuse and overdose 
(Boehnke et al., 2016). Because cannabinoid receptors are not on the brain stem, 
cannabinoid-based drugs may have an advantage over opioid-based drugs concerning 
overdose potential (Lucas, 2012). The growing rates of opiate addiction, abuse, and 
mortality are public health concerns with significant social costs (CDC, 2016; Lucas, 
2012; Rudd et al., 2016). Wilsey et al. (2013) demonstrated that low-dose (i.e., 1.29% 
THC), vaporized cannabis had a favorable risk-benefit ratio in the treatment of 
neuropathic pain in some patients. Future studies could examine cannabis concerning 
pain and side effects relief to better understand the analgesic effects and implications 
(Wilsey et al., 2013). 
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Many medical clinicians, researchers, and leaders agree that opportunities exist 
concerning the potential use of cannabis for pain (Savage et al., 2016). Patients with 
cancer-related pain may benefit from using cannabis and opioids complementarily 
(Johnson et al., 2013; Kral et al., 2015). In a short-term study, cannabis used in 
conjunction with opioids significantly reduced pain in participants, which may lower 
opioid doses and related side effects (Abrams et al., 2011). Cannabis could be a safe and 
effective treatment for chronic pain and serve as an alternative or complementary 
treatment to relieve society from the growing costs related to the opioid epidemic (Lucas, 
2012). Bowles et al. (2012) and van den Beuken-van Everdingen et al. (2016) noted a 
lack of data concerning various cannabis and conventional pain medications concerning 
cancer-related pain. 
There are some studies indicating success with adjuvant cannabis use and cancer 
pain but further research is needed. Significant improvements in pain were indicated in 
short and long-term studies related to cancer pain when using the THC/CBD spray (i.e., 
Sativex®; Johnson et al., 2013; Portenoy et al., 2012). In a small sample of advanced 
cancer patients over a long-term period, level doses of a cannabis extract reduced the pain 
of participants when use of strong opioids alone had failed (Johnson et al., 2013). Further, 
participants displayed improvements in sleep outcomes throughout the complementary 
treatment period, and the cannabis treatment was well tolerated without increased safety 
concerns (Johnson et al., 2013). Because evidence suggests cannabis could be a safer 
alternative to or complement with opioids, further research is warranted (Boehnke et al., 
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2016; Carter et al., 2015; Haroutounian et al., 2016; Joshi et al., 2014; Lucas, 2012; 
Lucas et al., 2015).  
Cohen et al. (2016) suggested comparing the efficacy and side effects of cannabis 
to opioids in future pain management studies. Many clinical studies have been 
accomplished concerning opioid administration and noncancer and cancer pain 
management. Some studies have been accomplished concerning cannabinoid products, 
noncancer pain, cancer pain, and related QOL for patients. The gap in current literature 
concerns use of opioids and/or cannabinoids for pain management and the relationship to 
the QOL of cancer patients. Given further research and similar findings, medical 
marijuana legislation could become part of a comprehensive effort to reduce the 
ramifications of the opioid epidemic affecting society (Bachhuber et al., 2014). 
There are many cannabis varieties and ways to intake the substance, so patients 
must find the right dose for their condition and circumstances (Hazekamp et al., 2013). 
According to Paice et al. (2016), each cancer survivor has unique needs because no two 
cancers are the same and patients have different capabilities and experiences. Concerning 
the optimal pain management treatment for cancer pain, the personal situation and 
preference of patients should be primary factors (van den Beuken-van Everdingen et al., 
2016). The present study incorporated the pain management preferences of cancer 
patients and their related QOL. 
In Chapter 2, I reviewed a breadth and depth of studies related to cannabis, 
opioids, pain management, and QOL related to cancer patients. In Chapter 3, I will 
describe the research design and rationale, methodology, population, sampling 
59 
 
procedures, data collection, instrumentation, threats to validity, and ethical procedures in 
detail. 
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Chapter 3: Research Method 
Introduction 
The purpose of the causal–comparative research was to determine the effects 
different types of cancer pain management treatments may have on the QOL of cancer 
patients. The study involved elements of the HBM (Hochbaum et al., 1952) using an 
existing validated and reliable instrument (i.e., WHOQOL-BREF) measuring the 
dependent variable, QOL (Skevington et al., 2004; WHOQOL Group, 1996). Pain 
management is an essential determinant of patient outcomes because unrelieved pain 
significantly comprised patient QOL and effective pain management was associated with 
patient survival (Mendes, Boaventura, Castro, & Oliveira Mendonça, 2014; Perlman et 
al., 2013).  
Pain is a secondary health problem that many cancer patients suffer which may 
relate to their QOL (Shneerson et al., 2013). Even with strong doses of opioids, many 
cancer patients are still undertreated and encounter severe pain, which impacts their QOL 
(Nerseyan & Slavin, 2007; Tanco et al., 2014; Zoëga et al., 2013). Zaller et al. (2015) 
studied 200 medial cannabis users and found chronic pain management, improved pain 
relief, and opioid alternative as the predominant reasons for cannabis use. Johnson et al. 
(2013) indicated a reduction in pain levels in a small sample of advanced cancer patients 
over the long-term while level doses of an adjuvant THC/CBD oromucosal spray was 
used. My research focused on nontraditional (i.e., cannabis) and/or traditional pain 
management (i.e., opioids) treatments and their relationship to the QOL of cancer 
patients. 
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In this chapter, I review the details of the causal–comparative research study. Key 
areas include the research design and rationale, methodology, sampling, recruitment, 
participation, data collection, threats to validity, and ethical procedures.  
Research Design and Rationale 
The quantitative nonexperimental research design included causal-comparative 
design, descriptive statistics, and cross-sectional survey data. Questionnaires were 
distributed through SurveyMonkey to collect data from cancer patients. Causal–
comparative does not seek cause and effect relationships because data are collected 
through environmental course and not experimental design (Field, 2013). This approach 
provided the method to assess the difference between participant dependent variable (i.e., 
QOL as measured by the WHOQOL-BREF), the independent variable (i.e., cancer pain 
management choice [opioids and/or cannabis]), and a moderator (i.e., gender). The 
research variables, as related to the specific participants, were analyzed using ANOVA 
and inferential statistics (Creswell, 2009). Data were gathered at a specific time rather 
than over multiple time periods to reduce the effects that time might have on QOL 
(Creswell, 2009; Field, 2013).   
Quantitative research uses instruments and “processes of measurement, counting, 
association, and causality" to identify characteristics of social phenomena (Frankfort-
Nachmias & Nachmias, 2015, p. 242). Researchers use collected data and statistical 
procedures to identify relationships and deductively test the research questions, which are 
derived from theory (Creswell, 2009; Frankfort-Nachmias & Nachmias, 2015). The QOL 
of a participant is a measured numeric value representing a present truth. The relationship 
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between pain management and QOL is assumed to be objective and externally observable 
vice subjective (Jean-Lee, 1992). Researchers using positivism attempt to study parts of 
the whole situation by uncovering causal relationships to understand the world (Jean-Lee, 
1992). Positivist researchers provide unbiased reports of empirical findings and 
descriptions of the observed reality (Wicks & Freeman, 1998). My research took the 
positivist perspective through survey methodology, data collection, and analysis to reveal 
the relationships between relevant variables. Because HBM originators established a 
relationship between the health perceptions and behaviors of individuals (Hochbaum et 
al., 1952; Rosenstock, 1974), a quantitative design was used. More information is needed 
to broaden categories of health attitudes, chronic disease, and health access to promote 
the health of cancer patients (Venters & Gany, 2011). 
The causal comparative, ex post facto design was used to enhance the study. In 
social science research, ex post facto research can be used to test a hypothesis concerning 
possible correlations when experimentation on participants is not appropriate (Simon & 
Goes, 2013). Because independent variables are not manipulated and participants are not 
randomly assigned to groups, the causal comparative design enables comparisons defined 
by biological factors (i.e., gender) to uncover correlational characteristics of the 
dependent variable (i.e., QOL; Simon & Goes, 2013). Because a validated and reliable 
survey was used to collect data (i.e., WHOQOL-BREF; Skevington et al., 2004), the 
corresponding numerical values provided opportunity for multivariate comparisons and 
analysis (WHO, 1997b; WHOQOL Group, 1996). 
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Cannabis could be a safer alternative to or complement with opioids concerning 
analgesic effects, but further research is warranted (Boehnke et al., 2016; Carter et al., 
2015; Haroutounian et al., 2016; Joshi et al., 2014; Lucas, 2012; Lucas et al., 2015).  
Zoëga et al. (2013) used a convenience sample of 150 participants, who were 18 years or 
older and had a diagnosis of cancer, in their cross-sectional, descriptive, and correlational 
study on opioid use and QOL. The WHOQOL-BREF is a 26-item survey that was used to 
determine the difference in the QOL of cancer patients, between types of cancer pain 
management therapy (i.e., traditional prescription based therapy [e.g., opioids], 
nontraditional based therapy [e.g., cannabis], and combined traditional and nontraditional 
therapy). Additionally, the gender (i.e., male and female) of each cancer patient was 
examined to determine if it affects the relationship between pain management therapy 
and QOL. Because cancer patients are inadequately treated for pain and more than 70% 
of advanced cancer patients suffer significant pain (Dalal et al., 2013), this societal issue 
and gap in literature needed further investigation. 
Methodology 
Population 
The number of annual cancer cases worldwide will reach over 20 million in the 
next 15 years while pain management and QOL for cancer patients remain a primary 
concern to health providers and affected patients (Kwon et al., 2013; Pelayo-Alvarez et 
al., 2013; WHO, 2015). In the United States, nearly 14.5 million Americans were alive 
with a previous history of cancer (i.e., as of January 1, 2014); in 2016, nearly 1.7 million 
Americans will be diagnosed with a new cancer (i.e., aforementioned data do not include 
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many noninvasive or squamous cell skin cancers); and in 2016, nearly 600,000 cancer 
related deaths are expected (American Cancer Society, 2016). For this research, the study 
population consisted of individuals who have been formally diagnosed with cancer, were 
at least 18 years of age, read English, have suffered from chronic pain, and may or may 
not be undergoing treatment. 
Participants included male and female patients of all ethnicities with no filtering 
by socio-economic status or educational achievement. Because responders not part of the 
target population have the potential to invalidate web-based surveys through unsolicited 
participation (Rudestam & Newton, 2015), several control measures were taken. These 
control steps included the following: (a) precollaboration with participant pool providers 
(e.g., medical providers, associations, support networks, and/or online forums); (b) used 
marketing flyer to attract appropriate participants; (c) obtained digital informed consent 
prior to participant data collection; (d) obtained organizational data use and contact 
permission letters, as appropriate; and (e) used anonymous survey methods (Walden 
University, 2016). 
Sampling and Sampling Procedures 
Both convenience and purposive sampling technique were used to extract the 
sample from the population. Social scientists use nonprobability sampling under certain 
circumstances: (a) when a sampling population cannot be properly defined, (b) when a 
sampling population list is unavailable, (c) for exploratory research, and (d) when 
convenience and economy outweigh any advantages of using probability sampling 
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(Frankfort-Nachmias & Nachmias, 2014). For this research study, all of the previous 
factors could be applied.  
There are four major designs that use nonprobability samples (i.e., convenience, 
snowball, purposive, and quota), and I used a combination of convenience with purposive 
when selecting sample participants for this research (Frankfort-Nachmias & Nachmias, 
2014). Snowball sampling was not appropriate because anonymous techniques were used 
and the applicable target sample was reached through regular survey measures. Quota 
sampling was not appropriate because breakdowns of inclusion criteria were not known 
or relevant to the study. Convenience samples use whatever sampling units are available, 
and purposive sampling encompasses selecting participants that are readily available to 
be researched, meet specific inclusion criteria, and appear to represent the population 
(Frankfort-Nachmias & Nachmias, 2014; Merriam, 1998). These last two sampling types 
can be used when time, funding, and location and availability of inclusion participants are 
restricted (Merriam, 1998). 
Purposive sampling is an extension of convenience sampling and is commonly 
used during nonprobability sampling when researchers are confident the data collected 
will represent the study population (Frankfort-Nachmias & Nachmias, 2014; StatPac, 
2014). These techniques are often used during preliminary research to get estimates of 
results “without incurring the cost or time required to select a random sample” (StatPac, 
2014, para. 8). Because “most social science studies are not based on representative 
samples” (Ellis, 1994, p. 171), this sampling method enabled action within a limited 
period of time and under specific conditions that facilitated data collection. Due to these 
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factors, purposive sampling sacrifices some degree of generalizability and results may not 
provide sufficient representation of the target population; however, the research design 
choice is better than not conducting the research (Ellis, 1994; Frankfort-Nachmias & 
Nachmias, 2014).  
The results may only partially represent the population under investigation, and 
replication may be required to fully validate the results (Keppel & Zedeck, 2001). 
Despite these limitations, purposive sampling is the best design to obtain participants to 
represent the research population when time, resources, and conditions prohibit random 
sampling (StatPac, 2014). Use of purposive sampling allowed a search for an 
approximate truth when obtaining a probability random sampling was prohibitive.  
A power analysis using G*Power 3.1 statistical software was conducted to 
determine the required sample size for the ANOVA analysis (Field, 2013). 
Determining the optimal sample size prior to research execution can maximize 
statistical power and minimize sampling costs (Liu, 2014). When conducting research, 
an a priori power analysis is often necessary (Cohen, 1992). An important component 
of power analysis is the effect size. An effect size can be estimated from a pilot study, 
prior research, or theory (Cohen, 1992). Because no specific research or theory exists 
on the given research topic, a medium effect size, as defined by Cohen (1992), will be 
used. 
G*Power 3.1 uses Cohen’s f   as an effect size measure for ANOVA  analysis. 
Within G*Power, Cohen’s f  was set to its medium effect size value of .25 (Cohen, 
1992). The desired power for the analysis was set to the conventional level of .80, and 
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the significance (i.e., alpha) level was set to the conventional .05. The ANOVA model 
tested included three groups (i.e., traditional prescription based therapy, nontraditional 
based therapy, and traditional and nontraditional therapy); therefore, the number of 
groups was set to three. The overall significance of the model was tested with an F-
Ratio; therefore, the test family setting in G*Power was F-tests. Because the analysis 
was conducted in advance of the actual study, the type of power analysis was set to a 
priori. Using these parameters and analysis settings, the estimated minimum sample 
size for the study was 158 cases (See Table 1 for parameter settings [i.e., under the 
header Analysis Inputs] and the results for the power analysis [i.e., under the header 
Analysis Output] and Figure 1 for the complete power plot graph). 
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Table 1.  
Power Analysis Estimated Parameters and Results 
Analysis Inputs: 	 Statistic 
Test Family = F-tests 	 	
Statistical Test = ANOVA: Fixed effects, main effects and interactions 
Type of Power Analysis = A priori: Compute required sample size 
Effect size f 	 = 0.25 
(Significance Level) α err probability = 0.05 
Power (1-β err probability) 	 = 0.80 
Numerator df  2 
Number of groups  3 
Number of covariates 	 = 1 
 
Analysis Output: 
 
Noncentrality parameter λ 
 
= 
 
9.88 
	 Critical F = 3.05 
	 Denominator df = 154 
	 Total sample size = 158 
	 Actual power = 0.802 
 
 
 
Figure 1. Power plot graph. 
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The study population included at least 158 survey participants from various 
locations. The sample size of n = 158 meets the 80% power requirement, significance 
(i.e., alpha) level of .05, and two degrees of freedom for the three groups represented 
(i.e., traditional prescription based therapy, nontraditional based therapy, and traditional 
and nontraditional therapy) per G*Power 3.1 statistical software calculation (Field, 2013; 
Petchenik & Watermolen, 2011; Vaske, 2014). Because this research was targeted 
towards patients who have access to different pain management options (i.e., traditional 
and nontraditional), web-based techniques allowed a large number of responses from 
participants living in multiple states with different medical marijuana legislation to be 
efficiently collected and analyzed (Rudestam & Newton, 2015).   
The WHOQOL-BREF was converted into a web-based survey to facilitate 
administration, collection, and analysis of survey results. Survey data collected online 
gives significant improvements concerning geographic coverage, speed relative to mailed 
options and interviews, and offers lower cost and better response rates than some other 
methods (Frankfort-Nachmias & Nachmias, 2015). Many researchers use online survey 
data collection, and many have found no difference between data collected through 
traditional means and from Internet research (Ahern, 2005; Frankfort-Nachmias & 
Nachmias, 2015). 
Procedures for Data Collection, Recruitment, and Participation 
I collected demographic, treatment, and QOL related information using the 
WHOQOL-BREF, which is an existing valid and reliable QOL questionnaire 
(Skevington et al., 2004), via SurveyMonkey. Use of a valid and reliable instrument is an 
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important aspect when conducting quantitative research (Creswell, 2009). SurveyMonkey 
is an appropriate method to collect sensitive information because it is based on secure 
protocols (SurveyMonkey, 2016a; Walden University, 2016). The WHOQOL-BREF is 
more objective than other QOL instruments (e.g., SF-36) and is able to differentiate 
between the QOL of two cancer patients even though they are experiencing similar 
symptoms and side effects (Keogh et al., 2013). My purposive sampling methodology 
collection plan did have a shortcoming because generalizations to the whole population 
are limited (Frankfort-Nachmias & Nachmias, 2015). 
All participants were recruited anonymously through various organizations. I 
contacted both brick and mortar and web-related healthcare organizations and entities to 
request permission to obtain volunteer participants from their pools of patients, members, 
or readers via public flyer. Additionally, the SurveyMonkey participation group program 
(i.e., SurveyMonkey Contribute) was used to target individuals who were at least 18 
years of age, were previously diagnosed with cancer, and experienced chronic pain. I did 
not initiate contact with participants directly because the survey data were collected 
anonymously.  
Participant recruitment procedures included both active and passive techniques. 
Fleming et al. (2015) evaluated the effectiveness of active versus passive recruitment for 
a group-based intervention study and determined that both methods were needed to reach 
effective sample sizes. Active recruitment methods included contacting participants 
through healthcare professional organizations, and passive recruitment methods included 
use of flyers, posters, public events, and media (Fleming et al., 2015). Although both 
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passive and active recruitment techniques can yield a sufficient participant pool, passive 
recruitment typically costs less per participant recruited (Fleming et al., 2015).  
The participant pool was obtained through various techniques. Participants were 
recruited passively through flyer advertisement with cooperating medical-related 
organizations or entity populations and specific SurveyMonkey contributors. An 
Institutional Review Board (IRB) approved flyer was digitally posted on the websites of 
and/or physically posted in participating organizations. Fleming et al. (2015) experienced 
a 73% recruitment rate when flyers were targeted in medical related areas. Given Health 
Insurance Portability and Accountability Act of 1996 (HIPAA) and informed consent 
procedures, organizations or entities could make active recommendations of specific 
participants for the study. Participants gathered actively were sent the same marketing 
flyer that was used for passively recruited participants. 
No matter how participants are gathered (i.e., passively or actively), all IRB and 
HIPAA guidelines were followed to ensure health and personal information were 
protected appropriately (U.S. Department of Health & Human Services, n.d.; Walden 
University, 2016). Most of the participants were recruited passively, but whether 
participants were gathered actively or passively, all identities remained anonymous. The 
website data collection process was the same for both actively or passively recruited 
participants. 
Data collection, consent, and access were accomplished through SurveyMonkey. 
Participants accessed a provided web link to begin the survey process. Once the 
participant selected the link, partial access to the survey was allowed. Once the 
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participant completed and agreed to the informed consent agreement, full access to the 
survey was granted. The SurveyMonkey interactive version of the WHOQOL-BREF 
measured social and environmental aspects of QOL along with physical and 
psychological factors relevant to the participant (Keogh et al., 2013). Thus, the 
WHOQOL-BREF has distinct measures beyond side effects and symptoms that might be 
affecting the QOL of participants (Keogh et al., 2013).  
Self-reported data are generally as valid as non-self-reported data in assessments 
concerning the perception of participants (Chan, 2009). Participants were assured that 
their identity and responses would remain confidential throughout the research process. 
Furthermore, researchers have used web-based informed consent procedures (Colvin & 
Lanigan, 2005), and I used a similar method for informed consent requirements because 
sensitive information was collected. 
Completed survey data were downloaded, collected, and stored into an Excel file 
and backed up on a secure jump drive. After data were downloaded, it was transferred to 
Statistical Package for the Social Sciences (SPSS) for processing and analysis. Both the 
computer and jump drive were password protected and kept in a private residence. Only I 
had access to the data. 
During these processes, no personal data were collected or associated. Data were 
collected excluding all respondent information (e.g., name, email address, and IP address; 
SurveyMonkey, 2016b). Through the informed consent procedure, participants 
understood their survey data could not be removed once submissions were complete 
because no participant identifiers were collected. No participant identifier information 
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was collected through active recruitment. All passive recruitment and web-based survey 
data collection used anonymous collection techniques. 
The anonymity of participants was assured because only aggregate data will be 
published. I will make overall study results available to participants once completed and 
allowed contact with me concerning any questions or concerns. The specific information 
concerning post-research data web link was provided at the end of the survey. Specific 
information concerning individuals will not be available or allowed.  
Instrumentation and Operationalization of Constructs 
 The WHO has defined health as more than the absence of disease, but as an 
assessment of QOL related to "physical, mental, and social well-being” (WHO, 1997b, p. 
1). In 1991, the WHO developed a generic QOL instrument, known as the WHOQOL-
100, to be used for various diseases, severities, and cultural groups (Bonomi et al., 2000). 
The 4-domain WHOQOL-BREF was developed from the 6-domain WHOQOL-100, was 
confirmed for use with sick and well participants, and showed generally consistent results 
when compared to the WHOQOL-100 (Skevington et al., 2004). The WHOQOL-BREF 
has shown cross-cultural validity and covers a broad range of factors (Skevington et al., 
2004). The 26-question WHOQOL-BREF contains two overall QOL questions and 24 
questions for the four QOL domains and corresponding items (i.e., physical health [7 
items], psychological [6 items], social relationships [3 items], and environmental [8 
items]; Skevington et al., 2004; WHO, 1997a; see Figure 2). These domains and 
corresponding items are assessed through use of 5-point scales and descriptors (Szabo, 
Orley, & Saxena, 1997). 
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Social scientists use scales and indexes to enable reduction and compilation of 
data to scores that increases reliability and allows quantitative measurement (Frankfort-
Nachmias & Nachmias, 2015). The WHOQOL-BREF has been used to assess cancer 
patients (Cristina Mansano-Schlosser & Filomena Ceolim, 2012; Jeong, Sim, Hwang, & 
Kim, 2011; Keyzer-Dekker et al., 2012; Mendes et al., 2014; Oliveira, Costa, Manzoni, & 
Cabral, 2014; Peretti-Watel, Bendiane, Spica, & Rey, 2012; Vaz et al., 2007). According 
to a multidimensional QOL instrument study, the WHOQOL-BREF scored acceptable 
concerning the following: (a) overall measures of internal consistency, test-retest 
reliability, content validity, and inter-domain correlation; (b) similar with SF-36 
concerning convergent validity; and (c) factorial validity of its domains and known-group 
validity between well and sick individuals (Zeng, Ching, & Loke, 2010). The WHOQOL-
BREF performed well concerning item–response distributions, reliability, construct 
validity, and discriminant validity and may be one of the leading instruments for 
measuring generic QOL (Skevington et al., 2004). 
The QOL measure has yielded important information concerning interventions 
and clinical care of cancer patients and survivors (Jacobsen & Jim, 2011). There are 
many different types of QOL instruments including generic (e.g., SF-36 and WHOQOL-
BREF) and cancer specific ones (e.g., FACT-B+4). Oliveira et al. (2014) evaluated the 
SF-36 and WHOQOL-BREF with the FACT-B+4 on 106 women with breast cancer and 
determined that the WHOQOL-BREF and FACT-B+4 were similar in most measurement 
properties and adequate to assess QOL.  
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Many of the cancer specific QOL instruments provide a more comprehensive 
assessment of symptoms than generic QOL instruments for cancer participants (Jacobsen 
& Jim, 2011). In a small sample of breast cancer patients, the WHOQOL-BREF did not 
always capture the iatrogenic chronic pain of the participant (Peretti-Watel et al., 2012). 
Generic instruments are typically used to make QOL comparisons between specific 
cancer groups (i.e., cervical cancer survivors) and the general population (Zeng et al., 
2010). Cancer specific QOL instruments are used on a group of participants with the 
same type of cancer (Jacobsen & Jim, 2011). The WHOQOL-BREF “permits the 
comparison of QOL in patients with different diseases” (Vaz et al., 2007, p. 586). Given 
that my participant pool includes individuals with many types of cancer, the use of the 
WHOQOL-BREF (See Appendix A) was most appropriate. 
Health self-assessments (e.g., WHOQOL-BREF) have shown to be reliable 
predictors of cancer patient QOL and can help medical providers assess symptoms and 
direct treatments (Cristina Mansano-Schlosser & Filomena Ceolim, 2012). Quality of life 
instruments help produce “objective data from subjective realities” to allow investigation 
of associated factors (Vaz et al., 2007, p. 584). Using data from a large, diverse sample 
(i.e., 11,830 participants from 23 countries) and factor analysis, Skevington et al. (2004) 
indicated that the WHOQOL-BREF showed internal consistency (i.e., > .7 per Cronbach 
α), item-total correlations (i.e., p < .001 per Pearson), construct validity, discriminant 
validity (i.e., p < .001 per multiple regression), and good to excellent reliability of 
psychometric properties. 
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Van Esch, Den Oudsten, and De Vries (2011) evaluated women with breast 
problems (i.e., benign or malignant) and concluded that the WHOQOL-BREF appeared 
to be a reliable and valid instrument. The WHOQOL-BREF provided comparable results 
to the WHOQOL-100, good test-retest reliability, and good psychometric properties (Van 
Esch et al., 2011). The 100-question WHOQOL-100 may be burdensome for some 
participants, and the WHOQOL-BREF served as an alternative instrument (Skevington et 
al., 2004; Van Esch et al., 2011). Evidence indicated shorter measures typically have 
higher response rates (Harper & Power, 1998; Van Esch et al., 2011). The WHO 
approved use of the WHOQOL-BREF for my dissertation research (See Appendix B). 
 Researchers should consider the purpose, psychometric properties, and 
inclusiveness of a study when selecting a QOL instrument (Zeng et al., 2010). Jeong et al. 
(2011) used the WHOQOL-BREF in a cross-sectional, convenience sample of 39 women 
with breast cancer-related lymphedema to study the QOL of various subgroups. Cancer 
participants with greater disability and pain were observed to have lower QOL (Jeong et 
al., 2011). Vaz et al. (2007) used the WHOQOL-BREF in a cross-sectional study of 103 
women with gynecologic cancer and identified cancer-related symptoms that interfered 
with QOL. Vaz et al. (2007) noted a relationship between cancer-related pain and impacts 
on multiple QOL factors indicating the importance of pain management considerations 
on the QOL of cancer patients. Mendes et al. (2014) used the WHOQOL-BREF in a 
cross-sectional, convenience sample of 56 cancer patients in palliative care to study 
analgesic treatments (i.e., adjuvants, opioids, or nonopioids) and QOL. 
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Data collected in the study included standard demographic and healthcare 
information (e.g., gender, date of birth, education level, marital status, health status, and 
pain management method) and the 26-scaled items in the WHOQOL-BREF. The WHO 
defines QOL as “individuals’ perceptions of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns” (WHOQOL Group, 1996, p. 5). The WHOQOL Group views the 
perspective and beliefs of individuals concerning the nature of disease as important 
elements influencing the quality of their lives (WHO, 1997b). 
Cancer pain management was operationalized as the independent variable, QOL 
as the dependent variable, and gender as a moderator. Cancer pain management was 
defined as traditional prescription based therapy (i.e., opioids), nontraditional based 
therapy (i.e., cannabis), or traditional and nontraditional therapy. These three pain 
management categories were the primary analysis groups to address the research 
questions: (1) Use of opioids, (2) use of cannabis, and (3) use of opioids and cannabis. 
Specific types and quantities of opioids, cannabis, complementary, alternative, nonopioid, 
and adjuvant treatments were not analyzed. 
Many complementary, alternative, nonopioids, and adjuvant treatments have been 
addressed in past research. Mendes et al. (2014) indicated that the majority of cancer 
patients used adjuvants, to counter opioid side effects, and nonopioids; therefore, these 
two categories of treatments were excluded. Shneerson et al. (2013), Bao et al. (2014), 
Ben-Arye et al. (2014), and Bar-Sela et al. (2015) explored various complementary and 
alternative treatments for cancer care but only Bao et al. (2014) included cannabis. 
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Further, Mendes et al. (2014) did not include cannabis use as a complementary or 
alternative treatment in their QOL related study. Bowles et al. (2012) and van den 
Beuken-van Everdingen et al. (2016) noted a lack of data concerning various cannabis 
and conventional pain medications concerning cancer-related pain. 
The QOL variable is operationalized through techniques developed and 
established in the cross-culturally validated and reliable WHOQOL-BREF (Skevington et 
al., 2004). The 26-item WHOQOL-BREF is broken down into areas identified in 
Appendix A (i.e., items 27 to 30). After reversing the values for three questions, domain 
questions are scored from 1 to 5 per the raw item Likert-like score (Likert, 1932; Szabo et 
al., 1997). Each of the four domains (i.e., physical health, psychological, social 
relationships, and environment) and overall QOL dimensions has different number of 
corresponding questions and raw domain score range (WHO, 1997a). Higher scores 
indicate a higher QOL (WHO, 1997a). 
The WHO has established procedures for missing data and transformation of raw 
scores (WHO, 1997a). Both the physical health and environment domains can tolerate 
one missing value through an average process, but questions applicable to the 
psychological and social relationship domains must all be coded (WHO, 1997a). The 
transformation of the raw data domain totals converts the possible scores for each domain 
into a scale from zero to 100 (WHO, 1997a). For example, the minimum and maximum 
raw values for the social relationships domain are 3 and 15, respectively (WHO, 1997a). 
If a participant scored 9, then the transformed score would be 50 (See Figure 3). These 
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transformed values can then be compared and analyzed to the various pain management 
options and gender, as appropriate, with the SPSS program, version 23. 
 
Figure 3. Transformation of Scale Scores (WHO, 1997a) 
The two quantitative research questions (RQs) and corresponding null and 
alternative hypotheses were derived from theory and provided the focus for this study. 
First Research Question. RQ1: To what extent, if any, is there a difference 
between cancer patient’s quality of life (QOL) and types of cancer pain management 
therapy (i.e., traditional prescription based therapy [i.e., opioids], nontraditional based 
therapy [i.e., cannabis], and combined traditional and nontraditional therapy)? 
Independent Variable: Cancer pain management, described as:  
• Traditional prescription based therapy (opioids) 
• Nontraditional based therapy (cannabis) 
• Traditional and nontraditional therapy 
Dependent Variable: Quality of life 
H01: Quality of life will not differ between cancer pain management types. 
Ha1: Quality of life will differ between cancer pain management types. 
Second Research Question. RQ2: To what extent, if any, does gender affect the 
relationship between cancer patient’s quality of life (QOL) and types of cancer pain 
management therapy (i.e., traditional prescription based therapy [i.e., opioids], 
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nontraditional based therapy [i.e., cannabis] and combined traditional and nontraditional 
therapy? 
Independent Variable: Cancer pain management, described as:  
• Traditional prescription based therapy (opioids) 
• Nontraditional based therapy (cannabis) 
• Traditional and nontraditional therapy 
Dependent Variable: QOL 
Moderator: Gender (female or male) 
H02:  The impact of cancer pain management type on QOL is not moderated by 
gender. 
Ha2:  The impact of cancer pain management type on QOL is moderated by 
gender. 
Given the nature and number of the variables, ANOVA was the appropriate 
statistical approach (Creswell, 2009). The dependent variable was scaled at the ratio level 
because overall scores were obtained through averaging techniques set forth by WHO 
(1997a). The independent variable was scaled at the nominal level meaning that the pain 
management type of participants was categorical vice mathematical in nature (Field, 
2013). Specifically, it was assumed no mathematical relationship exists between 
traditional pain management and nontraditional pain management use. Gender was used 
as a moderator for the relationship as specified in the second research question.  
Detailed Analysis. For a single dependent variable, the F-test assesses the overall 
mean differences through calculations using the systematic and unsystematic variances 
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(Field, 2013). In addition to the F-test and specific contrasts, the effect size (i.e., eta 
squared) was also used to measure the overall effect of the ANOVA (Field, 2013). Eta 
squared is often considered biased because it only describes the variance in the dependent 
variable by the independent variable in the sample but not population (Field, 2013). 
Cohen’s (1992) guidelines for eta-square (η2) are .01 for small effect, .06 for moderate 
effect, and .14 for large effect. Eta squared is calculated using the following equation: 
Eta squared = model (between groups) sum of squares ÷ total sum of squares 
For both research questions, the SPSS software program, student version 23.0, 
was used to process data with the ANOVA testing. ANOVA testing compares means 
across two or more independent groups to determine if they differ significantly (Field, 
2013). Because the causal variable was not manipulated, only determination of co-
occurrence, not causality, was possible (Field, 2013). Fisher and Kelly derived the 
probability distribution and corresponding correlation ratio in the 1920s and 1930s, 
respectively (Huberty, 2002). The ANOVA equation is simply the between-groups 
variability divided by the within-groups variability or error variance (Mertler & Vannatta, 
2013):  
F = variance between participants ÷ variance expected due to chance (error) 
The calculation assesses the variation in scores found between the three groups 
and divides that by the error variance or variation in scores found within these groups 
(Mertler & Vannatta, 2013). If an F-ratio was less than 1, then unsystematic variance was 
greater than systematic variance, and a result could be due to mere chance (Field, 2013). 
The F-test is referred to as an omnibus test because it assesses the overall fitness of the 
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model but does not provide specific information concerning individual groups (Field, 
2013).  
If the F-ratio was statistically significant, then contrast procedures were 
accomplished to determine which specific group comparisons were significant (Field, 
2013). Because there are three groups, two contrasts were required (Field, 2013). First 
contrast was traditional score versus both nontraditional score and traditional and 
nontraditional scores. The second contrast was nontraditional score versus traditional and 
nontraditional score. Planned contrasts of the different groups helped identify if cannabis 
was associated with changes in the QOL of cancer patients (See Figure 4). 
 
 
Figure 4. Planned Contrasts for Variance (Field, 2013) 
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The concept of moderation helps identify limits of an effect (e.g., circumstance or 
type of person) and the level of this effect (e.g., present or absent; Hayes, 2013). Gender 
was used as a dichotomous, categorical moderator to help identify any level of effect 
between the independent and dependent variables (See Figure 5). To test the potential 
moderating effects of gender on the pain management type-quality of life relationship, a 
multiple regression analysis was conducted using SPSS and the PROCESS (v2.15) macro 
(Field, 2013; Hayes, 2013). The criterion variable pain management type, predictor 
variable quality of life, and moderator variable gender were entered into the regression 
model number 1 PROCESS macro for SPSS to identify the appropriate interactions 
(Hayes, 2013).  
 
 
Figure 5. Gender as Categorical Moderator (Field, 2013; Hayes, 2013) 
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Hayes (2013) developed the PROCESS application for regression based 
mediation, moderation, and conditional processing. The moderator process helps identify 
variable(s) that change the size or direction of relationships through the pick-a-point 
approach or analysis of simple slopes (Hayes, 2013). The output of the moderation 
should indicate regression points for gender given the different pain management types 
concerning QOL. Figure 6 illustrates the proposed statistical model of pain management 
type, gender, and QOL. The regression analysis should indicate relationships between 
pain management type and QOL concerning gender. Relationships were analyzed for 
significance concerning possible similarity (Hayes, 2013). The analysis of the statistical 
model helped determine whether the null hypothesis should be rejected or if it failed to be 
rejected. 
 
Figure 6. Moderation Statistical Model (Field, 2013; Hayes, 2013) 
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Threats to Validity 
Extrinsic and intrinsic factor interactions are considered potential threats to 
validity (Frankfort-Nachmias & Nachmias, 2015). Selection-history is one such extrinsic 
threat factor (Frankfort-Nachmias & Nachmias, 2015). Because the WHOQOL-BREF 
has shown cross-cultural validity concerning QOL across the four measured domains 
(Skevington et al., 2004), the potential selection-history threat was countered. The current 
treatment phase of the participant could cause variability in QOL unrelated to pain 
management type (Oliveira et al., 2014). Such variability could warrant use of a more 
homogeneous sample concerning treatment (Oliveira et al., 2014). Because the reactions 
of cancer patients to various treatments are often related (Tazaki et al., 1998), it was 
assumed that the various treatment groups assessed would have similar treatment phase 
participants. 
 Intrinsically, the four WHOQOL-BREF domain scores showed a strong 
association to overall QOL measures (Skevington et al., 2004). The WHOQOL-100 
successfully evaluated the QOL of cancer patients (Tazaki et al., 1998). The WHOQOL-
BREF served as an alternative instrument to the WHOQOL-100 for women with benign 
or malignant breast problems (Van Esch et al., 2011) and was adequate to assess the QOL 
of women with breast cancer (Oliveira et al., 2014). Although randomized, experimental 
research can help counteract threat factors, cross-sectional or correlational design is often 
employed in social science, survey research (Frankfort-Nachmias & Nachmias, 2015).  
Mansano-Schlosser and Ceolim (2012) assessed cancer patients with the 
WHOQOL-BREF in a cross-sectional descriptive study. Self-reported data were as valid 
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as non-self-reported data concerning the perception of participants (Chan, 2009). Self-
reported data indicated reliability in predicting participant QOL (Mansano-Schlosser & 
Ceolim, 2012). Van Esch et al. (2011) evaluated the WHOQOL-BREF concerning the 
QOL of women with benign or malignant breast problems and concluded it a reliable and 
valid instrument. The generic nature and cross-cultural validity of the WHOQOL-BREF 
allows QOL comparisons for patients with different diseases (Vaz et al., 2007). Given 
these findings, I planned to build upon previous evidence (i.e., concerning the possible 
relationship between cannabis and opioids regarding pain and QOL) using appropriate 
statistic techniques in order to examine possible relationships or causal inference 
(Frankfort-Nachmias & Nachmias, 2015). 
Ethical Procedures 
Ethical considerations were addressed to ensure protection and confidentiality of 
participants. These measures were consistent with Walden IRB privacy, security, and 
ethical standards. In order to protect the health information of the anonymous and 
voluntary participant pool, I complied with HIPAA, IRB, and related regulations. All 
information was collected anonymously and securely using standards set up through data 
collection criteria in SurveyMonkey (SurveyMonkey, 2016a, 2016b). Permission 
documentation from organizations was not required because research invitations were 
anonymous and voluntary. Also, a number identifier was used to represent the data of 
each participant.  
All information was held securely and privately. All primary data and analysis 
results were kept on a password-protected home computer and were backed up with a 
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USB drive. Security procedures were taken to protect data during all research steps 
including data collection, data transfer, data analysis, and archiving (e.g., password 
protection and locks). The transferred data were de-identified, as required, and data will 
be password protected, secured, locked, and protected for 5 years. After that time period, 
all data will be destroyed. 
All of the various research risks and burdens were minimized in order to protect 
participants. Psychological risks were minimized in use of a standardized, valid, and 
reliable instrument in a private setting (i.e., personal computer). Relationship risk was 
minimal because a participant may recognize my last name, but I had no power over any 
participant. There were minimal economic, professional, or physical risks and no 
conflicts of interest. Survey data were collected anonymously for all participants.  
Summary 
The QOL measure has yielded important information concerning interventions 
and clinical care of cancer patients and survivors (Jacobsen & Jim, 2011). The 
WHOQOL-BREF was used in cross-sectional studies to indicate the effects of pain on 
the QOL of cancer patients (Mendes et al., 2014; Vaz et al., 2007). Researchers used the 
WHOQOL-BREF to study the QOL of cancer patients with different (Mendes et al., 
2014) and similar (Vaz et al., 2007) types of cancers using cross-sectional, convenience 
studies. According to Mendes et al. (2014), the majority of cancer patients used adjuvants 
(i.e., to counter opioid side effects) and nonopioids, but cannabis was not included in 
their study. Vaz et al. (2007) indicated the importance of the QOL of cancer patients on 
pain management considerations. 
89 
 
Cancer pain management was specified as the independent variable, QOL as the 
dependent variable, and gender as a moderator. Cancer pain management was defined as 
traditional prescription based therapy (i.e., opioids), nontraditional based therapy (i.e., 
cannabis), or traditional and nontraditional therapy. These three categories were the 
primary analysis groups to address the research questions. Data collected included 
standard demographic and healthcare information (e.g., gender, date of birth, education 
level, marital status, health status, and pain management method) and the 26-scaled items 
in the WHOQOL-BREF. 
The WHOQOL-BREF “permits the comparison of QOL in patients with different 
diseases” (Vaz et al., 2007, p. 586). Given that my participant pool included individuals 
with many types of cancer, the use of the WHOQOL-BREF was most appropriate. 
SurveyMonkey was used to streamline the self-assessment data collection (See Appendix 
C). Health self-assessments (e.g., WHOQOL-BREF) have shown to be reliable predictors 
of cancer patient QOL and can help medical providers assess symptoms and direct 
treatments (Mansano-Schlosser & Ceolim, 2012). QOL instruments help produce 
“objective data from subjective realities” to allow investigation of associated factors (Vaz 
et al., 2007, p. 584). 
The results of the study will be included in Chapter 4 using three sections (i.e., 
data collection, results, and summary). The data collection section will include response 
rates, discrepancies, and baseline characteristics of participants during the survey process. 
The results section will include descriptive statistics, complete statistical analysis, 
hypothesis and assumption evaluation, and post-hoc inferential results. In the summary 
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section, I will summarize the research questions, overview the study design and 
hypotheses results, and introduce the reader to Chapter 5 content. 
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Chapter 4: Results 
Introduction 
The purpose of the nonexperimental research was to determine the effects 
different types of cancer pain management treatments may have on cancer patients’ QOL. 
The study involved elements of the HBM (Hochbaum et al., 1952) including benefits, 
barriers, cues to action, and self-efficacy concepts (Abraham & Sheeran, 2005; Broussard 
& Weber-Breaux, 1994; Rosenstock et al., 1988; Wallace, 2002). Pain management 
therapies for cancer patients (i.e., defined by traditional [i.e., opioids], nontraditional [i.e., 
marijuana, also known as cannabis], and combined nontraditional and traditional) are 
often related to these HBM concepts and QOL is affected. Pain management is an 
essential determinant of patient outcomes because unrelieved pain significantly 
comprised patient QOL and effective pain management was associated with patient 
survival (Perlman et al., 2013).  
Gender (i.e., male and female) was also examined to determine if it affects the 
difference in cancer patient pain management and QOL. Studies indicate mixed results 
concerning use and abuse of both opioids and marijuana when gender is considered 
(Greenfield et al., 2010). Relationships concerning gender, pain sensitivity, and pain 
management treatments warrant further investigation (Cooper & Haney, 2016; Lenz et 
al., 2011). Gender provided a research opportunity because effects of opioid and 
marijuana on cancer patient QOL have not been evaluated under these conditions. 
Pain is a secondary health problem that many cancer patients suffer which may 
relate to their QOL (Shneerson et al., 2013). My research focused on nontraditional (i.e., 
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cannabis) and/or traditional pain management (i.e., opioids) treatments and their 
relationship to cancer patients’ QOL. Two quantitative research questions (RQs) and 
corresponding null and alternative hypotheses were derived from theory and provided the 
focus for this study. 
First Research Question and Hypotheses 
Research Question 1: To what extent, if any, is there a difference between cancer 
patient’s quality of life (QOL) and types of cancer pain management therapy (i.e., 
traditional prescription based therapy [i.e., opioids], nontraditional based therapy [i.e., 
cannabis], and combined traditional and nontraditional therapy)? 
The independent variable (i.e., cancer pain management) and the relationship to 
the dependent variable (i.e., QOL) were examined using the following hypotheses: 
H01: Quality of life will not differ between cancer pain management types. 
Ha1: Quality of life will differ between cancer pain management types. 
Analysis of variance (ANOVA), planned contrasts, and post hoc tests were used 
to evaluate the research question and corresponding hypotheses. 
Second Research Question and Hypotheses 
Research Question 2: To what extent, if any, does gender affect the relationship 
between cancer patient’s quality of life and types of cancer pain management therapy 
(i.e., traditional prescription based therapy [i.e., opioids], nontraditional based therapy 
[i.e., cannabis] and combined traditional and nontraditional therapy? 
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The independent variable (i.e., cancer pain management) and the relationship to 
the dependent variable (i.e., QOL) as moderated by gender were examined using the 
following hypotheses:  
H02: The impact of cancer pain management type on quality of life is not 
moderated by gender. 
Ha2: The impact of cancer pain management type on quality of life is moderated 
by gender. 
Moderated ANOVA analyses were used to evaluate the research question and 
corresponding hypotheses. 
Results of the study were included in this chapter using three sections (i.e., data 
collection, results, and summary). The data collection section includes response rates, 
discrepancies, and baseline characteristics of participants during the survey process. The 
results section includes descriptive statistics, complete statistical analysis, hypothesis and 
assumption evaluation, and post-hoc inferential results. The summary section includes 
analysis of the research questions, overview of the study design, and hypotheses results. 
Data Collection 
Data collection began about a week after IRB approval. The IRB approval date 
was March 6, 2017 (i.e., approval number 03-06-17-0311376), and data were collected 
from March 14, 2017 until April 21, 2017. Over 70 cancer and medical-related 
individuals with group affiliations were communicated with concerning community 
partnership. Approximately 25% of these points of contact responded favorably to 
coordinate the research flyer information to potential participants.  
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Participants were reached through three main sources. First, approximately 17 
cancer and medical-related groups, which varied in size (i.e., approximately 50 to 250 
members), contributed to the research. Second, the SurveyMonkey Contribute program 
was used, but less than 10 participants (15%) of the chronic pain group addressed 
responded being a cancer patient. Third, the largest participant group was reached 
through a community partnership with a cancer patient research firm. This firm 
coordinated the research flyer information to their full list of 20,000 cancer patients on 
two occasions (i.e., original and follow-up distributions). Not counting the 
SurveyMonkey Contribute group, response rate of potential participants, once the 
research flyer information coordinated, was approximately 1.5%. Because the survey 
information was collected anonymously, exact response rates from each group could not 
be determined. 
The data collection process was consistent with procedures set up in Chapter 3. 
Because participant response rate was approximately 1.5%, the community partnership 
with the cancer patient research firm helped speed up the data collection timeframe. A 
summary of research results will be coordinated with points of contact of the cancer 
patient research firm, and these summary findings will be coordinated to their group 
members. At the conclusion of the survey, all participants were given notice of a public 
website which will contain a report of the same summary of research findings. During the 
data collection timeframe, I answered several questions from possible participants via 
email since my contact information was provided on the research flyer and informed 
consent. 
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Data Analysis Procedure 
The sample data were coded, screened, and tested with descriptive and inferential 
statistics. Excel was used to code the SurveyMonkey data. The Excel worksheet was 
imported into the Statistical Package for the Social Sciences (SPSS) version 23.0. The 
SPSS was used to further code, screen, and organize the collected survey data. Where 
appropriate, summarized values were tabulated including demographic frequency counts 
and percentages. Computations were also preformed on the variables, which included 
mean, variance, and standard deviation. Prior to research question analysis, tests were 
performed to ensure statistical assumptions were met. 
The variables were explored for various characteristics prior to analyzing the 
research questions using the general linear model. Exploration included checks for 
missing data and outliers using frequency counts, graphs, and plots, and checks for 
normality and homoscedasticity (i.e., homogeneity of variance). After this evaluation, 
ANOVA, planned contrasts, post hoc tests, and moderated ANOVA analyses (i.e., using 
the PROCESS tool in SPSS; Field, 2013; Hayes, 2013) were run to test the two research 
questions. Displayed in Table 2 is a summary of the dependent and independent variables 
and statistical analyses used to evaluate the two research questions. 
Table 2 
Variables and Statistical Tests Used to Evaluate Research Questions 1 and 2 
Research 
Question 
Dependent 
Variable Independent Variable Moderator Analysis 
RQ1 Quality of Life Pain Management Therapy Type  ANOVA 
RQ2 Quality of Life Pain Management Therapy Type Gender PROCESS tool* 
* (Field, 2013; Hayes, 2013) 
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Demographics 
Data were collected from 617 individuals via SurveyMonkey. However, 60 
participants (i.e., from SurveyMonkey Contribute group) stated that they did not nor had 
they ever had cancer, 17 participants did not complete the WHOQOL-BREF survey (i.e., 
no dropout pattern), and 304 stated they did not use one or more of the traditional and 
nontraditional pain management therapies evaluated in the current study. Therefore, the 
aforementioned 381 participants were removed from all analyses and a sample of 236 
individuals was evaluated in current study (N = 236). Females (86.4%, n = 204) made up 
the majority of participants, and the remaining 13.6% were male (n = 32). Further, 41.1% 
of participants were between 55 and 64 years old (n = 97), and 31.8% were between 45 
and 54 years old (n = 75). The frequency and percent statistics of participants’ gender and 
age groups are displayed in Table 3.   
Table 3 
Frequency and Percent Statistics of Participants’ Gender and Age Groups 
Demographic Frequency (n) Percent (%) 
Gender   
   Male 32 13.6 
   Female 204 86.4 
     Total 236 100.0 
   
Age Group   
   18 - 34 years 9 3.8 
   35 - 44 years 27 11.4 
   45 - 54 years 75 31.8 
   55 - 64 years 97 41.1 
   65+ years 28 11.9 
     Total 236 100.0 
Note.  Total N = 236 
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The sample of 236 individuals was evaluated in the current study (N = 236) for 
highest level of education and marital status. The majority of participants had some 
college (51.7%, n = 122), and 23.7% had a Bachelor’s degree (n = 56). Additionally, 
58.5% of participants were married (n = 138), and 14% were divorced (n = 33). 
Frequency and percent statistics of participants’ highest level of education and marital 
status are displayed in Table 4.   
Table 4 
Frequency and Percent Statistics of Participants’ Highest Level of Education and 
Marital Status 
 
Demographic Frequency (n) Percent (%) 
Education   
   Less than High School 1 0.4 
   High School 17 7.2 
   Some college 122 51.7 
   Bachelor's degree 56 23.7 
   Graduate degree 40 16.9 
     Total 236 100.0 
   
Marital Status   
    Single 26 11.0 
   Married 138 58.5 
   Living as married 14 5.9 
   Separated 9 3.8 
   Divorced 33 14.0 
   Widowed 16 6.8 
     Total 236 100.0 
Note.  Total N = 236 
The sample of 236 individuals was evaluated in the current study (N = 236) for 
level of chronic pain, cancer stage, and type of pain management therapy used. The 
majority of participants were experiencing chronic pain (95.8%, n = 226), and 4.2% self-
reported not experiencing chronic pain (n = 10). Additionally, 41.5% of participants were 
Stage IV (n = 98), and 23.7% were Stage III (n = 56). Concerning pain management 
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therapy used, the majority of participants used opioids (72%, n = 170), 15.3% (n = 36) 
used a combination of opioids and marijuana, and 12.7% (n = 30) used marijuana. 
Frequency and percent statistics of participants’ chronic pain, cancer stage, and type of 
pain management therapy used are displayed in Table 5.   
Table 5 
Frequency and Percent Statistics of Participants’ Level of Chronic Pain, Cancer Stage, 
and Type of Pain Management Therapy 
 
Demographic Frequency (n) Percent (%) 
Chronic Pain   
   Yes 226 95.8 
   No 10 4.2 
     Total 236 100.0 
   
Cancer Stage   
   Stage I 16 6.8 
   Stage II 42 17.8 
   Stage III 56 23.7 
   Stage IV 98 41.5 
   None 23 9.7 
   Missing 1 .4 
     Total 236 100.0 
   
Pain Management Therapy   
   Opioids 170 72.0 
   Marijuana 30 12.7 
   Opioids and marijuana 36 15.3 
     Total 236 100.0 
Note.  Total N = 236 
The sample of 236 individuals was evaluated in the current study (N = 236) for 
cancer type. The majority of participants were experiencing breast or metastatic breast 
cancer (41.9%, n = 99), and 9.3% reported lung or metastatic lung cancer (n = 22). 
Additionally, 6.4% of participants reported lymphoma (n = 15), and 4.2% reported 
leukemia (n = 10). Other cancers reported were 37.7% (n = 89) of the participants. 
Displayed in Table 6 are the frequencies and percent statistics of participants’ highest 
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reported cancer types. Frequency and percent statistics of all participant cancer types are 
reported in Appendix D. 
Table 6 
Frequency and Percent Statistics of Participants’ Highest Reported Cancer Types 
Demographic Frequency (n) Percent (%) 
Cancer Type   
   Breast / Metastatic Breast 99 41.9 
   Lung / Metastatic Lung 22 9.3 
   Lymphoma 15 6.4 
   Leukemia 10 4.2 
   Other 89 37.7 
   Missing 1 .4 
     Total 236 99.9 
Note.  Total N = 236 
Purposive sampling is commonly used during nonprobability sampling when 
researchers are confident the data collected will represent the study population 
(Frankfort-Nachmias & Nachmias, 2014; StatPac, 2014). Although convenience 
sampling has limitations, social scientists use nonprobability sampling when a sampling 
population cannot be properly defined and when a sampling population list is unavailable 
(Frankfort-Nachmias & Nachmias, 2014). Zoëga et al. (2013) used a convenience sample 
of 150 participants, who had a diagnosis of cancer, in a cross-sectional, descriptive, and 
correlational study on opioid use and QOL. Peters (2013) used a small, convenience 
qualitative study to examine participant cannabis use as an alternative or reduction agent 
for traditional opiate medicines. Researchers used the WHOQOL-BREF to study the 
QOL of cancer patients with different (Mendes et al., 2014) and similar (Vaz et al., 2007) 
types of cancers using cross-sectional, convenience studies.  
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Purposive sampling sacrifices some degree of generalizability and results may not 
provide sufficient representation of the target population (Ellis, 1994; Frankfort-
Nachmias & Nachmias, 2014). Use of purposive sampling allows a search for an 
approximate truth when obtaining a probability random sampling is prohibitive. Although 
the majority of participants were female, the purposive sampling methodology produced 
a sample of participants with various types of cancers represented in society. 
Overall Quality of Life 
The sample of 236 individuals was evaluated in the current study (N = 236) for 
overall QOL and health satisfaction. The top two categories concerning general QOL of 
participants were good (41.1%, n = 97) and neither poor nor good (33.5%, n = 79). 
Concerning, overall health satisfaction, the top three categories concerning general health 
satisfaction of participants were dissatisfied (42.8%, n = 101), satisfied (24.2%, n = 57), 
and neither satisfied nor dissatisfied (21.6%, n = 51). Frequency and percent statistics of 
participants’ overall QOL and health satisfaction are displayed in Table 7.  
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Table 7 
Frequency and Percent Statistics of Participants’ Overall Quality of Life 
Demographic Frequency (n) Percent (%) 
Overall Quality of Life (Q11)   
   Very poor 2 0.8 
   Poor 42 17.8 
   Neither poor nor good 79 33.5 
   Good 97 41.1 
   Very good 16 6.8 
     Total 236 100.0 
   
Overall Health Satisfaction (Q12)   
   Very dissatisfied 20 8.5 
   Dissatisfied 101 42.8 
   Neither satisfied nor dissatisfied 51 21.6 
   Satisfied 57 24.2 
   Very satisfied 7 3.0 
     Total 236 100.0 
Note.  Total N = 236 
Analyses of Research Questions 1 and 2 
Research Questions 1 and 2 (i.e., RQ1 and RQ2) were evaluated using ANOVA, 
planned contrasts, post hoc tests, and moderated ANOVA. Specifically, any significant 
differences in cancer patient’s QOL between types of cancer pain management therapy 
(i.e., RQ1) and whether those differences were significantly moderated by gender (i.e., 
RQ2) were addressed. The dependent variable for RQ1 and RQ2 was cancer patient’s 
QOL scores as measured by the 26-question version of the World Health Organization 
Quality of Life Survey (WHOQOL-BREF; Appendix A). Participants’ QOL scores were 
measured by 24-items on similar 5-point standard intensity scales. Response parameters 
were 1 = not at all/very poor/very dissatisfied/never, 2 = a 
little/slightly/poor/dissatisfied/seldom, 3 = a moderate amount/moderately/neither poor 
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nor good/neither poor nor well/neither satisfied nor dissatisfied/quite often, 4 = very 
much/mostly/good/well/satisfied/very often, and 5 = an extreme 
amount/extremely/completely/very good/very well/very satisfied/always. These 24-items 
were combined to produce domain scores related to individual QOL. 
The WHOQOL-BREF produces a participant profile with four domain scores 
(i.e., physical health, psychological, social relationships [social relations], and 
environment) and two individually scored items concerning overall QOL and health 
perception (Skevington et al., 2004). The four domain scores and two individually scored 
items are scaled in a positive direction and higher scores indicate greater QOL or overall 
health perception. Additionally, three negatively framed questions (i.e., research survey 
#13, #14, and #36 coded f1_4, f11_3, and f8_1, respectively; see Appendix E) of the 
WHOQOL-BREF were reversed before scoring per WHO (1997a) instructions. The 
breakdown of questions in each domain is displayed in Appendix F. 
Following details in WHO (1997a) scoring guidelines, composite QOL scores 
were calculated for each participant for the four domains and overall measures. The two 
overall QOL and health-related WHOQOL-BREF survey questions were used for 
correlation identification. The summary results of the 24-domain-related WHOQOL-
BREF survey questions were used as the dependent variable for RQ1 and RQ2. The 
independent variable for RQ1 and RQ2 were participants’ cancer pain management (PM) 
therapy types including traditional prescription based (i.e., opioids), nontraditional based 
(i.e., cannabis), and a combination of traditional and nontraditional therapy types (i.e., 
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opioids and cannabis). The moderating variable for RQ2 was participants’ gender (male 
and female). The SurveyMonkey format of all the questions is displayed in Appendix G. 
Assumptions, Data Cleaning, and Conversion 
The sample data of 236 participants were then cleaned and converted to evaluate 
RQ1 and RQ2. Frequency tests, outliers, and plots were checked before parametric 
assumptions were tested. No missing or unusual cases were uncovered. For the 24-items 
related to the four domains, a raw score was computed for each item in each of the four 
domains. The raw numbers were checked against the valid frequency ranges of each 
domain (i.e., physical health from 7 to 35, psychological from 6 to 30, social 
relationships from 3 to 15, and environment from 8 to 40; WHO, 1997a). All raw domain 
scores for each participant were within these valid ranges. These raw scores were then 
transformed into a 0 to 100 scale score for each participant concerning the four domains. 
The scale scores were used in the ANOVA computations. 
The assumptions for conducting ANOVA analysis include independent 
observations, normal populations, and homogeneity of variance (Field, 2013; Laureate 
Education, 2009). Composite QOL scores were calculated for each participant by 
averaging case scores across the 24 domain-related WHOQOL-BREF survey items. 
Preliminary exploratory data analysis employed frequency, outliers, standardized 
skewness and kurtosis (i.e., z-test), normal Q-Q plots, histograms, box plots, and Shapiro-
Wilk’s (S-W) inspections/tests of normality (Field, 2013; Kim, 2013; Shapiro & Wilk, 
1965). For the sample using the composite QOL score (N = 236), visual inspection of 
plots, skewness of -0.208 (SE = 0.158), kurtosis of 0.244 (SE = 0.316), and S-W test (p > 
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.05) all indicated normal distribution results. Because large sample sizes can lead to 
normal distribution results, variable-related groups should be analyzed when parametric 
tests are conducted (Field, 2013). 
Similar exploratory data analysis was employed on the smaller variable-related 
groups using frequency, outliers, z-skewness and z-kurtosis, normal Q-Q plots, 
histograms, box plots, and S-W inspections tests of normality (Field, 2013; Kim, 2013; 
Shapiro & Wilk, 1965). Although ANOVA is not heavily dependent on the normal 
assumption when sample sizes are adequate (Mertler & Vannatta, 2013), the exploratory 
results on the smaller groups yielded results consistent with normality where sample sizes 
were large enough. In one case, the sample size was very small (n = 2), and skewness 
calculations require the sample to be greater than two (Zaiontz, 2014).  
This one group (i.e., males using marijuana) did not hinder the case for normality. 
Extremely small samples (n = 2) have been used without objections for t-tests when the 
effect size is large (de Winter, 2013). Further, many studies using Likert-type scaled data 
are not normally distributed, and normalcy is commonly assumed even if the data are not 
normal (Likert, 1932; Westland, 2010). Whether the group (i.e., males using marijuana) 
is normal or not, it was assumed to be normally distributed. These results helped identify 
the sample of participants used in the ANOVA models for RQ1 and RQ2. Descriptive 
statistics and S-W scores of participants’ overall composite QOL scores and by pain 
management therapy types and gender are displayed in Table 8. 
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Table 8 
Descriptive Statistics and S-W Scores of Participants’ Overall Composite QOL Scores 
and by Pain Management Therapy Type and Gender 
 
Composite QOL 
by PM & Gender n Min Max Mean 
S-W 
Sig. Std. Dev. Skewness Kurtosis 
Overall QOL 236 1.250 4.630 3.126 .644 0.570 -0.208 0.244 
         
PM Types         
   Opioids 170 1.250 4.250 3.089 .178 0.549 -0.368 0.247 
   Marijuana 30 2.000 4.630 3.347 .634 0.656 0.205 -0.418 
   Combination 36 1.750 4.210 3.119 .509 0.568 -0.496 0.211 
         
Gender     
 
   
   Male 32 2.46 4.250 3.319 .337 0.456 0.376 -0.325 
   Female 204 1.250 4.630 3.096 .686 0.581 -0.196 0.182 
         
PM by Gender         
   Opioids     
 
   
     Male 20 2.460 4.250 3.356 .311 0.471 0.253 0.003 
     Female 150 1.250 4.210 3.053 .166 0.550 -0.390 0.172 
     
 
   
   Marijuana     
 
   
     Male 2 2.670 3.500 3.083 N/A* 0.589 N/A* N/A* 
     Female 28 2.000 4.630 3.366 .676 0.666 0.162 -0.449 
         
   Combination     
 
   
     Male 10 2.790 4.080 3.292 .169 0.439 0.862 -0.521 
     Female 26 1.750 4.210 3.053 .364 0.605 -0.519 -0.195 
* Skewness and kurtosis statistics require n > 2 (Zaiontz, 2014) 
   Note. Total N = 236 
 
Normal Populations 
The aforementioned parametric assumptions were tested before the two research 
questions were examined. Descriptive statistics of the dependent variable (i.e., QOL) 
assumptions of normality and homoscedasticity were analyzed. Standardized skew and 
kurtosis coefficients (i.e., skew and kurtosis divided by their standard errors resulted in z-
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skew and z-kurtosis coefficients) were used to test the normality of distributions (Kim, 
2013; Tabachnick & Fidell, 2014). When N < 1,000, Tabachnick and Fidell (2014) 
associate z-skew and z-kurtosis coefficients as non-normal if exceed the range between 
+3.29 (p = .001). Kim (2013) breaks down N values as small (n < 50), medium (50 < n < 
300), and large (n > 300) sample sizes and specifies non-normal criteria accordingly (i.e., 
+ 1.96, + 3.29, and n/a, respectively). Based on these previous criteria, evaluation of the 
z-skew and z-kurtosis coefficients resulted in no distributions that exceeded the critical 
ranges. Hence, the distributions were assumed to be normally distributed because the 
assumption of normality was not violated. Standardized skewness and kurtosis statistics 
of participants’ composite QOL scores by pain management therapy types and gender are 
displayed in Table 9. 
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Table 9 
Standardized Skewness and Kurtosis Statistics of Participants’ Overall Composite QOL 
Scores by Pain Management Therapy Types and Gender 
 
Quality of Life by 
PM Types n Skewness 
Skew Std. 
Error z-skew Kurtosis 
Kurtosis 
Std. Error z-kurtosis 
Overall QOL 236 -0.208 0.158 -1.32 0.244 0.316 0.772 
        
PM Types        
   Opioids 170 -0.368 0.186 -1.978 0.247 0.370 0.668 
   Marijuana 30 0.205 0.427 0.480 -0.418 0.833 -0.502 
   Combination 36 -0.496 0.393 -1.262 0.211 0.768 0.275 
        
Gender        
   Male 32 0.376 0.414 0.908 -0.325 0.809 0.402 
   Female 204 -0.196 0.170 -1.153 0.182 0.339 0.537 
        
PM by Gender        
   Opioids        
     Male 20 0.253 0.512 0.494 0.003 0.992 0.003 
     Female 150 -0.390 0.198 -1.970 0.172 0.394 0.437 
        
   Marijuana        
     Male 2 N/A* N/A* N/A* N/A* N/A* N/A* 
     Female 28 0.162 0.441 0.367 -0.449 0.858 -0.523 
        
   Combination        
     Male 10 0.862 0.687 1.255 -0.521 1.334 -0.391 
     Female 26 -0.519 0.456 -1.138 -0.195 0.887 -0.220 
*Skewness and kurtosis statistics require n > 2 (Zaiontz, 2014) 
   Note. Total N = 236 
 
Homoscedasticity 
The variances of the dependent variable (i.e., QOL), across levels of the 
independent variables (i.e., pain management therapy and gender), were tested for 
equality of error variances using the Levene’s test. Results indicated that no distributions 
violated the assumption of homogeneity of variance (p  > .05). Specifically, Levene’s test 
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for homogeneity of variance failed to detect any significant difference between the RQ1 
(F[2,233] = 0.589, p = .556) and RQ2 (F[5,230] = 0.753, p = .585) group variances, 
which indicated equal variances. Because there was an equal distribution of error 
variances across levels of the independent variables, the assumption of homogeneity of 
variance was not violated. These results helped identify the sample of 236 cases used in 
the ANOVA models for RQ1 and RQ2 (N = 236). Table 10 contains the composite QOL 
Levine’s test summary details for RQ1 and RQ2. 
Table 10 
Summary of Levene’s Tests for Research Questions 1 and 2 (Composite QOL) 
Research 
Question Independent Variable F df1 df2 Sig. (p) 
RQ1 Pain Management Therapy 0.589 2 233 0.556 
RQ2 Pain Management Therapy and Gender 0.753 5 230 0.585 
Note. Dependent variable = Composite quality of life score, total N = 236 
 
Although normality and homogeneity of variance were evaluated using composite 
QOL scores for the participants and research-related groups, transformed domain scores 
(i.e., physical health, psychological, social relationships, and environment) related to the 
research-related groups were also analyzed. Overall the physical domain had the lowest 
mean domain score (42.45, SD = .178) and the environment domain had the highest mean 
domain score (63.37, SD = .509). Concerning z-skewness and z-kurtosis, all transformed 
overall domain scores and domain scores by pain management therapy type and gender 
indicated normal characteristics except the z-skewness for opioids in the environment 
domain (i.e., -3.468 exceeded +3.29 threshold). Results indicated that no distributions 
violated the assumption of homoscedasticity (p  > .05) except for gender in the social 
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relations domain (F[1,234] = 4.815, p = .029 which is < .05). Homogeneity of variance 
tests for pain management therapy by gender in the marijuana group was not calculated 
(i.e., n was not > 2; O’Neill & Mathews, 2000). In sum, all values analyzed indicated 
normality, except the z-skewness for opioids in the environment domain, and 
homogeneity of variance, except for the gender group related to the social relations 
domain. Descriptive statistics of participants’ overall transformed domain scores and by 
gender and pain management (PM) therapy type are displayed in Table 11. Levene’s test 
scores based on transformed domain scores can be found in Table 12.  
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Table 11 
Descriptive Statistics of Participants’ Overall Transformed Domain Scores and by Pain 
Management Therapy Type and Gender 
 
Transform 
Domain by PM 
Type & Gender 
n Min Max Mean 
Std. 
Dev. Skewness Kurtosis z-Skewness 
z-
Kurtosis 
Trans Domain     
  
   
   Physical 236 3.570 89.29 42.45 .178 0.361 -0.276 2.285 -0.873 
   Psychological 236 4.170 91.67 52.95 .634 -0.351 -0.158 -2.222 -0.500 
   Social Relations 236 0.000 100.0 51.31 .509 -0.111 -0.699 -0.703 -2.212 
   Environment 236 3.130 100.0 63.37 .509 -0.499 0.499 -3.158 -1.579 
          
Domain by PM     
  
   
  Physical          
     Opioid 170 3.57 85.71 40.29 16.04 0.331 -0.311 1.780 -0.841 
     Marijuana 30 25.00 89.29 54.52 17.34 0.358 -0.775 0.838 -0.930 
     Combination 36 3.57 82.14 42.56 18.12 0.273 -0.357 0.695 -0.465 
  Psychological          
     Opioid 170 4.17 87.50 51.42 17.31 -0.338 -0.182 -1.817 -0.492 
     Marijuana 30 25.00 91.67 60.97 17.07 -0.227 -0.877 -0.532 -1.053 
     Combination 36 4.17 87.50 53.47 18.41 -0.642 0.432 -1.634 0.563 
  Social Relations          
     Opioid 170 0.000 100.0 49.75 21.42 -0.107 -0.804 -0.575 -2.173 
     Marijuana 30 8.330 100.0 58.06 24.12 -0.220 -0.795 -0.515 -0.954 
     Combination 36 0.000 91.67 53.01 22.37 -0.260 -0.041 -0.662 -0.053 
  Environment          
     Opioid 170 3.13 96.88 64.17 16.19 -0.645 0.828 -3.468 2.238 
     Marijuana 30 28.13 100.0 60.83 18.75 0.236 -0.482 0.553 -0.579 
     Combination 36 18.75 93.75 61.72 14.76 -0.749 1.157 -1.906 1.507 
          
Domain by Gender     
  
   
..Physical          
     Male 32 21.43 85.71 50.11 15.51 0.300 -0.143 0.725 -0.177 
     Female 204 3.57 89.29 41.25 17.08 0.417 -0.218 2.453 -0.643 
  Psychological          
     Male 32 20.83 87.50 58.72 15.89 -0.602 0.036 -1.454 0.044 
     Female 204 4.17 91.67 52.04 17.79 -0.307 -0.147 -1.806 0.434 
  Social Relations          
     Male 32 16.67 91.67 51.56 18.51 0.351 -0.162 0.848 -0.200 
     Female 204 0.000 100.0 51.27 22.55 -0.146 -0.765 -0.859 -2.257 
  Environment          
     Male 32 46.88 93.75 66.70 12.34 0.290 -0.300 0.700 -0.371 
     Female 204 3.13 100.0 62.85 16.81 -0.501 0.380 -2.947 1.121 
   Note. Total N = 236 
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Table 12 
Summary of Levene’s Tests for Research Questions 1 and 2 (Transformed Domain) 
Research 
Question Independent Variable F df1 df2 Sig. (p) 
RQ1 Pain Management Therapy     
   Physical 0.665 2 233 0.515 
   Psychological 0.118 2 233 0.889 
   Social Relations 0.730 2 233 0.483 
   Environment 1.406 2 233 0.247 
      
RQ2 Gender     
   Physical 0.356 1 234 0.551 
   Psychological 0.613 1 234 0.434 
   Social Relations 4.815 1 234 0.029 
    Environment 3.856 1 234 0.051 
      
 Pain Management Therapy and Gender     
   Opioids     
    Physical 0.211 1 168 0.646 
    Psychological 0.613 1 168 0.813 
    Social Relations 4.815 1 168 0.515 
    Environment 0.356 1 168 0.160 
      
   Marijuana* N/A* - - N/A* 
      
   Opioids and Marijuana     
    Physical 0.001 1 34 0.981 
    Psychological 0.915 1 34 0.345 
    Social Relations 2.930 1 34 0.096 
    Environment 0.822 1 34 0.371 
*Levene’s tests require n > 2 (O’Neill & Mathews 2000) 
Note. Dependent variable = transformed domain (tdom1, tdom2, tdom3, & tdom4); N = 236 
 
The significant values could be related to the transformation process or relatively 
large sample size. According to Field (2013), skew and kurtosis significance tests should 
not be used in large samples because ambiguous results may occur. Because the 
significant z-skew (i.e., environment) and homogeneity of variance (i.e., social relations) 
results occurred in the two domains where no significant ANOVA results occurred (i.e., 
discussed in next section), no corrective data procedures were taken. Further, many 
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studies using Likert-type scaled data are not normally distributed, and the normalcy 
assumption is commonly taken even if the data are not normal (Likert, 1932; Westland, 
2010). Additionally, the transformed domain data were calculated values per standardized 
and validated WHO procedures (Skevington, 2004; WHO, 1997a). 
The four domains were also analyzed concerning reliability. The physical, 
psychological, and environment domains all had high reliabilities (all Cronbach’s α > 
.80). The social relations domain had a lower reliability (Cronbach’s α = .67). According 
to Field (2013), Cronbach’s α values around 0.80 are considered good. Cortina (1993) 
cites values of at least 0.70 indicate internal consistency in many cases. Cronbach’s α 
based on questions related to each domain can be found in Table 13. 
Table 13 
Summary of Cronbach’s α for Domain-related Questions 
Domain N of Items* 
Cronbach’s 
α 
  Physical 7 0.824 
  Psychological 6 0.827 
  Social Relations 3 0.671 
  Environment 8 0.799 
* Total of 24-domain-related questions 
Results of Hypothesis 1 
H01: Quality of life will not differ between cancer pain-management types. 
Ha1: Quality of life will differ between cancer pain-management types. 
In accordance with WHOQOL-BREF criteria, QOL is broken into four distinct 
domains (i.e., physical health, psychological, social relationships, and environment; 
WHO, 1997a). These four QOL dimensions have different numbers of corresponding 
questions, raw domain score ranges, and transformed scales (WHO, 1997a). Transformed 
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scores (i.e., from 1 to 100) were calculated for each participant and domain, where higher 
scores indicate a higher QOL per domain (WHO, 1997a). These transformed domain 
scores were quantitatively analyzed.  
Using SPSS 23.0, ANOVA was conducted to assess if significant differences in 
cancer patient’s QOL existed between types of pain management therapy (i.e., traditional 
[opioids], nontraditional [marijuana], and combination [opioids and marijuana]) for each 
domain. Analysis of transformed domain results indicated that significant differences in 
the QOL scores of participants between pain management types in the physical and 
psychological domains existed but not in the social relations and environmental domains. 
Specific relationships and details were identified using ANOVA, effect size, planned 
contrasts, and post hoc tests. Planned contrasts and post hoc tests allow multiple 
comparisons in order to determine whether groups differed from each other (Field, 2013; 
Mertler & Vannatta, 2013). 
In the physical domain, several significant relationships were identified 
concerning pain management therapy. The between groups overall relationship was 
significant, F(2, 233) = 9.446, p < .001, partial η2 = .075. Per Cohen’s guidelines, partial 
eta-squared (partial η2) effects can be small, moderate, and large (i.e., .0099, .0588, and 
.1379, respectively; as cited in Richardson, 2011); thus, effect size was moderate. Results 
of planned contrasts and post hoc tests helped identify significant results of the various 
pain management therapy options. Concerning planned contrasts, there was a significant 
difference between participants who used opioids and participants who used both 
marijuana and marijuana and opioids combined, t(233) = 3.429, p = .001. Further, there 
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was a significant difference between participants who used marijuana and participants 
who used both marijuana and opioids combined, t(233) = -2.927, p = .004. 
Analysis of both Hochberg GT2 and Games-Howell post hoc tests confirmed 
previous significant results. Field (2013) recommends using the Hochberg GT2 when 
sample sizes are very different and using the Games–Howell if there is any doubt 
concerning homoscedasticity. Significant results were indicated for participants who used 
opioids and participants that used marijuana (p < .001 for both post hoc tests) and 
between participants that used marijuana and participants that used opioids and marijuana 
combined (p = .011 and p = .022, respectively for the two post hoc tests). Therefore, 
participants that used traditional (opioids) pain management therapy had a significantly 
lower physical QOL domain score (M = 40.29, SD = 16.04) as compared to those that 
received nontraditional pain management therapy (marijuana, M = 54.52, SD = 17.34). 
When opioid therapy use was compared to the combination of the two therapies (opioids 
and marijuana, M = 42.56, SD = 18.12), no significance difference was indicated (p = 
.838 and p = .768, respectively). However, when marijuana therapy was compared to the 
combination of the two therapies (opioids and marijuana), a significant difference was 
indicated (p = .011 and p = .022, respectively).  
In the psychological domain, a significant relationship was also identified 
concerning pain management therapy. The between groups overall relationship was 
significant, F(2, 233) = 3.839, p = .023, partial η2 = .032. Results of planned contrasts 
and post hoc tests helped identify significant results of the various pain management 
therapy options. Concerning planned contrasts, there was a significant difference between 
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participants who used opioids and participants who used both marijuana and marijuana 
and opioids combined, t(233) = 2.285, p = .023. In this domain, there was not a 
significant difference between participants who used marijuana and participants who used 
both marijuana and opioids combined, t(233) = -1.715, p = .083. 
Analysis of both Hochberg GT2 and Games-Howell post hoc tests confirmed 
previous significant results. Significant results were indicated for participants who used 
opioids when compared to participants that used marijuana (p = .018 and p = .020, 
respectively). Therefore, participants that used traditional (opioids) pain management 
therapy had a significantly lower psychological QOL domain score (M = 51.42, SD = 
17.31) as compared to those that received nontraditional pain management therapy 
(marijuana, M = 60.97, SD = 17.07). When opioid therapy use was compared to the 
combination of the two therapies (opioids and marijuana, M = 53.47, SD = 18.40) no 
significant difference was indicated (p = .891 and p = .813, respectively). In this domain, 
when marijuana therapy was compared to the combination of the two therapies (opioids 
and marijuana), no significant difference was indicated (p = .229 and p = .208, 
respectively). 
In the social relations and environment domains, no significant relationships were 
identified concerning pain management therapy. The between groups overall relationship 
for the social relations domain was not significant, F(2, 233) = 1.956, p = .144. The 
between groups overall relationship for the environment domain was not significant, F(2, 
233) = 0.752, p = .473. Therefore, the null hypothesis for RQ1 was rejected. Quality of 
life in the physical and psychological domains for cancer patients surveyed significantly 
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differed between cancer pain management types. Table 14 displayed a model summary of 
the ANOVA analysis for Hypothesis 1 and planned contrasts and post hoc test analysis 
were displayed in Table 15. 
Table 14 
Model Summary of the ANOVA Analysis for Hypothesis 1 
Source 
Type III 
Sum of 
Squares 
df Mean Square F Sig. (p) 
Partial 
Eta 
Squared 
Observed 
Power 
Physical Transformed        
Corrected Model 5163.869 2 2581.934 9.446 < .001 0.075 0.979 
Intercept 281707.5 1 281707.5 1030.631 < .001 0.816 1.000 
Therapy 1.667 2 0.834 2.588 < .001 0.075 0.979 
Error 63687.04 233 0.322     
Total 494094.4 236      
Corrected Total 68850.91 235      
        
Psychological Transformed        
Corrected Model 2337.636 2 1168.818 3.839 0.023 0.032 0.693 
Intercept 410660.0 1 410660.0 1348.787 < .001 0.853 1.000 
Therapy 2337.636 2 1168.818 3.839 0.023 0.032 0.693 
Error 70940.60 233 304.466     
Total 734913.2 236      
Corrected Total 73278.23 235      
        
Social Relations Transformed        
Corrected Model 1880.138 2 940.069 1.956 0.144 0.017 0.403 
Intercept 386052.3 1 386052.3 803.463 < .001 0.775 1.000 
Therapy 1880.138 2 940.069 1.956 0.144 0.017 0.403 
Error 111953.1 233 480.486     
Total 735069.4 236      
Corrected Total 113833.3 235      
        
Environment Transformed        
Corrected Model 400.757 2 200.378 .752 0.473 0.006 0.177 
Intercept 520441.5 1 520441.5 1952.868 < .001 0.893 1.000 
Therapy 400.757 2 200.378 .752 0.473 0.006 0.177 
Error 62094.77 233 266.501     
Total 1010332 236      
Corrected Total 62495.53 235           
Note. Dependent variable = transformed domain (tdom1, tdom2, tdom3, & tdom4); N = 236 
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Table 15 
Model Summary of Planned Contrasts and Post Hoc Test Analysis for Hypothesis 1 
 
Source 
Value 
of 
Contrast 
df Std. Error t 
Sig. 
(p) 
Mean 
Diff 
95% 
Lower CI Upper 
Physical Transformed         
 Planned Contrasts         
  Opioid vs Mar & Combined  16.495 233 4.810 3.429  0.001  
 
 
  Marijuana vs Combined  -11.964 233 4.087 -2.927  0.004  
 
 
 Hochberg Post Hoc Test         
  Opioid vs Marijuana   3.274  < .001 -14.230 
-22.10 -6.36 
  Opioid vs Combined   3.033  0.838 -2.265 -9.56 5.03 
  Marijuana vs Combined   4.087  0.011 11.964 2.14 21.79 
 Games-Howell Post Hoc         
  Opioid vs Marijuana   3.397  < .001 -14.230 -22.51 -5.95 
  Opioid vs Combined   3.261  0.768 -2.265 
-10.15 5.62 
  Marijuana vs Combined   4.375  0.022 11.964 
1.46 22.47 
         
Psychological Transformed         
 Planned Contrasts         
  Opioid vs Mar & Combined  11.601 233 5.076 2.285  0.023    
  Marijuana vs Combined  -7.500 233 4.314 -1.739  0.083    
 Hochberg Post Hoc Test         
  Opioid vs Marijuana   3.455  0.018 -9.551 
-17.86 -1.24 
  Opioid vs Combined   3.201  0.891 -2.051 
-9.75 5.65 
  Marijuana vs Combined   4.314  0.229 7.500 
-2.87 17.87 
 Games-Howell Post Hoc         
  Opioid vs Marijuana   3.388  0.020 -9.551 -17.80 -1.31 
  Opioid vs Combined   3.205  0.813 -2.051 -10.13 6.03 
  Marijuana vs Combined   4.374  0.208 7.500 -3.00 18.00 
         
Social Relations Transformed         
 Planned Contrasts         
  Opioid vs Mar & Combined  11.555 233 6.377 1.812  0.071  
 
 
  Marijuana vs Combined  -5.046 233 5.419 -0.931  0.353  
 
 
 Hochberg Post Hoc Test         
  Opioid vs Marijuana   4.341  0.161 -8.301 -18.74 2.14 
  Opioid vs Combined   4.022  0.803 -3.254 -12.92 6.42 
  Marijuana vs Combined   5.419  0.728 5.046 -7.98 18.08 
 Games-Howell Post Hoc         
  Opioid vs Marijuana   4.700  0.195 -8.301 
-19.77 3.17 
  Opioid vs Combined   4.075  0.706 -3.254 
-13.01 6.59 
  Marijuana vs Combined   5.771  0.658 5.046 
-8.82 18.91 
Note. Dependent variable = transformed domain (tdom1, tdom2, tdom3, & tdom4); N = 236 
(table continues) 
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Source Value of Contrast df 
Std. 
Error t 
Sig. 
(p) 
Mean 
Diff 
95% 
Lower 
CI 
Upper 
Environment Transformed         
 Planned Contrasts         
  Opioid vs Mar & Combined  -5.794 233 4.749 -1.220  0.224    
  Marijuana vs Combined  0.885 233 4.036 0.219  0.827    
 Hochberg Post Hoc Test         
  Opioid vs Marijuana   3.233  0.660 3.339 
-4.43 11.11 
  Opioid vs Combined   3.000  0.797 2.454 
-4.75 9.66 
  Marijuana vs Combined   4.036  0.995 -0.885 
-10.59 8.82 
 Games-Howell Post Hoc         
  Opioid vs Marijuana   3.641  0.633 3.339 -5.55 12.23 
  Opioid vs Combined   2.755  0.648 2.454 -4.19 9.09 
  Marijuana vs Combined   4.215  0.976 -0.885 -11.04 9.27 
Note. Dependent variable = transformed domain (tdom1, tdom2, tdom3, & tdom4); N = 236 
 
Figure 7 displayed the transformed physical domain QOL score for each pain 
management therapy group. Participants that employed marijuana to manage pain 
reported higher levels of physical domain QOL (M = 54.52 [significant at p < .05]) 
compared to those that used either opioids or opioids and marijuana (M = 40.29, M = 
42.56, respectively).  
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Figure 7. Transformed physical QOL across pain management therapy. 
Figure 8 displayed the transformed psychological domain QOL score for each 
pain management therapy group. Participants that employed marijuana to manage pain 
reported higher levels of psychological domain QOL (M = 60.97 [significant at p < .05]) 
compared to those that used opioids (M = 51.42).  
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Figure 8. Transformed psychological QOL across pain management therapy. 
Results found in H01 were compared to the two general WHOQOL-BREF 
questions concerning overall quality of life and health of the participants using ANOVA 
and post hoc tests. Analyzing the general QOL question (i.e., How would you rate your 
quality of life?) results, several significant relationships were identified concerning pain 
management therapy. The between groups overall relationship was significant, F(2, 233) 
= 5.361, p = .005, partial η2 = .044. Results of post hoc tests helped identify significant 
results concerning participant use of the various pain management therapy options and 
the overall QOL question.  
Analysis of both Hochberg GT2 and Games-Howell post hoc tests identified 
significant results. Significant results were indicated for participants who used opioids 
when compared to participants that used marijuana (p = .004 and p = .003, respectively) 
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and between participants that used marijuana when compared to participants that used 
opioids and marijuana combined (p = .042 and p = .048, respectively). Participants that 
used traditional (opioids) pain management therapy had a significantly lower overall 
QOL score (M = 3.28, SD = 0.85) as compared to those that used nontraditional pain 
management therapy (marijuana, M = 3.83, SD = 0.79). When opioid therapy use was 
compared to the combination of the two therapies (opioids and marijuana, M = 3.31, SD 
= 0.98) no significant difference was indicated (p = .997 and p = .985, respectively). 
However, when marijuana therapy was compared to the combination of the two therapies 
(opioids and marijuana), a significant difference was indicated (p = .042 and p = .048, 
respectively). Therefore, participants that used marijuana had a significantly higher 
overall QOL perception than those participants that used either opioids or combined 
opioids and marijuana pain therapies. 
Analyzing the general health question (i.e., How satisfied are you with your 
health?) results, one significant relationship was identified concerning pain management 
therapy. The between groups overall relationship was significant, F(2, 233) = 5.653, p = 
.004, partial η2 = .046. Results of post hoc tests helped identify significant results 
concerning participant use of the various pain management therapy options and the 
overall health question.  
Analysis of both Hochberg GT2 and Games-Howell post hoc tests identified 
significant results. Significant results were indicated for participants who used opioids 
when compared to participants that used marijuana (p = .003 and p = .001, respectively). 
Participants that used traditional (opioids) pain management therapy had a significantly 
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lower overall health score (M = 2.60, SD = 1.00) as compared to those that received 
nontraditional pain management therapy (marijuana, M = 3.27, SD = 0.83). When opioid 
therapy use was compared to the combination of the two therapies (opioids and 
marijuana, M = 2.72, SD = 1.14), no significant difference was indicated (p = .879 and p 
= .822, respectively). When marijuana therapy was compared to the combination of the 
two therapies (opioids and marijuana), no significant difference was indicated (p = .084 
and p = .071, respectively). Therefore, participants that used marijuana had a significantly 
higher health perception than those participants that used opioids. A model summary of 
the ANOVA analysis for general QOL and health questions was displayed in Table 16 
and post hoc test analysis in Table 17. 
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Table 16 
Model Summary of the ANOVA Analysis for General QOL and Health Questions 
Source 
Type III 
Sum of 
Squares 
df Mean Square F Sig. (p) 
Partial 
Eta 
Squared 
Observed 
Power 
General QOL Question        
Corrected Model 7.998 2 3.999 5.361  0.005 0.044 0.838 
Intercept 1619.258 1 1619.258 2170.669 0.005 0.903 1.000 
Therapy 7.998 2 3.999 5.361 0.005 0.044 0.838 
Error 173.811 233 0.746     
Total 2833.000 236      
Corrected Total 181.809 235      
        
General Health Question        
Corrected Model 11.348 2 5.674 5.653 0.004 0.046 0.858 
Intercept 1101.137 1 1101.137 1096.953 < .001 0.852 1.000 
Therapy 11.348 2 5.674 5.653 0.004 0.046 0.858 
Error 233.889 233 1.004     
Total 1970.000 236      
Corrected Total 245.237 235           
Note. Dependent variable = General QOL and Health question scores; N = 236 
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Table 17 
Model Summary of Post Hoc Test Analysis for General QOL and Health Questions 
Source Std. Error Sig. (p) Mean Diff 95% Lower 
CI 
Upper 
General QOL Question      
 Hochberg Post Hoc Test      
  Opioid vs Marijuana 0.171 0.004 -0.56 -0.97 -0.15 
  Opioid vs Combined 0.158 0.997 -0.03 -0.41 0.35 
  Marijuana vs Combined 0.214 0.042 0.53 0.01 1.04 
 Games-Howell Post Hoc      
  Opioid vs Marijuana 0.159 0.003 -0.56 -0.94 -0.17 
  Opioid vs Combined 0.176 0.985 -0.03 -0.45 0.40 
  Marijuana vs Combined 0.218 0.048 0.53 0.00 1.05 
      
General Health Question      
 Hochberg Post Hoc Test      
  Opioid vs Marijuana 0.198 0.003 -0.67 -1.14 -0.19 
  Opioid vs Combined 0.184 0.879 -0.12 -0.56 0.32 
  Marijuana vs Combined 0.248 0.084 0.54 -0.05 1.14 
 Games-Howell Post Hoc      
  Opioid vs Marijuana 0.169 0.001 -0.67 -1.08 -0.26 
  Opioid vs Combined 0.204 0.822 -0.12 -0.62 0.37 
  Marijuana vs Combined 0.242 0.071 0.54 -0.04 1.13 
Note. Dependent variable = General QOL and Health question scores; N = 236 
 
The findings for overall QOL and health perceptions of participants were 
consistent with the findings for the QOL domain perceptions of participants. The physical 
and psychological domain findings indicated higher QOL perceptions in participants that 
used marijuana for pain management therapy when compared to participants that used 
opioids. Analysis of the general QOL and health questions ANOVA and post hoc tests 
results indicated a similar correlation. Interpreting both general questions indicated a 
higher QOL and health perceptions in cancer patients that used marijuana for pain 
management therapy when compared to cancer patients that used opioids.  
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Results of Hypothesis 2 
H02: The impact of cancer pain-management type on quality of life is not 
moderated by gender. 
Ha2: The impact of cancer pain-management type on quality of life is moderated 
by gender. 
Hypothesis 2 was evaluated using moderation (i.e., PROCESS tool; Field, 2013; 
Hayes, 2013) to determine if gender significantly moderated the relationship between 
cancer patients’ QOL and their pain management therapy types. In accordance with 
WHOQOL-BREF criteria, QOL was broken down into four distinct domains (i.e., 
physical health, psychological, social relationships, and environment; WHO, 1997a). 
These four QOL dimensions had different numbers of corresponding questions, raw 
domain score ranges, and transformed scales (WHO, 1997a). Transformed scores (i.e., 
from 1 to 100) were calculated for each participant and domain, where higher scores 
indicate a higher QOL per domain (WHO, 1997a).  
These four transformed domain scores were quantitatively analyzed using the 
PROCESS tool. Concerning the transformed physical domain, results indicated that there 
were no significant differences between male and female participants and their pain 
management therapy types, b = 3.749, 95% CI [-3.884, 11.382], t = .968, p = .334. 
Concerning the transformed psychological domain, results indicated that there were no 
significant differences between male and female participants and their pain management 
therapy types, b = 0.076, 95% CI [-7.036, 7.188], t = .021, p = .983. Concerning the 
transformed social relations domain, results indicated that there were no significant 
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differences between male and female participants’ and their pain management therapy 
types, b = 4.827, 95% CI [-3.803, 13.458], t = 1.102, p = .272. Concerning the 
transformed environment domain, results indicated that there were no significant 
differences between male and female participants and their pain management therapy 
types, b = 1.660, 95% CI [-3.959, 7.278], t = .582, p = .561. 
The Null Hypothesis 2 was not rejected. The impact of cancer pain-management 
type on QOL was not moderated by gender. None of the four QOL domains indicated any 
significant differences between male and female participants and their pain management 
therapy types. A model summary of the moderated ANOVA analysis (i.e., PROCESS 
tool) for Hypothesis 2 was displayed in Table 18. 
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Table 18 
Model Summary of the PROCESS Tool Analysis for Hypothesis 2 
Source Coeff SE t Sig. (p) LLCI ULCI 
Model Summary       
 Transformed Physical        
   Constant 42.578 1.117 38.131 < .001 40.378 44.778 
   Gender -8.899 3.109 -2.862 0.005 -15.024 -2.774 
   Therapy 2.618 1.676 1.562 0.120 -0.684 5.920 
   Int_1 3.749 3.874 0.968 0.334 -3.884 11.382 
       
 Transformed Psychological       
   Constant 52.951 1.167 45.368 < .001 50.652 55.251 
   Gender -6.178 3.318 -1.862 0.064 -12.715 0.359 
   Therapy 1.761 1.700 1.036 0.301 -1.588 5.110 
   Int_1 0.076 3.610 0.021 0.983 -7.036 7.188 
       
 Transformed Social Relations        
   Constant 51.474 1.465 35.134 < .001 48.587 54.360 
   Gender -0.481 3.986 -0.121 0.904 -8.334 7.373 
   Therapy 2.894 2.138 1.354 0.177 -1.319 7.105 
   Int_1 4.827 4.380 1.102 0.272 -3.803 13.458 
       
 Transformed Environment       
   Constant 63.431 1.074 59.070 < .001 61.316 65.547 
   Gender -4.693 2.621 -1.791 0.075 -9.856 0.471 
   Therapy -1.654 1.469 -1.126 0.261 -4.548 1.240 
   Int_1 1.660 2.852 0.582 0.561 -3.959 7.278 
       
Corrected Total 76.718 235         
Note. Dependent variable = transformed domain (tdom1, tdom2, tdom3, & tdom4); N = 236 
Int_1 = Therapy * Gender 
LLCI = Lower level confidence interval 
ULCI = Upper level confidence interval 
 
 
Summary 
The purpose of the nonexperimental research was to determine the effects 
different types of cancer pain management treatments may have on cancer patients’ QOL. 
Pain management therapies for cancer patients were defined by traditional (i.e., opioids), 
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nontraditional (i.e., marijuana, also known as cannabis), and combined nontraditional and 
traditional. Gender (i.e., male and female) was also examined to determine if it affected 
the difference in cancer patient pain management and QOL. Pain is a secondary health 
problem that many cancer patients suffer which may relate to their QOL (Shneerson et 
al., 2013). Pain management is an essential determinant of patient outcomes because 
unrelieved pain significantly comprised patient QOL and effective pain management was 
associated with patient survival (Perlman et al., 2013). 
Research participants were reached through cancer and medical-related groups, 
SurveyMonkey Contribute program, and a cancer patient research firm. Data were 
collected from 617 individuals via SurveyMonkey, but 381 participants were removed 
from all analyses and a sample of 236 individuals was evaluated in the current study (N = 
236). Using SPSS 23.0, this sample was analyzed for its various characteristics (e.g., 
gender, age group, education level, and cancer type and stage). Analysis of variance 
(ANOVA), planned contrasts, post hoc tests, and moderated ANOVA (i.e., PROCESS 
tool) were used to evaluate the two research questions.   
Significant results concerning cancer patient QOL were indicated from some of 
the research tests. In accordance with WHOQOL-BREF criteria, QOL is broken down 
into four distinct domains (i.e., physical health, psychological, social relationships, and 
environment; WHO, 1997a). Concerning Research Question 1, results from the ANOVA 
indicated significant differences in the QOL scores of cancer patients between pain 
management types in the physical and psychological domains but not in the social 
relations and environmental domains. In the physical domain, there was a significant 
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difference between cancer patients who used opioids and cancer patients who used 
marijuana (p < .001 for Hochberg GT2 post hoc test) and cancer patients who used 
marijuana and those that used marijuana and opioids combined (p = .011). In the 
psychological domain, there was a significant difference between cancer patients who 
used opioids and cancer patients who used marijuana (p = .018). Therefore, participants 
that used traditional (opioids) pain management therapy had a significantly lower 
physical and psychological QOL domain score as compared to those that used 
nontraditional pain management therapy (marijuana). Further, participants that used 
marijuana and opioids combined pain management therapy had a significantly lower 
physical QOL domain score as compared to those that used marijuana pain management 
therapy. Results from Research Question 2 indicated that there were no significant 
differences between the four domains of QOL for male and female cancer patients and 
their pain management therapy types (i.e., physical health [p = .334], psychological [p = 
.983], social relations [p = .272], and environment [p = .561]). Displayed in Table 19 are 
summary details of the results for Research Questions 1 and 2. 
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Table 19 
Summary of Results for Research Questions 1 and 2 
Research 
Question 
Dependent 
Variable/Domain Independent Variable Moderator Analysis Sig. (p)* 
RQ1 Quality of Life Pain Management Type  ANOVA  
   Physical     
  Opioid vs Marijuana   < .001   Opioid vs Combined   0.838   Marijuana vs Combined   0.011 
      
   Psychological Opioid vs Marijuana   0.018 
  Opioid vs Combined   0.891 
  Marijuana vs Combined   0.229       
   Social Relations     
  Opioid vs Marijuana   0.161   Opioid vs Combined   0.803 
  Marijuana vs Combined   0.728 
      
   Environment     
  Opioid vs Marijuana   0.660 
  Opioid vs Combined   0.797 
  Marijuana vs Combined   0.995 
      
RQ2 Quality of Life Pain Management Type Gender Moderated ANOVA   
   Physical    0.334 
   Psychological    0.983 
   Social Relations    0.272 
   Environment    0.561 
Note. N = 236 
*Hochberg GT2 post hoc test result 
 
These results indicated a different dimension to previous research concerning use 
of opioids and/or marijuana and cancer patient pain management. Previous studies have 
been conducted concerning advanced cancer pain, opioids, and adjuvant use of various 
cannabinoid formulations (Johnson et al., 2013; Portenoy et al., 2012). Adjunct use of the 
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THC/CBD oromucosal spray (i.e., Sativex®) along with opioids indicated improvements 
in pain in both short and long-term studies for both noncancer and cancer pain (Hoggart 
et al., 2015; Johnson et al., 2013; Portenoy et al., 2012; Serpell et al., 2014). Further, the 
substitution of cannabis for prescription drugs occurred in 80.3% of participants and the 
highest rated reason for conversion was pain-related conditions (Lucas et al., 2015). For 
chronic pain participants, cannabis reset opiate analgesia, decreased opiate dosage, and 
reduced pain levels experienced (Lucas, 2012). In this study, cancer patients who used 
marijuana indicated a higher QOL score in both physical and psychological domains as 
compared to those that used opioids. Cancer patients that used marijuana also indicated a 
significantly higher QOL when compared to cancer patients that used both opioids and 
marijuana combined in the physical domain scores. Results indicated that there were no 
significant differences between the four domains of QOL for male and female cancer 
patients and their pain management therapy types. This result was consistent with 
previous research that indicated mixed results concerning use and abuse of both opioids 
and marijuana when gender was considered (Greenfield et al., 2010).  
In Chapter 5 of this study, an overview of the importance of this study and its 
contribution to the understanding of the topic will be provided. Specific findings, 
limitations, and recommendations based on the data analyses will be covered. 
Additionally, theoretical and future implications, including positive social change, and 
recommendations for future research will conclude the study. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of the nonexperimental research was to determine the effects 
different types of cancer pain management treatments may have on cancer patients’ QOL. 
Pain management is an essential determinant of patient outcomes because unrelieved pain 
significantly comprised patient QOL and effective pain management was associated with 
patient survival (Perlman et al., 2013). Pain management therapies for cancer patients 
were defined by traditional (i.e., opioids), nontraditional (i.e., marijuana, also known as 
cannabis), and combined nontraditional and traditional. Gender (i.e., male and female) 
was also examined to determine if it affects the difference in cancer patient pain 
management and QOL. Gender provided a research opportunity because effects of opioid 
and marijuana on cancer patient QOL have not been evaluated under these conditions. 
Significant results concerning cancer patient QOL were indicated from some of 
the research tests. In accordance with WHOQOL-BREF criteria, QOL is broken down 
into four distinct domains (i.e., physical health, psychological, social relationships, and 
environment; WHO, 1997a). Significant differences in the QOL scores of cancer patients 
were indicated between pain management types in the physical and psychological 
domains but not in the social relations and environmental domains. No significant 
differences were indicated between the four domains of QOL for male and female cancer 
patients and their pain management therapy types. 
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Interpretation of Findings 
Many medical clinicians, researchers, and leaders agree that opportunities exist 
concerning the potential use of cannabis for pain (Savage et al., 2016). Patients with 
cancer-related pain may benefit from using cannabis and opioids complementarily 
(Johnson et al., 2013; Kral et al., 2015). Bowles et al. (2012) and van den Beuken-van 
Everdingen et al. (2016) noted a lack of data concerning various cannabis and 
conventional pain medications concerning cancer-related pain.  
There are some studies indicating success with adjuvant cannabis use and cancer 
pain but further research is needed. In a short-term study, cannabis used in conjunction 
with opioids significantly reduced pain in participants, which may lower opioid doses and 
related side effects (Abrams et al., 2011). Significant improvements in pain were 
indicated in short and long-term studies related to cancer pain when using the THC/CBD 
spray (i.e., Sativex®; Johnson et al., 2013; Portenoy et al., 2012). Wilsey et al. (2013) 
demonstrated that low-dose (i.e., 1.29% THC), vaporized cannabis had a favorable risk-
benefit ratio in the treatment of neuropathic pain in some patients. In a small sample of 
advanced cancer patients over a long-term period, level doses of a cannabis extract 
reduced the pain of participants when use of strong opioids alone had failed (Johnson et 
al., 2013). Further, participants displayed improvements in sleep outcomes throughout the 
complementary treatment period, and the cannabis treatment was well tolerated without 
increased safety concerns (Johnson et al., 2013). Because evidence suggests cannabis 
could be a safer alternative to or complement with opioids, further research is warranted 
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(Boehnke et al., 2016; Carter et al., 2015; Haroutounian et al., 2016; Joshi et al., 2014; 
Lucas, 2012; Lucas et al., 2015). 
In the present study, ANOVA, planned contrasts, post hoc tests, and moderated 
ANOVA (i.e., PROCESS tool) were used to evaluate the two research questions. 
Concerning the first research question, cancer patients who used marijuana indicated a 
significantly higher QOL score in both physical and psychological domains as compared 
to those that used opioids. Cancer patients that used marijuana also indicated a 
significantly higher QOL score when compared to cancer patients that used both opioids 
and marijuana combined in the physical domain. There were no significant differences 
between cancer patients using opioids, marijuana, or combined opioids and marijuana 
therapies in either the social relations or environment domains. See Appendix F for a list 
of domain questions, scaling, and scoring criteria. 
Concerning the second research question, results indicated that there were no 
significant differences between the four domains of QOL for male and female cancer 
patients and their pain management therapy types. The gender-related results were 
consistent with previous research that indicated mixed results concerning use and abuse 
of both opioids and marijuana when gender was considered (Greenfield et al., 2010). My 
research was focused on pain therapy (i.e., use of opioids and/or marijuana) and cancer 
patient QOL and indicated consistent findings with previous research while a somewhat 
unexplored dimension was also uncovered. 
Previous studies have primarily focused on advanced cancer pain, opioids, and 
adjuvant use of various cannabinoid formulations (Johnson et al., 2013; Portenoy et al., 
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2012). Adjunct use of the THC/CBD oromucosal spray (i.e., Sativex®) along with 
opioids indicated improvements in pain in both short and long-term studies for both 
noncancer and cancer pain (Hoggart et al., 2015; Johnson et al., 2013; Portenoy et al., 
2012; Serpell et al., 2014). Very few studies have compared cancer patient QOL and 
opioid, marijuana, and combined opioid and marijuana criteria. In this study, cancer 
patients that used marijuana indicated a significantly higher QOL when compared to 
cancer patients that used both opioids and opioids and marijuana combined in the 
physical domain. 
The self-assessment of the physical domain included seven questions, and the 
psychological domain included six questions. The self-assessments concerning the 
physical and psychological domains cover many areas. Questions in the physical domain 
covered physical pain, need for treatment, energy levels, mobility, sleep, performance of 
activities, and capacity for work criteria. Questions in the psychological domain covered 
life enjoyment, meaningful life, concentration, bodily appearance, satisfaction with self, 
and negative feelings criteria. Cancer patients using cannabis scored significantly higher 
in both of these QOL domains when compared to opioid users. Many of the physical and 
psychological domain questions could be related to the overall perception of well-being 
of individuals and the efficacy and side effects of current treatments. (Keogh et al., 2013; 
WHO, 1997b). See Appendix F for a list of domain questions, scaling, and scoring 
criteria.  
Cohen et al. (2016) suggested comparing the efficacy and side effects of cannabis 
to opioids in future pain management studies. Many clinical studies have been 
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accomplished concerning opioid administration and noncancer and cancer pain 
management. Some studies have been accomplished concerning cannabinoid products, 
noncancer pain, cancer pain, and related QOL for patients. Further, the substitution of 
cannabis for prescription drugs occurred in 80.3% of participants and the highest rated 
reason for conversion was pain-related conditions (Lucas et al., 2015). For chronic pain 
participants, cannabis reset opiate analgesia, decreased opiate dosage, and reduced pain 
levels experienced (Lucas, 2012). 
Some recently published research results correlate with my findings. Goldenberg, 
Reid, IsHak, and Danovitch (2017) conducted a systematic review and meta-analysis of 
20 cannabis and cannabinoid studies, from 2004 to 2014 for over 2,400 participants, 
concerning health related QOL. Goldenberg et al. included eight pain-related studies that 
indicated a weakly positive relationship between cannabis-related treatments and QOL. 
Corroon, Mischley, and Sexton (2017) studied 2,774 cannabis users in Washington State 
and found 35.8% of participants substituted cannabis for opioids. Shi (2017) studied State 
Inpatient Databases from 1997 to 2014 and found significant reductions in opioid related 
hospitalizations (i.e., due to dependence, abuse, and/or overdose) in states where medical 
marijuana was legal. In a study of 271 Canadian medical marijuana patients, Lucas and 
Walsh (2017) found 32% self-reported using cannabis as a substitute for opioids, and 
73% used cannabis for chronic pain symptoms. Further, cannabis was perceived to often 
or always help relieve symptoms in 95% of participates, and 77% of participants reported 
different strains of cannabis may not be equally effective (Lucas & Walsh, 2017). 
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My research incorporated the pain management preferences of cancer patients and 
the relationship to their QOL as measured in four domains (i.e., physical, psychological, 
social relations, and environment) using the HBM theoretical framework. According to 
Paice et al. (2016), each cancer survivor has unique needs because no two cancers are the 
same and patients have different capabilities, perspectives, and experiences. Concerning 
the optimal pain management treatment for cancer pain, the personal situation and 
preference of patients should be primary factors (van den Beuken-van Everdingen et al., 
2016).  
The controversy concerning cannabis use for chronic and cancer pain is 
multifaceted. Medical professionals who have patients using cannabis for pain or other 
symptoms should educate themselves on existing cannabis research and monitor the side 
effects, symptoms, and impending effects on the QOL of their patients (Savage et al., 
2016). Because there are many cannabis varieties and ways to intake the substance, 
patients must find the right dose for their condition and circumstances (Hazekamp et al., 
2013). Specific dosing and recommendations concerning cannabis treatments are 
challenging because scientific studies concerning product variability, method of 
administration, effects, and side effects are lacking (Savage et al., 2016).  
Limitations of the Study 
There are several limitations to the theoretical framework and design of the study. 
The HBM does not account for personality traits and habitual schemas (e.g., extraversion, 
agreeableness, neuroticism, openness, or conscientiousness; Abraham & Sheeran, 2005; 
Davey, 2011). Abraham and Sheeran (2005) cite that HBM fails to account for many 
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environmental factors during personal decision-making. Researchers have consistently 
used the flexibility of the HBM, but this practice has led to a lack of standardization in 
interpreting results (Janz & Becker, 1984). This study used a comprehensive, summary 
measure for HBM (i.e., four QOL domains of the WHOQOL-BREF which includes 
physical, psychological, social relations, and environment factors) and does not evaluate 
the specific type or methodology of cannabis or opioid use in pain management choice. 
Badr et al. (2013) did not assess treatment or cancer type into their QOL study, which 
may limit the impact of various cancer types and treatment options causing a differential 
in participant QOL.  
Extrinsic and intrinsic factor interactions are considered potential threats to 
validity (Frankfort-Nachmias & Nachmias, 2015). Selection-history is one such extrinsic 
threat factor (Frankfort-Nachmias & Nachmias, 2015). Because the WHOQOL-BREF 
has shown cross-cultural validity concerning QOL across the four measured domains 
(Skevington et al., 2004), the potential selection-history threat was countered. The current 
treatment phase of the participant could cause variability in QOL unrelated to pain 
management type (Oliveira et al., 2014). Such variability could warrant use of a more 
homogeneous sample concerning treatment (Oliveira et al., 2014). Because the reactions 
of cancer patients to various treatments are often related (Tazaki et al., 1998), it was 
assumed that the various treatment groups assessed would have similar treatment phase 
participants. 
The participants in each pain management therapy group were examined 
corresponding to the cancer stage of each participant. A sample of 236 individuals was 
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evaluated in the current study (N = 235; one missing entry) for cancer stage of participant 
and pain management therapy group. The majority (43.5%, n = 74) of participants in the 
opioid group were Stage IV, and 26.5% (n = 45) were Stage III. Concerning the 
marijuana group, the majority of participants were Stage II (30%, n = 9), and 26.7% (n = 
8) were Stage III. In the combined opioid and marijuana group, the majority (51.4%, n = 
18) of participants were Stage IV, and 22.9% (n = 8) were Stage II. Frequency and 
percent statistics of participants’ cancer stage and pain management therapy group are 
displayed in Table H1. Because both the opioid and combined opioid and marijuana 
groups had a majority of Stage IV participants, further examination was accomplished. 
Analysis of variance (ANOVA) tests were conducted on cancer stage using 
transformed domain scores as the dependent variable. When comparing all the 
transformed domain scores by the cancer stage of the participants, there were no 
significant differences (except for the psychological domain between Stage II and Stage 
IV participants). In the psychological domain, Stage II participants had a significantly 
lower QOL domain score (M = 46.83, SD = 20.43) when compared to Stage IV 
participants (M = 57.02, SD = 14.92). Further, the Stage IV participants had greater QOL 
scores in all four transformed domains when compared to participants that were Stage I, 
II, and III. Descriptive statistics of participants’ overall transformed domain scores and 
cancer stage were displayed in Table H2. Table H3 displayed a model summary of the 
ANOVA analysis for transformed domain scores and cancer stage. The model summary 
of post hoc test analysis for the psychological domain and cancer stage was displayed in 
Table H4. 
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The previous analysis provides support for original assumptions. The greater 
percentage of Stage IV participants in the opioid and combined opioid and marijuana 
groups and higher mean QOL scores of Stage IV participants over Stage I, II, and III 
participants did not seem to affect the overall research results. In general, the cancer stage 
of participants did not significantly affect domain scores. Each cancer survivor has 
unique needs because no two cancers are the same and patients have different capabilities 
and experiences (Paice et al., 2016). Cancer patients need long-term pain management 
options that are individualized and positively affect their QOL (Taverner, 2015). 
Generalization of results to the greater population may be limited because a 
purposive sampling methodology was used (Frankfort-Nachmias & Nachmias, 2015). It 
was assumed that the targeted sample would be a representative sample of the population 
under study. The research survey was made available to over 20,000 cancer patients, but 
the population of millions of cancer patients made a true experimental methodology using 
random assignment prohibitive. Because the survey invitation targeted tens of thousands 
of cancer patients and confidence level to determine acceptance of the null hypothesis 
was set to .05, a case toward limited generalizability may be made. However, the 
correlational design does not support causal direction in variable relationships (Field, 
2013). 
Opioid and cannabis use for pain management offer a complex array of choices. 
There are multiple clinical guidelines concerning use of opioids (Caraceni et al., 2012) 
and hundreds of different cannabis strains and many different methods of consumption or 
use (e.g., smoking, vaporizing, oil, edible, and topical; Kral et al., 2015) for pain relief. 
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Given all of these possible variations, the assumptions were opioid and cannabis users 
have experimented with many of the possible types, strains, and methods available and 
have determined the options that best meet their situation. The personal preferences of 
cancer patients should be a vital factor in their own pain management therapies (van den 
Beuken-van Everdingen et al., 2016). 
Cost and legality were not factored into the analysis. Two barriers to cannabis use 
include affordability and fear because prescription medications are typically subsidized in 
most medical insurance programs and cannabis is not widely accepted legally at various 
governmental levels (Lucas et al., 2015). Despite sending out the survey to over 20,000 
cancer patients, the proportion of participants in the marijuana and combined marijuana 
and opioid groups was very small when compared to the opioid group. Without federally 
approved synthetic cannabis medications for pain, U.S. patients must self-fund cannabis-
related products through legal state controlled dispensaries or illegally through other 
suppliers (Boehnke et al., 2016). 
All of the above limitations and delimitations may constrain the research, 
findings, and conclusions. Overall, survey participation rate was approximately 1.5%. 
This low response percentage could be due to several factors. The survey was directed at 
cancer patients and was completely voluntary without any extrinsic incentive. Higher 
participation rates could be achieved if some appropriate level of incentive was given. 
Further, higher response rates from cancer patients using marijuana could be achieved by 
surveying individuals associated with university-related dispensaries. During the data 
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collection phase, I contacted one such dispensary, but this contact yielded no 
participation. 
There were other factors that could affect findings. The QOL of participants was 
self-reported using a standardized instrument during a specific period of time. Although 
participants were asked to consider the last 2 weeks when taking the survey, the data 
collected only provided a static assessment of QOL. Although the specific cancer and 
stage of each participant were collected, the specific stage of treatment for each 
participant was not assessed. Specifically, some participants could have been undergoing 
chemotherapy or radiation treatments while other participants were in a pre- or post-
treatment phase. Even though over 95% of participants reported suffering chronic pain, 
the exact level of pain each participant suffered was not assessed.  
Participant data concerning state of residence, availability of pain management 
options, and other adjuvants or nonopioids used were also not collected. Each of these 
factors could influence the perceived QOL of participants and serve as possible 
covariates. All of these factors could be included in future studies.  
Researchers have identified other barriers that have prevented research and 
acceptance of cannabis as a normal pain management therapy. According to Penington 
(2015), patients should be able to use cannabis to seek relief given proper medical 
recommendation and following state laws. Several barriers have prevented research and 
medical acceptance of marijuana. These barriers include the following: (a) political 
hesitancy and nonacceptance, (b) practitioner educational and training deficiencies, (c) 
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patient-practitioner communication breakdown, and (d) practitioner concern over opioid 
abuse and hesitancy to advocate marijuana (Carter et al., 2015). 
Recommendations 
Opioid and cannabis prescription and/or use for pain should focus on side effects, 
physical function, symptom management, possible addiction, and QOL of patients 
(Savage et al., 2016). Cannabis treatments have been modestly effective and safe 
treatments in chronic pain patients, but most studies have focused on noncancer pain vice 
cancer-related pain (Aggarwal, 2013). More high quality, large sample size, long-term 
exposure, and analgesic comparative assessments concerning pain relief and physical 
functioning are needed (Aggarwal, 2013; Degenhardt et al., 2015; Kahan, 2014). Results 
from this current study align with results from previous studies. The implications of this 
alignment drive recommendations for medical practitioners, researchers, and health 
policy-makers. 
For Medical Practitioners 
Specific dosing and recommendations concerning cannabis treatments are 
challenging because scientific studies concerning product variability, method of 
administration, effects, and side effects are lacking (Savage et al., 2016). There are only a 
few approved cannabinoid-related prescription medications on the market (i.e., 
dronabinol [Marinol®; synthetic THC], nabilone [Cesamet®; synthetic molecule similar 
to THC], and nabiximols [Sativex®; THC and CBD extract]; Savage et al., 2016). The 
small number of cannabis treatment options available are most likely due to the lack of 
clinical research, cost issues, inconsistent insurance coverage, little to no standardization 
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or guidance in use, and medical professional reluctance to support (Savage et al., 2016). 
Medical professionals should educate themselves on existing cannabis research and 
monitor the side effects, symptoms, and impending effects on the QOL of any patients 
using cannabis (Savage et al., 2016). 
The controversy concerning cannabis use for chronic and cancer pain is 
multifaceted. In Canada, despite being a legal option, marijuana was often not prescribed 
for chronic noncancer pain due to the uncomfortableness of medical providers in using 
cannabis as a pain management option (i.e., only 23% prescribed; St-Amant et al., 2015). 
Opioids are one of the most commonly used medications for palliative pain but may be 
inappropriate for chronic noncancer pain because short-term vice long-term effectiveness 
and efficacy have been indicated (Manchikanti et al., 2010). Although concrete evidence 
concerning opioid safety and effectiveness in the treatment of chronic pain is 
inconclusive, opioids remain a reasonable and primary treatment option (Manchikanti et 
al., 2010). Ineffective long-term efficacy of opioids opens up opportunities to find 
solutions for the long-term pain management care and QOL enhancement for both 
noncancer and cancer patients. 
In this current study, cancer patients that used marijuana for pain indicated 
significantly greater physical QOL over cancer patients that used opioids and combined 
opioids and marijuana. Cancer patients that used marijuana for pain indicated 
significantly greater psychological QOL over cancer patients that used opioids. Cancer 
patients deserve the best QOL possible. If medical marijuana is legal in your jurisdiction, 
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then seriously consider prescribing it for your cancer patients. Cancer patients should be 
free to use marijuana in accordance with their state jurisdictions.  
For Researchers 
Marijuana may be an effective substitute or adjunct treatment to prescription 
drugs; therefore, long-term studies using cannabis with comparative and efficacy 
emphasis are warranted to determine QOL implications (Lucas & Walsh, 2017). 
Cannabis could be a safe and effective treatment for chronic pain and serve as an 
alternative or complementary treatment to relieve society from the growing costs related 
to the opioid epidemic (Lucas, 2012). As results from this study indicated, cannabis 
should be pursued as a viable option for cancer patients to increase their QOL when 
dealing with chronic pain. Future researchers could examine cannabis concerning pain 
and side effects relief to better understand the analgesic effects and implications (Wilsey 
et al., 2013).  
Cannabis dosing mechanisms and strain types are two variables that need further 
research. There is a lack of data concerning various cannabis use mechanisms (e.g., 
smoked, ingested, vaporized; Bowles et al., 2012; Schauer et al., 2016) and conventional 
versus unconventional pain medications concerning cancer-related non-neuropathic or 
neuropathic pain (Bowles et al., 2012). Cannabis strains differ in potency of THC and 
CBD levels, so fine-tuning the right treatment for specific situations can be very 
individualized (Savage et al., 2016). High-THC cannabis strains were associated with 
physical and mental side effects while high-CBD strains had less mental side effects 
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while associated with various types of pain relief (Savage et al., 2016). Research 
concerning the amounts of THC and/or CBD to use for pain treatments is also needed. 
There are many opportunities for researchers to study marijuana concerning 
noncancer and cancer pain. Health self-assessments have shown to be reliable predictors 
of cancer patient QOL and can help medical providers assess symptoms and direct 
treatments (Mansano-Schlosser & Ceolim, 2012). Researchers should examine long-term 
effects of cannabis concerning strains, dosage, intake methods, side effects, analgesia, 
and overall health implications.  
Pain management treatments are often correlated to the QOL of patients (Baek et 
al., 2013; Kwon et al., 2013; Wengström et al., 2014). Opioids are the primary treatment 
for chronic pain (Manchikanti et al., 2010) even though they have been associated with 
abuse, overdose, and death (Rowe & Caprio, 2013). Researchers should appeal to health 
policy-makers to loosen the legislative controls on cannabis in order to facilitate potential 
pain management treatment opportunities. 
For Health Policy-makers 
The current Schedule I status of cannabis has limited past and limits future 
research (Savage et al., 2016). Concerning cannabis, scientific evidence and political 
ideology often collide when efficacy, safety, individual choice, and public health are 
debated (Savage et al., 2016). Researchers have been affected by strict government 
control limiting funding, restricting cannabis supplies and types, and risks of criminal 
prosecution (Aggarwal, 2013; Savage et al., 2016). Although some medical associations 
and groups (e.g., Institute of Medicine [IOM], American Medical Association [AMA], 
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and American College of Physicians [ACP]) have supported reclassification of cannabis 
to enhance future studies, the Schedule I status remains (Aggarwal, 2013; Cohen 2009a, 
2009b, 2010; DEA Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 
2016).  
In order to allow appropriate research, marijuana should be rescheduled to less 
than a Schedule I drug. Results from this current study indicated cancer patients that used 
marijuana had a significantly greater physical and psychological QOL domain score than 
cancer patients that used opioids. Although health self-assessments have shown to be 
reliable predictors of cancer patient QOL and can help medical providers assess 
symptoms and direct treatments (Mansano-Schlosser & Ceolim, 2012), researchers need 
to conduct more long-term clinical trials using marijuana. These clinical trials are 
hindered due to the current Schedule I drug status of marijuana. Reducing the 
ramifications of the opioid epidemic and increasing cancer patient QOL are important 
issues for society. Legislators should reschedule marijuana to less than a Schedule I drug. 
In the interim of reducing the Schedule I status of marijuana, federal policy-
makers should pass legislation to protect state medical marijuana programs and enable 
research into the medicinal properties of marijuana. Current legislation (Compassionate 
Access, Research Expansion, and Respect States Act of 2017 [CARERS Act of 2017]) 
was recently introduced into both the U.S. House and Senate. This legislation would help 
protect state medical marijuana laws from federal interference (i.e., even for veterans 
through the U.S. Department of Veterans Affairs) and enable marijuana research (H.R. 
2920, 2017; S. 1374, 2017). Medical marijuana laws have been passed in more than half 
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the U.S. states. Cancer patients should be free to use marijuana in accordance with their 
state jurisdictions without fear of federal interference and prosecution.   
Implications for Social Change 
Determining relationships between pain management methods and cancer 
patients’ QOL may help to enhance lives and contribute to positive social change. The 
number of annual cancer cases worldwide will reach over 20 million in the next 15 years, 
and pain management and QOL for cancer patients are primary concerns to health 
providers and affected patients (Kwon et al., 2013; Pelayo-Alvarez et al., 2013; WHO, 
2015). New medical therapies hold the potential to create positive social change if they 
are found to provide significant benefit over current therapies (Benton et al., 2013). Pain 
management alternatives with less side effects, morbidity, or related mortality that 
provide patients equal or greater QOL could provide positive social value. 
Overall, opioid related abuse, morbidity, and mortality have reached epidemic 
proportions in society (CDC, 2012, 2016; Garcia, 2013; Rowe & Caprio, 2013). Political 
obstacles and corporate influences (e.g., pharmaceutical industry) have created barriers 
for researchers studying cannabis (Bostwick, 2012; Cohen, 2009a, 2009b, 2010). These 
researchers have been excluded from participating in established drug testing protocols 
and processes (Bostwick, 2012; Cohen, 2009a, 2009b, 2010). As researchers examine 
evidence concerning pain management options, benefits, barriers, cues to action, and self-
efficacy could be affected. The potential effects of medical interventions on 
psychological factors, such as QOL, have been inadequately studied, and assessment of 
cancer patients’ QOL is a neglected research area (Barre et al., 2015). 
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Opioids are unreliable in predicting the response, tolerance, or superiority for 
each type on every patient (Prommer & Ficek, 2012). Due to insufficient evidence, 
cancer patients should help tailor their pain treatments with personal preferences (van den 
Beuken-van Everdingen et al., 2016). Even though many cancer patients used strong 
doses of opioids, the common occurrence of severe pain and decreased QOL indicated 
under treatment and presented an opportunity for future research (Zoëga et al., 2013). 
Findings from my study could provide medical practitioners greater 
understanding of how pain management preference affects cancer patients’ QOL and 
contribute to positive social change. Effective pain management is an essential 
determinant of patient QOL, outcome, and survival (Perlman et al., 2013). Many cancer 
patients suffer pain related symptoms and problems and these health related factors may 
correspond to their QOL (Shneerson et al., 2013). Cancer patients experienced 
significantly lower QOL with higher levels of pain; despite use of strong opioids, many 
cancer patients regularly encountered severe pain (Zoëga et al., 2013). 
Because the majority of cancer patients take opioids for pain management and 
patients are often undertreated for pain (Nersesyan & Slavin, 2007; Tanco et al., 2014), 
individual pain management choice needs to be more personalized (Tanco et al., 2014). 
Enhancement of available pain management mechanisms of action that reduce negative 
side effects and improve patient QOL would provide significant benefit to society. 
Exploration into the under treatment of cancer pain is a necessity because improving 
cancer patient QOL is an important goal of health care (Zoëga et al., 2013).  
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The long-term effect of opioid use is mostly negative because only the minority of 
patients experience benefits (Becker et al., 2016). The negative consequences of long-
term opioid use include safety issues (e.g., mild to severe toxicities), overdose, and death 
(Becker et al., 2016). The adverse effects of opioid use make it a poor long-term option 
(Hayes & Brown, 2014). In the majority of cases concerning opioid treatments, patients 
are either being undertreated and experience constant pain or over treated and experience 
various levels of harmful toxicity. Determining acceptable treatment alternatives to help 
balance these extreme situations could lead to policy changes and treatment options that 
could contribute to positive social change.  
Research into substituting cannabis for or adjutant with opioids in pain-related 
cases is justified for public health reasons due to cannabis being a potentially safer 
mechanism of action (Lucas et al., 2015). The United States is a prime area of concern 
because its population typically consumes 80% of the world’s opioid supply while having 
less than 5% of the global population (Manchikanti et al., 2010). Between 1999 and 2010, 
U.S. states with medical marijuana legislation had nearly a 25% lower mean annual rate 
of opioid overdose and mortality than states without such laws (Bachhuber et al., 2014). 
Potentially reducing the toxic effect of opioids on cancer patients should be a treatment 
consideration. A single focused strategy to decrease cancer patient pain without 
consideration of these toxic and potentially deadly side effects seems counterintuitive to 
overall patient QOL.  
More pain management options and enhanced communication could provide 
solutions for cancer patients. The most effective cancer pain management decision-
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making included collaboration between the medical providers and patients (Dalal et al., 
2013; Paice et al., 2016). Each cancer survivor has unique needs because no two cancers 
are the same and patients have different capabilities and experiences (Paice et al., 2016). 
Cancer patients need long-term pain management options that are individualized and 
positively affect their QOL (Taverner, 2015). Opioids are a poor long-term option due to 
their adverse effects (Hayes & Brown, 2014). Due to the many problems, side effects, 
and complications associated with pharmacological treatments that decreased patient 
QOL, complementary and alternative treatments for pain management are needed (Park 
et al., 2015). 
Complementary and alternative medicines (CAM) provide a challenge to 
practitioners providing conventional cancer treatment (Bar-Sela et al., 2015). Worldwide, 
CAM is used by 30-40% of cancer patients yet many of these therapies do not have 
evidence-based assessments of interactions with conventional treatments (Bar-Sela et al., 
2015). A majority of cancer patients (i.e., 83%) would incorporate CAM into cancer 
treatments to supplement care (e.g., help improve QOL and reduce pain) if they were part 
of normal protocols (Ben-Arye et al., 2014). Shneerson et al. (2013), Bao et al. (2014), 
Ben-Arye et al. (2014), and Bar-Sela et al. (2015) explored CAM in cancer care and 
determined a relationship with expected and significant QOL improvement. Although all 
these researchers considered herbs in their studies, only Bao et al. (2014) included 
cannabis and found evidence of potential benefit for cancer pain. Further research 
concerning the efficacy and safety of CAM treatments are needed so medical providers 
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can counsel patients appropriately concerning integrative cancer care options (Bauml et 
al., 2015). 
Cannabis prescriptions remain relatively low because information on potential 
side effects and effects, insurance coverage, cost, and medical provider advocacy are 
lacking (Savage et al., 2016). Cannabis was used primarily for pain, sleep, and anxiety 
problems although further research and familiarity were needed to connect therapeutic 
use with risk and benefit perceptions of participants (Walsh et al., 2013). In a small, 
convenience, qualitative study, Peters (2013) found some participants used cannabis as an 
alternative or reduction agent for traditional opiate medicines. Although most participants 
viewed cannabis as a less effective analgesic than strong opioids, many preferred 
cannabis over opiates due to reduced adverse side effects and increased QOL (Peters, 
2013).  
In other studies, cannabis has shown significant analgesic results, but the diversity 
in plant strain types and concentrations and lack of FDA guidance make specific efficacy 
and side effect predictions difficult (Savage et al., 2016). According to Hazekamp et al. 
(2013), although participants scored herbal nonpharmaceutical cannabis more 
satisfactorily than pharmaceutical cannabis products, patients are different and must find 
the right dose and application method for their situations. Further, there is a need to 
compare cannabis with the traditional pharmaceutical treatments (Walsh et al., 2013). 
Cannabis may be an effective pain treatment to reduce opioid abuse and overdose 
(Boehnke et al., 2016). Because cannabinoid receptors are not on the brain stem, 
cannabinoid-based drugs may have an advantage over opioid-based drugs concerning 
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overdose potential (Lucas, 2012). The growing rates of opiate addiction, abuse, and 
mortality are public health concerns with significant social costs (CDC, 2016; Lucas, 
2012; Rudd et al., 2016). These effects could impact social change at every level (i.e., 
individual, family, organizational, and society/policy). 
Conclusion 
There were significant findings from this research. Finding from this study 
indicated significant benefit in cancer patient physical and psychological QOL in 
participants using marijuana when compared to participants using opioids. Cancer 
patients that used marijuana also indicated a significantly higher QOL score when 
compared to cancer patients that used both opioids and marijuana combined in the 
physical domain. Because improving the QOL of cancer patients will contribute to 
positive social change, several recommendations for medical practitioners, researchers, 
and health policy-makers were presented.  
Reducing the ramifications of the opioid epidemic and increasing cancer patient 
QOL are important issues for society. Concerning medical practitioners, if medical 
marijuana is legal in your jurisdiction, then seriously consider prescribing it for your 
cancer patients. Carter et al. (2015) identified various barriers related to medical 
practitioners incorporating cannabis into their standard of practice (i.e., political, 
educational, training, and communication). There are concerns with the current pain 
management approach (e.g., patient perception of intervention and patient-medical 
provider communication problems; Butow & Sharpe, 2013). Concerning the optimal pain 
management treatment for cancer pain, the personal situation and preference of patients 
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should be primary factors (van den Beuken-van Everdingen et al., 2016). Cancer patients 
should be free to use marijuana in accordance with their state jurisdictions. 
Researchers and legislators should also take action. Researchers should examine 
the long-term effects of cannabis concerning strains, dosage, intake methods, side effects, 
analgesia, and overall health implications. Researchers should appeal to health policy-
makers to loosen the legislative controls on cannabis in order to facilitate research into 
pain management treatment options. Legislators should reschedule marijuana to less than 
a Schedule I drug in order to empower researchers. In the interim of reducing the 
Schedule I status of marijuana, federal policy-makers should pass legislation to protect 
state medical marijuana programs and enable research into the medicinal properties of 
marijuana. Legislators should support the CARERS Act of 2017 that was recently 
introduced into both the U.S. House and Senate concerning these issues (H.R. 2920, 
2017; S. 1374, 2017). Medical marijuana laws have been passed in more than half the 
U.S. states. Cancer patients should be free to use marijuana in accordance with their state 
jurisdictions without fear of federal interference and prosecution. 
Cancer patients deserve the best QOL possible. Marijuana may be an effective 
substitute to opioids concerning physical and psychological QOL factors of cancer 
patients. I support IOM, AMA, and ACP perspective to reclassify marijuana to less than a 
Schedule I drug to enhance the ability of researchers to conduct future studies. The 
ineffective long-term efficacy of opioids opens up opportunities to find solutions for the 
long-term pain management care and QOL enhancement for both noncancer and cancer 
patients. Because pain endured and corresponding pain management treatments often 
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correlate to the QOL of patients (Baek et al., 2013; Kwon et al., 2013; Wengström et al., 
2014), future pain management options in standard of care should incorporate research 
findings and evidence even if it counters political ideology. 
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Appendix D: Frequency Counts of Participants’ Cancer Types 
 
Cancer Type Frequency (n) Percent (%) 
Adenocarcinoma  1 0.4 
Anal 2 0.8 
Appendix 1 0.4 
Bone 2 0.8 
Brain 2 0.8 
Breast 91 38.6 
Breast and bone 1 0.4 
Breast and colon 1 0.4 
Breast and kidney 1 0.4 
Breast and ovarian 2 0.8 
Breast and skin 1 0.4 
Breast, bone, and liver 1 0.4 
Breast, skin, and rectal 1 0.4 
Carcinoid 1 0.4 
Cervical 5 2.1 
Colon 5 2.1 
Colon and liver 1 0.4 
Colon and lymphoma 2 0.8 
Esophageal 2 0.8 
Endometrial 3 1.3 
Gastrointestinal 1 0.4 
Head and neck 4 1.7 
Kidney 3 1.3 
Leiomyosarcoma 4 1.7 
Leukemia 2 0.8 
Leukemia (AML) 3 1.3 
Leukemia (CLL) 3 1.3 
Leukemia (Myleofibrosis and ET) 1 0.4 
Leukemia (SLL) 1 0.4 
Liposarcoma 1 0.4 
Liver 1 0.4 
Lung 21 8.9 
Lung and brain 1 0.4 
Lymphoma 7 3.0 
Lymphoma (Hodgkin) 1 0.4 
Lymphoma (Non-Hodgkin) 5 2.1 
Lymphoma and thyroid 1 0.4 
Melanoma 1 0.4 
Melanoma and ganglia nuero blastoma 1 0.4 
Myeloma 9 3.8 
Neuroendocrine 1 0.4 
Oral 1 0.4 
Ovarian 7 3.0 
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Ovarian and uterine 2 0.8 
Pancreatic 6 2.5 
Prostate 2 0.8 
Rectal 4 1.7 
Skin 3 1.3 
Stomach 1 0.4 
Testicle 1 0.4 
Throat 1 0.4 
Thyroid 3 1.3 
Uterine 4 1.7 
Vaginal 1 0.4 
Vulvar  1 0.4 
Missing 1 0.4 
   Total 236 100.0 
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Appendix E: WHOQOL-BREF 26-Question SPSS Coding and Question Numbers 
WHOQOL-
BREF 
Question# 
Research 
Survey 
Question# 
SPSS 
code 
Question Text 
1 11 g1 "How would you rate your quality of life"  
2 12 g4 "How satisfied are you with your health" 
3 13 f1_4 "To what extent do you feel pain prevents you from 
doing what you need to do" 
4 14 f11_3 "How much do you need any medical treatment to 
function in your daily life" 
5 15 f4_1   "How much do you enjoy life" 
6 16 f24_2 "To what extent do you feel your life to be 
meaningful" 
7 17 f5_3   "How well are you able to concentrate" 
8 18 f16_1 "How safe do you feel in your daily life" 
9 19 f22_1 "How healthy is your physical environment" 
10 20 f2_1   "Do you have enough energy for everyday life" 
11 21 f7_1   "Are you able to accept your bodily appearance" 
12 22 f18_1 "Have you enough money to meet your needs" 
13 23 f20_1 "How available to you is the information that you 
need in your day-to-day life" 
14 24 f21_1 "To what extent do you have the opportunity for 
leisure activities" 
15 25 f9_1   "How well are you able to get around" 
16 26 f3_3   "How satisfied are you with your sleep" 
17 27 f10_3 "How satisfied are you with your ability to perform 
your daily living activities" 
18 28 f12_4 "How satisfied are you with your capacity for work" 
19 29 f6_3   "How satisfied are you with yourself" 
20 30 f13_3 "How satisfied are you with your personal 
relationships" 
21 31 f15_3 "How satisfied are you with your sex life" 
22 32 f14_4 "How satisfied are you with the support you get from 
your friends" 
23 33 f17_3 "How satisfied are you with the conditions of your 
living place" 
24 34 f19_3 "How satisfied are you with your access to health 
services" 
25 35 f23_3 "How satisfied are you with your mode of 
transportation" 
26 36 f8_1   "How often do you have negative feelings, such as 
blue mood, despair, anxiety, depression" 
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Appendix F: WHOQOL-BREF Domains, Questions, Scaling, and Scoring 
 
Domain Code and Question Direction 
of Scaling 
Raw Domain 
Score 
Raw Item Score 
Ov
er
all
 
QO
L 
an
d 
He
alt
h 
 g1 How would you rate your 
quality of life? 
+ 
(2-10) 
(1-5) 
 g2 How satisfied are you 
with your health? 
+ (1-5) 
D
om
ai
n 
1 
Ph
ys
ic
al
 H
ea
lth
 
 f1_4 To what extent do you 
feel that physical pain 
prevents you from doing 
what you need to do? 
-(reverse) 
(7-35) 
(1-5) 
f11_3 How much do you 
need any medical treatment 
to function in your daily 
life? 
-(reverse) (1-5) 
f2_1 Do you have enough 
energy for everyday life? 
+ (1-5) 
f9_1 How well are you able 
to get around? 
+ (1-5) 
f3_3 How satisfied are you 
with your sleep 
+ (1-5) 
f10_3 How satisfied are you 
with your ability to perform 
your daily living activities? 
+ (1-5) 
f12_4 How satisfied are you 
with your capacity for work? 
+ (1-5) 
D
om
ai
n 
2 
Ps
yc
ho
lo
gi
ca
l 
f4_1 How much do you 
enjoy life? 
+ 
(6-30) 
(1-5) 
f24_2 To what extent do you 
feel your life to be 
meaningful? 
+ (1-5) 
f3_1 How well are you able 
to concentrate? 
+ (1-5) 
f7_1 Are you able to accept 
your bodily appearance? 
+ (1-5) 
f6_3 How satisfied are you 
with yourself? 
+ (1-5) 
f8_1 How often do you have 
negative feelings such as 
blue mood, despair, anxiety, 
depression? 
-(reverse) (1-5) 
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D
om
ai
n 
3 
So
ci
al
 
re
la
tio
ns
hi
ps
 
f13_3 How satisfied are you 
with your personal 
relationships? 
+ 
(3-15) 
(1-5) 
f15_3 How satisfied are you 
with your sex life? 
+ (1-5) 
f14_4 How satisfied are with 
the support you get from your 
friends? 
+ (1-5) 
D
om
ai
n 
4 
En
vi
ro
nm
en
t 
f16_1 How safe do you feel 
in your daily life? 
+ 
(8-40) 
(1-5) 
f22_1 How healthy is your 
physical environment? 
+ (1-5) 
f18_1 Have you enough 
money to meet your needs? 
+ (1-5) 
f20_1 How available to you 
is the information that you 
need in your daily-to-day 
life? 
+ (1-5) 
f21_1 To what extent do you 
have the opportunity for 
leisure activities? 
+ (1-5) 
f17_3 How satisfied are you 
with the condition of your 
living place? 
+ (1-5) 
f19_3 How satisfied are you 
with your access to health 
services? 
+ (1-5) 
f23.3 How satisfied are you 
with your mode of 
transportation? 
+ (1-5) 
 
(WHO, 1997a) 
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Appendix G: Research Questions (#2 – #38) in SurveyMonkey Format 
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Appendix H: Analysis of Participants’ Cancer Stage by Pain Management Therapy 
Table H1 
Frequency and Percent Statistics of Participants’ Cancer Stage and Type of Pain 
Management Therapy 
 
Pain Management Therapy Frequency (n)  Opioids 
[Percent (%)] 
Marijuana Opioids & Marijuana  
Cancer Stage  
 
 
   Stage I 12 (7.1) 2 (6.7) 2 (5.7) 
   Stage II 25 (14.7) 9 (30.0) 8 (22.9) 
   Stage III 45 (26.5) 8 (26.7) 3 (8.6) 
   Stage IV 74 (43.5) 6 (20.0) 18 (51.4) 
   None 14 (8.2) 5 (16.7) 4 (11.4) 
     Total 170 30 35 
Note.  Total N = 235, one missing 
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Table H2 
Descriptive Statistics of Participants’ Transformed Domain Scores by Cancer Stage 
 
Transform 
Domain by 
Cancer Stage 
N Mean 
Std. 
Dev. 
Physical   
 
   None 23 38.66 19.28 
   Stage I 16 41.96 10.31 
   Stage II 42 40.56 18.16 
   Stage III 56 42.22 16.84 
   Stage IV 98 44.13 17.21 
    
Psychological   
 
   None 23 53.99 17.97 
   Stage I 16 50.78 12.66 
   Stage II 42 46.83 20.43 
   Stage III 56 50.60 19.76 
   Stage IV 98 57.02 14.92 
    
Social Relations   
 
   None 23 54.35 23.55 
   Stage I 16 51.56 21.99 
   Stage II 42 46.03 21.17 
   Stage III 56 49.40 23.62 
   Stage IV 98 53.49 20.72 
    
Environment   
 
   None 23 62.77 13.26 
   Stage I 16 63.87 13.45 
   Stage II 42 58.93 18.42 
   Stage III 56 61.05 19.45 
   Stage IV 98 66.65 14.00 
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Table H3 
Model Summary of the ANOVA Analysis for Transformed Domain and Cancer Stage  
Source 
Type III 
Sum of 
Squares 
df Mean Square F Sig. (p) 
Partial 
Eta 
Squared 
Observed 
Power 
Physical Transformed        
Corrected Model 761.537 4 190.384 0.648 0.629 0.011 0.210 
Intercept 272879.4 1 272879.4 928.29 < .001 0.801 1.000 
Stage 761.537 4 190.384 0.648 0.629 0.011 0.210 
Error 67610.48 230 293.959     
Total 489961.7 235      
Corrected Total 68372.02 234      
        
Psychological Transformed        
Corrected Model 3605.492 4 901.373 2.976 0.020 0.049 0.789 
Intercept 425634.8 1 425634.8 1405.113 < .001 0.859 1.000 
Stage 3605.492 4 901.373 2.976 0.020 0.049 0.789 
Error 69671.25 230 302.918     
Total 731979.2 235      
Corrected Total 73276.74 234      
        
Social Relations Transformed        
Corrected Model 1880.138 2 940.069 1.956 0.144 0.017 0.403 
Intercept 386052.3 1 386052.3 803.463 < .001 0.775 1.000 
Stage 1880.138 2 940.069 1.956 0.144 0.017 0.403 
Error 111953.1 233 480.486     
Total 735069.4 236      
Corrected Total 113833.3 235      
        
Environment Transformed        
Corrected Model 400.757 2 200.378 .752 0.473 0.006 0.177 
Intercept 520441.5 1 520441.5 1952.868 < .001 0.893 1.000 
Stage 400.757 2 200.378 .752 0.473 0.006 0.177 
Error 62094.77 233 266.501     
Total 1010332 236      
Corrected Total 62495.53 235           
Note. Dependent variable = transformed domain (tdom1, tdom2, tdom3, & tdom4); N = 235 
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Table H4 
Model Summary of Post Hoc Test Analysis for Psychological Domain and Cancer Stage 
 
Source Mean Diff 
Std. 
Error 
Sig. 
(p) 
95% 
Lower 
CI 
Upper 
Psychological Transformed      
 Hochberg Post Hoc Test      
  None vs Stage I 3.2043 5.666 1.000 -12.80 19.21 
  None vs Stage II 7.1601 4.515 0.698 -5.60 19.92 
  None vs Stage III 3.3903 4.310 0.996 -8.79 15.57 
  None vs Stage IV -3.0298 4.033 0.997 -14.42 8.36 
  Stage I vs Stage II 3.956 5.113 0.997 -10.49 18.40 
  Stage I vs Stage III 0.186 4.934 1.000 -13.75 14.13 
  Stage I vs Stage IV -6.234 4.693 0.868 -19.49 7.026 
  Stage II vs Stage III -3.770 3.553 0.966 -9.56 5.03 
  Stage II vs Stage IV -10.190 3.210 0.017 -13.81 6.27 
  Stage III vs Stage IV -6.420 2.916 0.250 -14.66 1.82 
 Games-Howell Post Hoc      
  None vs Stage I 3.2043 4.904 0.965 -10.85 17.26 
  None vs Stage II 7.1601 4.896 0.591 -6.69 21.01 
  None vs Stage III 3.3903 4.583 0.946 -9.63 16.41 
  None vs Stage IV -3.0298 4.038 0.943 -14.75 8.69 
  Stage I vs Stage II 3.956 4.467 0.901 -8.75 16.66 
  Stage I vs Stage III 0.186 4.121 1.000 -11.61 11.98 
  Stage I vs Stage IV -6.234 3.505 0.410 -16.62 4.15 
  Stage II vs Stage III -3.770 4.112 0.890 -15.23 7.69 
  Stage II vs Stage IV -10.190 3.494 0.038 -20.01 -0.37 
  Stage III vs Stage IV -6.420 3.040 0.224 -14.88 2.04 
Note. Dependent variable = transformed psychological domain (tdom2); N = 235 
    No significant finding for physical, social relations, and environment domains were found; 
    therefore, their post hoc test results were not displayed. 
 
 
